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Summary 
 
Generally, conventional dendritic cells (cDCs) are highly phagocytic non-lymphocytic motile 
cells that screen their surroundings for pathogens or tissue damage and after activation 
migrate from non-lymphoid organs to lymph nodes, where they can present antigen to naïve 
thymus derived (T) cells. Most of the tissue cDCs can be subdivided into two main subsets 
cDC1 and cDC2. However, fate mapping of DC using a reporter mouse model identified a renal 
specific cluster of differentiation (CD) 64+ cell population that displays features commonly 
associated with cDCs and monocytes (MOs)/macrophages (MØs). This discovery raised the 
question, weather CD64+ cells are specialized to regulate locally immune responses in the 
kidney microenvironment. Moreover, cells with features of DC and CD64+ population have 
been described to play a protective role in some pathological processes in the kidney, like in 
nephrotoxic acute kidney injury (AKI). However, the fact that these CD64+ cells are difficult to 
distinguish based on phenotypic properties hinders the exact delineation of the individual 
contributions of DCs, CD64+ cells, MOs and MØs for kidney immunity. 
In order to investigate the specific function of CD64+ cells in kidney homeostasis, a novel 
transgenic mouse model was generated by clustered regularly interspaced short palindromic 
repeat (CRISPR)/CRIPSR-associated nuclease (Cas) technology in which cyclization 
recombination (Cre) recombinase-inducible diphtheria toxin receptor (iDTR) is expressed 
under the CD64 promoter. Here, Cre-mediated excision of a locus of crossover in P1 (loxP) 
sequenced flanked STOP cassette (LSL) and CD64 promoter activity renders the cell sensitivity 
to diphtheria toxin (DT) administration. Finally, the obtained transgenic CD64-LSL-2A-DTR 
strain was tested by breeding it with the DC specific C-type lectin domain family 9, member A 
(Clec9a)-Cre mouse line, and an efficient depletion of CD64+ cells in the offspring after DT 
treatment was observed. Importantly, DT exposure in these mice did not affect cDC1 and 
cDC2 and monocytosis or neutrophilia were not observed, as an unwanted side effects of cell 
ablation. 
The second part of this work was focused on the establishment of a protocol to induce 
nephrotoxic AKI for the investigation of cDC and CD64+ cell function during this pathogenesis 
in the Clec9a-Cre x Rosa26-iDTR and X-C motif chemokine receptor 1 (XCR1)-DTR-Venus 
depletion mouse models. 15 milligram (mg)/ kilogram (kg) cisplatin was identified as the 
optimal dose for the induction of the disease within 48 hours (h) as confirmed by increased 
BUN and creatinine levels. Additionally, it was shown that the administration of 25 nanogram 
(ng)/gram (g) DT was enough to deplete renal cDC1 and cDC2 in Clec9a-Cre x Rosa26-iDTR 
mice and cDC1 in XCR1-DTR-Venus mice. DT administration followed by cisplatin injection 
showed for both models no effect of cell depletion on kidney function and on infiltration of 
MOs and neutrophils in renal tissue. Interestingly, the depletion of cDC1 and cDC2 in Clec9a-
Cre x Rosa26-iDTR mouse model resulted in a slight decrease of CD64+ cell subsets. 
Taken together, these results confirmed the establishment of a new CD64-LSL-2A-DTR 
depletion mouse model as a future in vivo tool for the functional investigation of CD64+ cells. 
Furthermore, a first AKI induction protocol was established for two DC depletion mouse 
models. The novel generated mouse model alone or in combination with this nephrotoxic AKI 
protocol will hopefully substantially contribute for a better and detailed understanding of cDC 
and CD64+ cell functions in renal immunity and may help to develop improved therapeutic 
strategies to treat kidney diseases. 
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1. Introduction 
 
1.1. Innate immune system 
 
The mammalian immune system is a host defence system, which can be divided into an innate 
and adaptive arm1. Evolutionarily, the innate immune system is older than the adaptive arm 
and provides rapid, but non-specific responses against invading pathogens and presents the 
first line of defence1. The adaptive immune system includes immune cells that recognize a 
broad variety of potentially threatening pathogens with a high specificity and build a cellular 
memory against these infectious agents2. However, development of adaptive immune 
responses requires about 4-7 days, which would provide a window of opportunity for 
pathogens to spread in the host without the help of the innate immune system2-4. The major 
cells of this ancient immune system include cDCs, plasmacytoid DCs (pDCs), MOs, MØs, 
natural killer (NK) cells, mast cells and granulocytes5-9. 
 
1.1.1. Mononuclear phagocyte system (MPS) 
 
Within the innate immune system, the MPS is represented by cDCs, pDCs, MØs and MOs. At 
the time of host defence in the mouse these cells play a prominent role, because they are one 
of the first cells to react to pathogens or tissue injury10,11. Commonly, the cells of MPS are 
phenotypically similar, demonstrating stellate morphology and a capacity for fragment 
crystallizable region (Fc)-receptor mediated phagocytosis12-15. All MPS cells in tissue are 
mainly identified based on the expression of surface proteins (Fig. 1). However, most of these 
markers are not exclusively specific to a certain cell population and their expression levels can 
change based on the cell activation status, for instance after infection or during 
inflammation13. Nevertheless, all MPS cells express in common certain level of CD11c16. In 
consequence, cDCs are identified as double positive for CD11c and major histocompatibility 
complex II (MHCII) in all tissues. In addition, cDCs can express other markers such as C-X3-C 
motif chemokine receptor 1 (CX3CR1), CD24, CD135, CD8, CD103, XCR1, CD205, CLEC9A, CD4, 
CD172a, CD11b, CD64 (Fig. 1)13,17,18. pDCs can be discriminated from other MPS cells using 
CD45R and sialic acid-binding immunoglobulin-like lectin H (SiglecH) surface markers. Also, 
they express CD135, lymphocyte antigen 6 complex (Ly6C) and CLEC9A19. In case of MØs, the 
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most common expressed surface markers are CD64, CX3CR1 and epidermal growth factor-
like module-containing mucin-like hormone receptor-like 1 (EMR1 or alternative name 
F4/80), but also expression of MHCII, CD11b, CD14, Mer tyrosine-protein kinase (MerTK), 
sialic acid-binding immunoglobulin-like lectin F (SiglecF) and CD172a can be found20. The 
identification of MØs becomes even more aggravated, since they are well embedded into a 
tissue, where they adopt in addition a niche-specific phenotype and expression. For instance, 
CD11a and CD326 are more prominently expressed on lung MØs, but not on microglia, spleen 
and peritoneal MØs. In contrast to this, splenic MØs demonstrate higher expression of CD31, 
while peritoneal MØs are characterized by CD93 expression21. MOs represent a more 
phenotypically heterogeneous population generally characterised by Ly6C and CD11b 
expression and can be subdivided into Ly6C+CD11b+ and Ly6C-CD11b+ subsets. In addition, 
MOs can express surface markers such as CD64, CX3CR1 or MHCII, but also C-C chemokine 
receptor type 2 (CCR2), F4/80 (Fig. 1)22. However, the fact that MOs are able to differentiate 
into DC-like or MØ-like cells makes MO derived cells difficult to distinguish from DCs or 
MØs11,23,24. 
 
 
Figure 1. Phenotype of mononuclear phagocytic system cells. 
Surface markers, commonly used to identify cDCs, MØs, pDCs, MOs and MO-derived cells are shown for each 
MPS cell population. 
 
Even though the MPS represents a group of highly phenotypically similar cells, each cell 
population plays its specific role in tissue homeostasis. MØs are well known for their tissue 
sentience role21, where they are responsible for clearance of cellular debris and iron 
processing, regulation of tissue immune responses as well as being the first defence line 
against pathogens and environmental challenges25. In contrast to MØs, MOs mainly circulate 
in the blood, but can be also found in small amounts in healthy tissues 13,26,27. Specifically, 
during tissue damage or infection MOs infiltrate in huge numbers to the site of inflammation, 
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where they acquire a functionally distinct phenotype enabling host defense11,28. Similarly, 
pDCs are primarily found in the blood, but they can also infiltrate both lymphoid and non-
lymphoid organs19. The main role of pDCs is to produce large amounts of type I interferon 
(IFNI) during viral infection29-31. cDCs are non-lymphocytic motile cells located within the 
tissue at strategically important places to get in contact with cell associated antigens, bacteria 
or viruses. Consequently, cDCs are located in the spleen, which is highly rinsed by blood flow 
or found in the lymph node, where tissue draining lymphatic vessels enter the lymphoid 
system32-35. cDCs demonstrate the ability to process and present antigens following 
encounter with various pathogens and thus, their main function is to bridge the innate 
immune system to the adaptive part36. 
However, up to date the contrast between these distinct functions of the different myeloid 
populations within the MSP and coupled with the broad overlap in their phenotype create 
scientific challenges in the understanding of their individual specific contributions during 
pathogenic conditions, like infection or inflammation. 
 
1.1.2. cDC subsets 
 
cDCs can be further subdivided into so called cDC1 and cDC2 which can be discriminated 
based on specific transcription factor (TF) and surface marker expression13,17,18,35. Specifically, 
cDC1 are characterised by dependence on inhibitor of deoxyribonucleic acid (DNA) binding 2 
(ID2), basic leucine zipper activation transcription factor (ATF)-like transcription factor 3 
(BATF3), interferon regulatory factor 8 (IRF8) and by the expression of XCR1, CD24 and 
CLEC9A. cDC2 on the other hand are characterised by dependence on interferon regulatory 
factor 4 (IRF4), neurogenic locus notch homolog protein 2 (NOTCH2) and kruppel like factor 
4 (KLF4) and express CD11b or CD17218,37,38. 
Similarly to the before discussed MØs, the specific phenotype of surface markers of each cDC 
subset differs with their localization in the organism. It was shown, that lymphoid organs, 
such as thymus or spleen, contains two resident cDC1 and cDC2 subsets, which are described 
as CD8+CD4- and CD8-CD4+ cDCs, respectively (Fig. 2)37,39. In contrast, non-lymphoid tissue 
cDC subsets are phenotypically different and are identified as CD103+CD11b- cDC1 and CD103-
CD11b+ cDC2. Moreover, non-lymphoid tissues can also contain an additional tissue specific 
 Introduction  
 4 
cDC subset apart from the classical cDC1 and cDC218,37,40. Like this, the small intestine is 
equipped with a third CD103+CD11b+ cDC2 population, while the skin contains additional 
CD301b+ cDCs41-45. 
Therefore, any investigation aiming to understand the detailed contribution of each cDC 
subset in maintaining tissue homeostasis needs to consider, that each organ is equipped with 
two classical phenotypically and transcriptionally distinct cDC1 and cDC2 subsets, but may 
also contain additional cDC populations as a consequence of their adaptation to the niche-
specific requirements. 
 
 
Figure 2. Mouse cDC populations in lymphoid and non-lymphoid tissues. 
cDCs are subdivided into two main subsets cDC1 and cDC2 based on their TF and surface markers expression. 
Moreover, cDCs from lymphoid and non-lymphoid tissues can be distinguished by their specific phenotype as 
demonstrated by the indicated differentially expressed surface markers. 
 
1.1.3. Functional specialization of cDCs 
 
cDCs are the main antigen presenting cells, which regulate protective immune responses and 
the tolerance to self-antigens37,46,47. In this context, cDCs are located in tissues at strategically 
important places that permit close proximity and exchange with possible environmental 
influences. This allows cDCs to efficiently sample antigens and an after encounter, they 
migrate from the peripheral tissues via lymphatic vessels to the lymph nodes35,39. Here, cDCs 
present these antigens mainly via MHCII to naïve T cells and activate them35,39. Within the 
different cDC subsets, cDC1 is characterized by the key feature and unique ability to cross-
present various internalized antigens via MHCI molecules48,49. This unique feature predestines 
cDC1 to play an important role in tumour rejection as well as during viral infections50-53. 
Consequently, cDC1 are highly equipped with various receptors, such as toll-like receptors 
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(TLRs), C-type lectin receptors as well as chemokine receptors, that allow for the detection of 
particular pathogens, hence distinguishing cDC1 from cDC235,54. For example, cDC1 
specifically express TLR3 for detecting double-stranded viral ribonucleic acid (RNA), TLR11, 
which senses flagellin and/or profilin on parasites, and CLEC9A, which interacts with necrotic 
bodies55-58. Additionally, cDC1 also express TLR12 receptor, which is highly homologous to 
TLR11, and play an important role in controlling of Toxoplasma gondii infection57,59,60. 
Furthermore, cDC1 can shape immune responses by the secretion of specific cytokines. For 
instance, cDC1 are known to be the main source of interleukin (IL) 12, which is important in 
the defence against intracellular pathogens61-64. It was shown that IL-12, produced by cDC1 in 
response to Toxoplasma gondii infection, induces interferon gamma production by natural 
killer and T cells, which in turn activates various cell intracellular defence pathways, leading 
to the clearance of the pathogen63,65. 
Similarly, cDC2 are equipped with a broad variety of partially overlapping receptors, required 
for tracking various pathogens, such as TLR2, TLR4, TLR9, but specifically cDC2 express 
CD209a, RIG-I–like receptor (RLR) and Nod-like receptor (NLR)37,66. In contrast to cDC1, the 
cDC2 subset is more potent at activating CD4+ T cells than CD8+ T cells37,67. Moreover, cDC2 
are also highly involved in cytokine production and maintenance. As an example, they were 
identified as the essential IL-23 producers following bacterial flagellin administration or in 
response to Citrobacter rodentium infection68,69. Here, cDC2 locally shape immune reactions 
by producing IL-23, which, in consequence, induces IL-22 production by type 3 innate 
lymphoid cells (ILC3s), required for efficient pathogen clearance69. Other studies have shown, 
that cDC2 are involved in the promotion of T helper 2 (Th2) differentiation, by the production 
of IL-10 and IL-33 during lung inflammation70. The cDC2 role in Th2 induction as a key 
mediator was further demonstrated after subcutaneous immunization with ovalbumin along 
with papain or alum and in response to a protease allergen, as well as after infection with 
Nippostrongylus brasiliensis44,71. Finally, a potent implication of cDC2 in tissue homeostasis 
was demonstrated in mesenteric lymph nodes, where these cells maintained IL-17 producing 
CD4+ T cells72. In addition, cDC2 support skin IL-17 production by CD8+ T cells during 
commensal Staphylococcus epidermidis colonization73. 
Overall, specific cDC1 functions are better understood, since these cells are more easily 
distinguished from other myeloid cells by their surface markers and their targeted 
investigation is assisted by their TF dependency18,35,37. In comparison to cDC1, the specific 
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functions of the cDC2 population still remain less characterized, mainly due to the absence of 
available cell specific markers to target this more heterogeneous cell population even against 
ontogenetically less related MØs and monocyte derived DCs (moDCs)18,35,37,72,74. Therefore, 
studies investigating cDC2 function need to be always critically evaluated, like the data about 
the increased infiltration of cDC2 into the lungs of mice after ovalbumin induced asthma75, 
which was later challenged by a more recent study76. Here it was demonstrated, that moDCs, 
rather than cDC2, were the main infiltrating cells during asthma and producers of pro-
inflammatory cytokines76. 
Therefore, the distinct identification of different DC populations within the myeloid cell 
lineage and the detailed investigation of more specially defined subpopulations of cDCs or 
DC-related cells, like the kidney resident CD64+ cells, is an indispensable requirement for the 
detailed understanding of the individual contribution of each cell subset to tissue immune 
homeostasis. 
 
1.1.4. Development of cDCs 
 
Initially, it was believed that DCs formed a specific subset of MOs77-79. However, detailed DC 
lineage tracing unravelled that DCs represented an independent myeloid cell lineage, which 
develop from hematopoietic stem cells over a cascade of various bone marrow (BM) resident 
progenitors24,30,80-82. Macrophage and dendritic cell progenitors (MDPs) give rise to common 
dendritic cell precursors (CDPs), the first fully committed progenitors of the cDC lineage, 
which can be identified in tissue as lineage-CD115+CD135+CD117- cells. Moreover, they are 
also characterised by high expression of CLEC9A24. In the BM, these CDPs further differentiate 
into conventional DC precursors (pre-cDCs)83-85. These pre-cDCs can be identified in tissue as 
lineage−CD11c+CD135+CD172alo cells. Studies suggested that at the stage of pre-cDCs there is 
already a pre-commitment towards one or another cDC subset81,86,87. After differentiation 
these pre-cDCs egress from the BM and enter the blood stream. Here they do not circulate 
for a long time and settle down in different tissues, where they finally differentiate into fully 
mature cDC1 or cDC213,24. 
Development and survival of cDC are regulated by diverse endogenously expressed proteins 
and paracrine signalling molecules80. However, the basic network and detailed contribution 
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of these molecules responsible for development and survival are up to date only partially 
understood. Nevertheless, several factors were already identified to play a pivotal role during 
these processes, like fms-like tyrosine kinase 3 ligand (Flt3L)88,89. Others are granulocyte-
macrophage colony-stimulating factor (GMCSF), macrophage colony stimulating factor (M-
CSF) or CX3CL135,90-92. Beside these molecules, there are also others TFs and ligands required 
for development and/or survival of the specific cDC1 and cDC2 subsets. Like this it was shown, 
that cDC1 require IRF8, BATF3 as well as ID213,93, while cDC2 are dependent on IRF4, NOTCH2 
and KLF472,94,95. Moreover, ligands like transforming growth factor-beta (TGFβ) or 
lymphotoxin  were described as requirements for maintenance of cDC296-98. 
Nevertheless, it needs to be mentioned here, that even through it is generally accepted that 
cDCs evolved from the myeloid linage, recent studies have suggested that lymphoid 
progenitors may also contribute to the existing cDC2 pool99-101. This in turn raises the 
question, if the existing conception for the development of cDC is yet complete. Moreover, 
since the molecular basics for the development and survival are not fully understood more 
detailed investigations need to be done to elucidate the processes leading to the 
diversification of the DC lineage. 
 
1.2. Kidney structure, role and parameters of renal function 
 
The urinary system can be subdivided into the upper and lower parts (Fig. 3A). While the 
lower urinary tract is composed of the bladder and urethra, the upper urinary tract includes 
kidneys and ureters102. The kidneys are a pair of bean-shaped organs, located on the right and 
left side of the abdomen. Each kidney is highly supplied with blood, flowing through the renal 
artery and collecting in renal vein (Fig. 3B)103. Moreover, the kidney is covered by a thin 
fibrous layer, the kidney capsule, which protects it from trauma or damage. Each individual 
kidney can be further subdivided into two regions: an outer cortex and inner medulla103. The 
cortical columns and pyramids start in the cortex and extend into the medulla. The nephron, 
the functional and structural unit of the kidney, is located in both kidney zones (Fig. 3C). Each 
adult kidney contains thousands of nephrons103,104. The nephron by itself can be subdivided 
into renal corpuscle and renal tubules. The renal corpuscle is composed of glomerulus, a ball 
of blood capillaries, which is covered by Bowman’s capsule103. The renal proximal tubule 
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starts from the capsule, extends into the medulla, where it forms the so-called Henle’s loop, 
and comes back into cortex forming distal tubules103. Different distal nephron tubules join, 
forming a collecting duct, which enters the medulla, then the renal pelvis and finally fuses 
with the ureter103,105. 
 
 
Figure 3. The different compartments found in the murine kidney. 
(A) A diagram of the main parts that compose the murine urinary tract is shown. (B) A diagram of the main 
structures that make up the murine kidney is shown. (C) An overview of the main structures found in murine 
kidney is displayed. 
 
In the glomerulus various micro and macromolecules and partially serum are filtrated from 
the blood into the capsule, due to high water pressure in the blood103. This fluid from the 
capsule flows into the tubules, which are covered by capillaries. Here, most of the molecules 
are reabsorbed back, leaving behind toxic material, unnecessary salts, acids and excess water, 
which finally form the urine103. Due to the fact that the kidneys remove excess water, as well 
as salt and acids, they are responsible for the regulation of blood pressure and pH106-108. 
Moreover, the kidney participates in the synthesis of important metabolites. For instance, it 
has been demonstrated that kidney cells produce the active form of vitamin D, which is 
required for calcium and phosphorus absorption109,110. Aside the important role in regulating 
blood pH and salt homeostasis, the kidney is fully equipped for sensing and controlling the 
plasma volume as well as the mass of red blood cells111. Kidney tissue produces the hormone 
erythropoietin, which acts on BM to differentiate more red blood cells111,112. 
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Since a healthy kidney filtrates and removes toxic material as well as excess fluid from the 
organism, blood and urine are a commonly used materials to evaluate renal function113. Urine 
analysis can help to detect different kidney disorders, such as bladder infections, kidney 
stones, diabetes or chronic kidney diseases114.Typically, urine tests include a microscopic 
analysis of urine and dipstick test, measurement of protein amount in the urine, mostly 
albumin, and metabolic waste measurement, such as the muscle by-product creatinine or the 
liver waste product, blood urea nitrogen (BUN)113,114. Increased protein levels in the urine 
indicate that kidneys became leaky, while low level of creatinine and BUN in the urine is 
associated with filtration ratio reduction and kidney function disruption113. Blood tests are 
used to evaluate the amount of several metabolic waste products, such as creatinine or BUN. 
The accumulation of these molecules in the blood indicates any disruption of kidney 
function115,116. 
 
1.3. cDCs in the kidney 
 
 
1.3.1. Renal DCs 
 
The kidney contains a heterogeneous cDC population, which phenotypically and functionally 
significantly overlap with MOs and MØs117,118. Interestingly, the kidney exhibits typical non-
lymphoid tissue cDC1 and cDC2 subsets, but also a third, highly tissue specific cell 
population24,93,119. This specific population expresses CD64, a surface marker commonly used 
to separate MO derived cells from cDCs120,121. Classical renal cDCs are identified as 
CD45+CD11c+MHCII+CD64- cells and can be further subdivided as previously discussed before 
into cDC1 and cDC2 subsets based on their expression of additional surface markers, like 
CD24, CD103 or XCR1 and CD11b or CD17217,122,123. The kidney specific CD64+ population 
shares a MO/MØ phenotype as well as cDC characteristics17,24,124-126. CD64+ cells do not 
express zinc finger and BTB domain containing 46 (Zbtb46) TF, which is known to be restricted 
to DC lineage and some activated MOs, thereby supporting the notion that CD64+ cells are 
rather MØs37,125,127. In contrast, CD64+ cells differentiate, like other cDCs, from a CLEC9A+ 
progenitor and therefore indicative of the DC lineage origin24. In addition, these cells are able 
to stimulate in vitro T cells at a similar level as cDC2, further supporting the DC identity of 
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CD64+ cells24. Renal CD64+ cells can be further subdivided into F4/80hiCD11blo and 
F4/80loCD11bhi subsets24. F4/80hiCD11blo cells, like yolk sack derived MØs, are characterised 
by a long life-span, as these cells do not exchange between parabiotic partners or do so just 
poorly124,128. They also do not differentiate from DC progenitors in short-term transfer 
experiments24,124. F4/80hiCD11blo cells do not require FLT3 for their development and express 
low levels of the TFs IRF4 and IRF8, further supporting the notion that these cells are MØs 
rather than DCs. In contrast, the F4/80loCD11bhi subset differentiates from pre-cDCs in short-
term transfer experiments, depends on FLT3 and expresses high levels of IRF417,24. Taken 
together, the exact ontogeny of the unique kidney CD64+ cell population as well as 
F4/80hiCD11blo and F4/80loCD11bhi subsets is still an open question due to these opposing 
data. 
All kidney cDC1, cDC2 as well as CD64+ cells are located in the tubulointerstitium and absent 
from the glomeruli125,129-131. Specifically, the cDC1 subset preferentially seeds the cortex and 
is located around large blood vessels, while cDC2 subset is mainly found in the interstitium, 
close to smaller blood vessels122,125. In contrast, CD64+ cells can be found across the kidney, 
forming an extensive network91,125,132. Similar to cDC2, CD64+ cells express CX3CR1, which 
possibly is involved in the accumulation of these cells in the kidney91,131. In addition, renal 
tubular epithelial cells express high amounts of CX3CL1 suggesting that CX3CR1/CX3CL1 is 
important for the survival of these cells in the kidney91,133,134. 
The identification of this unique renal CD64+ cell population, demonstrating the described 
cDC and MØ characteristics, has raised the actual question about their ontogeny and tissue 
related function. Therefore, it is believed that beside the classical cDCs, CLEC9A+ progenitor 
derived CD64+ cells may represent an additional and distinct kidney specific cDC population, 
leading to questions as to why these cells are located mainly in the kidney and what their role 
in kidney immune homeostasis could be24. 
 
1.3.2. Function of renal DCs 
 
Even through, it is unquestionable today that renal DCs are critical for pathogen defence and 
tolerance to low-molecular-weight antigens, the elucidation of the specific functional role 
within the different renal DC subsets is still ongoing18,124,135. This functional attribution is even 
more complicated by the fact that in large part studies on renal DC function are focused on 
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CD11c+ MPS cells, which allow no distinct on conclusion on specific cDC subsets91,134,136-140. 
For instance, the important role of CD11c+ cells as renal immune sentinels was demonstrated 
in bacterial pyelonephritis, where in response to bacteria CD11c+ cells recruited neutrophilic 
granulocytes by producing chemokine C-X-C motif ligand 2 (CXCL2)136. In addition, renal 
CLEC9A+ progenitor derived cells play important protective role against systemic Candida 
albicans infection, by producing IL-23 in response to fungi, which further activates NK cells, 
which contribute to the elimination Candida albicans137. The protective role of CD11c+ cells 
was also investigated in nephrotoxic nephritis (NTN), mouse model of crescentic 
glomerulonephritis (cGC). Depletion of CD11c+ cells at early stage of NTN resulted in 
aggravated kidney damage. These CD11c+ cells isolated from NTN mice induced IL-10 
production in CD4+ T cells, indicating a possible CD11c+ cell protective mechanism, where IL-
10 was shown to be already associated with a better disease outcome during NTN141-144. 
Moreover, it was suggested that renal CD11c+ cells were important in the induction and 
maintenance of IL-17A production by renal resident gamma delta () T cells, which were 
shown to play a role at renal injury attenuation during cGC138. The important protective role 
of antigen presenting cells during the early stage of NTN/cGC was also confirmed using 
CX3CR1-deficient mice, demonstrating a reduced number of CD11c+MHCII+ cells in the 
kidney91,134. In contrast to this observed protective role, CD11c+ cell depletion at a later stage 
of NTN attenuated kidney damage. Such CD11c+ cells, isolated from mice at later stage of 
NTN, induced various pro-inflammatory cytokine production, like IL-2, TNFα, IFNγ, IL-17, IL-6 
in CD4 T cells, indicating that CD11c+ cells acquired a pro-inflammatory phenotype over 
time139. Additionally, CD11c+ cells were demonstrated to negatively contribute to sterile 
inflammation upon kidney ischemia reperfusion-injury by producing the pro-inflammatory 
cytokine tumour necrosis factor alpha (TNFα)140. 
A more subset-specific study of cGC demonstrated that cDC1 and cDC2 depletion prior to cGC 
induction attenuated kidney injury125. Although MØ and neutrophil numbers were similar in 
this investigation, T cells as well as Th17 memory cells were reduced in cDC1/cDC2 depleted 
cGC mice. Additional detailed analysis demonstrated that the cDC1 subset specifically plays 
the protective role by limiting the recruitment of neutrophils125,145. Moreover, another study 
demonstrated that the cDC1 subset fosters forkhead box P3 (FoxP3) expressing regulatory T 
(Treg) cell accumulation in the kidney145. Besides, it was also shown that during cGC cDC1 
expressed high levels of anti-inflammatory genes, while cDC2 produced the neutrophil 
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recruiting CXCL2 cytokine125. In contrast to the observed protective role of cDC1 subset in 
cGC, the same cell population acted in a pro-inflammatory manner by promoting renal 
damage in a murine model of adriamycin nephrotoxicity (AN). Here, a cDC1 mediated 
activation of CD8+ T cells and subsequent induction of kidney injury through cytotoxic CD8 T 
cells was observed122. 
Overall, the renal CD11c+MHCII+ population is a heterogeneous group of cells that play an 
important role in kidney immune homeostasis through their role in immune surveillance and 
the instigation of immunity or tolerance. However, depending on the disease model the cells 
behave ambiguously and could act pro- or anti-inflammatory. However, a multitude of studies 
are mainly focused on the CD11c+ cell bulk population and have not investigated the 
individual contribution of each cell type. Therefore, a more detailed analysis of the individual 
contribution of each CD11c+ cell subset, especially the CD64+ cell population, could help in 
future to explain their individual contribution for the kidney immune homeostasis. 
 
1.3.3. Renal DCs role during nephrotoxic AKI 
 
Cisplatin is a chemical compound and cytostatic drug commonly used to treat patients with 
various solid tumours146. However, cisplatin is also known to cause severe side effects, such 
as ototoxicity, gastrotoxicity, myelosuppression and nephrotoxicity146,147. In the kidney, 
tubular epithelia cells actively take up cisplatin resulting in cell death and the induction of 
AKI146,148. 
Since most of the studies, dealing with renal DC functions, investigated CD11c+ MPS cells as a 
homogenous group, the specific role of the different DCs during AKI is limited and largely 
unknown. However, it was shown that CD11c+ cells play a protective role during this 
pathogenesis149-151. Like this, inducible depletion of CD11c+ cells was shown to result in 
increased tubular necrosis, elevated blood BUN and creatinine levels during AKI16,149. 
Depletion of these cells prior to AKI also lead to increased leukocyte infiltration into the 
kidney, where neutrophils were the major population149. Even though, the extent of 
neutrophil infiltration has been shown to correlate with disease severity, their exact role 
during sterile kidney inflammation is not clear149-155. When CD11c+ cells were depleted at later 
time points of AKI, a disease protective effect was not observed, indicating that CD11c+ cells 
are important at the beginning of the disease149. The protective role of CD11c+ cells appears 
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to be mediated by the anti-inflammatory cytokine IL-10, which inhibits pro-inflammatory 
cytokine production and kidney fibrosis150,156,157. This observation was further supported by 
the use of mixed BM chimeric mice, lacking IL-10 in CD11c+ cells, which demonstrated a 
moderately increased disease severity compared with chimeric mice, still possessing 
functional CD11c+ cells150. In contrast to this, chimeric mice, lacking CD11c+ cells, showed a 
severe renal pathology, indicating that CD11c+ cells provided additional protection against 
cisplatin nephrotoxicity, beside their IL-10 production150. Interestingly, other studies 
observed no loss of protection against cisplatin nephrotoxicity in liposome-encapsulated 
clodronate treated mice or CX3CR1 deficient mice, which were characterized by a reduced 
number of renal CD11c+MHCII+ cells91,158. Nevertheless, both strategies to reduce the cells of 
interest in the kidney were not cell type specific, affected a broad variety of cells and are 
prone to unspecific side effects. For instance, liposome-encapsulated clodronate treatment 
affects all professional phagocytic cells, including MØs/MOs as well as DCs159. Similarly, 
CX3CR1 is not restricted to a specific cell type and can be found on MOs, pre-cDCs as well as 
on CD64+ cells and cDC2 subset. Moreover, CX3CR1 has been shown to play an important role 
in MO accumulation in the non-inflamed kidney as well as in ischemia–reperfusion injured 
kidney93,134,160-162. 
Although CD11c+ MPS cells were demonstrated to play a protective role during AKI, these 
investigations did not accommodate the heterogeneity of this cell system. Therefore, the 
individual contribution of each cDC subset, especially CD64+ cells, within this system is still 
not fully understood. Consequently, even the protective role of CD11c+ cells are indisputable, 
further detailed studies are still required to elucidate in the future the individual contribution 
of each cell population and their role during cisplatin nephrotoxicity. 
 
1.4. Transgenic mouse models to deplete DCs and MØs 
 
In vivo cell depletion mouse models are widely used in immunological studies and offer 
important tools to investigate cell specific functions in the development of various diseases163-
166. Classically, transgenic cell depletion mouse models are generated by inactivation of 
essential cell genes, locus specific integration of a DTR gene or locus specific integration of a 
recombinase gene127. 
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The first mouse models used to study cell specific functions were conventional gene knock-
outs to deplete a cell type of interest. These mouse models lacked one or more cell-specific 
TFs, cytokine receptors or cytokines, required for the specific cell development, homeostasis 
or migration of the cell to a particular tissue127,164,165. Consequently, such models were 
developed amongst others also to elucidate the functional impact of cDCs and MØs. Here, 
the most widely used knock-out mouse models for targeting DCs or specific cDC subset were 
FLT3L-, Batf3-, IRF8-, Notch2-, Klf4-52,89,167-169. Following the same strategy, several MØ 
depletion models relied on the disruption of the genes for colony-stimulating factor 1 (CSF1) 
or CSF1 receptor (CSF1R), which are primary regulators of survival, proliferation, 
differentiation and function of MØs170-175. Nevertheless, the drawback of these approaches 
became quickly obvious, because the elimination of the desired gene was not restricted in 
these mouse models and occurred systematically in all tissues and cells. Therefore, these gene 
deficient mice exhibited a global phenotype, without the possibility to link the observed 
phenomenon to a distinct cell type. 
Consequently, more advanced conditional cell depletion mouse models were developed on 
DTR-DT system basis, to prevent as much as possible the aforementioned side effects. DTR 
based mouse models are generated by knocking-in the DTR gene, which naturally does not 
occur in rodent cells, into a specific locus of choice within the murine genome, thereby making 
rodent cells susceptible to DT127,164,165. Basically, the DTR gene is placed in frame downstream 
of the promoter of the desired cell type specific gene, expressed at the mature state of the 
cell or one of its progenitors. In most of cell depletion mouse models, the disruption of the 
targeted gene is accompanied with the cell type specific expression of DTR under the control 
of the original promoter. Now, DT administration in such transgenic mice leads to the 
selective apoptosis of these DTR+ cells, due to the disruption of the cellular protein 
synthesis127,176,177. Therefore, selective cell depletion based on a DTR-DT system has a 
significant advantage over classical gene knock-out strategies, specifically if a heterozygote 
knock-in strategy is used or the knock-in does not disrupt the expression of the gene of 
interest. This is explained by the fact, that inducible cell depletion at a desired time point 
minimizes familiarization effects in the organism before an actual experiment starts176,177. 
Common examples to make use of this approach and to address cDC function are CD11c 
based mouse models, like CD11c-DTR and CD11c-DOG or CD11c-LuciDTR178-180. Other 
examples for cell-targeted depletion are Zbtb46-DTR, CD207-DTR, CD205-DTR, Clec9a-DTR or 
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XCR1-DTR-Venus82,181-185. There are several available MØ depletion models including CD11b-
DTR, CD64-DTR, CD169-DTR166,186-188. Even though DTR-DT based cell depletion mouse models 
became preferential over classical gene knock-out mouse models, they are still confronted 
with the problem and are criticized for their lack of specificity, because they also cannot solve 
the drawback, that one specific gene expression is rarely restricted to one particular cell 
population127. This became especially obvious, for the first CD11c-DTR model, because here 
DT injection led to death of the treated animals due to lack of specificity of the targeted 
gene189. Even with the approach to use BM chimeric animals to increase the targeted gene 
specificity for the CD11c-DTR mouse model or to generate more restricted CD11c.DOG mouse 
model, DT induced cell depletion was still not cDC specific and had a possible effect on pDCs, 
MØs, plasmablasts, activated T cells, NK cells or MOs127,164,178,189. Even the later generated 
BM chimeric Zbtb46-DTR mouse model, which was believed to be more specific than the 
CD11c based ones, was still impaired by the observation that beside the cDC lineage cell some 
activated MOs were also depleted30. 
Another approach to achieve conditional cell depletion mouse models, is based on Cre-loxP 
system derived from P1 bacteriophage190. Generally, these models are created by crossing 
two separately genetically manipulated mouse lines. One line is generated by knock-in a Cre 
gene into a specific locus of choice within the murine genome, thereby enabling the rodent 
cells to express this recombinase, which excises later any DNA sequence between two loxP 
sites190-192. Typically, the Cre recombinase is placed under the control of a cell-specific 
promoter, which is active at the mature state of the cell or one of its progenitors, allowing 
the targeting of all later differentiated progeny127. Similarly, the loxP sites need to be cloned 
into the genome of the second mouse line, thereby flanking a specific DNA sequence of 
interest. 
Initially, this system was used to condition conventional gene knock-outs to specific cell 
population193. This was achieved by cloning the Cre gene under the promoter of a cell 
population specific gene and to tag the gene for the actual cell depletion with the loxP 
sequences, which in turn ablate the desired cell population after the successful crossing. 
Typical examples for this strategy are Irf4fl and Notch2fl mouse models, to target the cDC2 
population, and IRF8fl for targeting cDC1167,194,195. 
Alternatively, such a cell depletion can be also made inducible, by crossing a Cre containing 
mouse line with any DTR containing mouse line, where the necessary constitutive DTR 
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expression is initially inhibited by the insertion of loxP sites tagged STOP cassette upstream 
of the transcriptional start side of the gene23. With this strategy, mouse models like Clec9a-
Cre, CD11c-Cre, XCR1-Cre, lysozyme M (LysM)-Cre, F4/80-Cre, CD64-Cre or CX3CR1-Cre, can 
be crossed with inducible DTR containing mouse lines to achieve DC, MO and MØ depletion, 
such as Rosa26-iDTR for instance resulting in Clec9a-Cre x Rosa26-iDTR mouse model allowing 
to target cDCs24,196-204. However, also here the limited differential expression of most of the 
genes set boundaries for the specificity of such models, as demonstrated by the results 
obtained after crossing LysM-Cre with Rosa26-iDTR, which allowed depletion of 83-98% of 
the MØs165,203. However, also in this example the presence of LysM is not restricted to MØs 
and can be also found in granulocytes and cDCs as well, supporting the notion that the pattern 
of one promoter activity is often insufficient to genetically define distinct cell populations198. 
To further improve this inducible DT depending Cre-loxP strategy, DTR expression can be 
restricted to a certain cell population by placing not only Cre, but also the Cre-inducible DTR 
gene downstream of another cell specific promoter204,205. Here, in contrast to the constitutive 
DTR expression before, now two specific promoter activities are required for cell depletion, 
which in turn can increase these mouse models specificity205,206. Such inducible DTR-DT 
system for the investigations of cDCs or other MPS cell subsets after crossing with suitable 
Cre containing models can be provided from CX3CR1-iDTR or CD11c-iDTR205,206. As an 
example, a study has generated CD11c-Cre x CX3CR1-iDTR mice, which demonstrated after 
DT treatment the specific deletion of small intestine CX3CR1hi cells without affecting 
significantly cDC1 or CX3CR1lo populations, even though all of these cells do express CD11c205. 
Finally, all these different approaches are strongly dependant on an accurate cell type-specific 
gene or transgene expression and the selection of the appropriate promoters127,207. 
Nevertheless, all presented strategies to deplete a specific cell population are so far in most 
studies just the closest approximation to the final aim to investigate their unique functions in 
the body. To overcome this limitations strategic combination of targeting more than two 
highly specific genes in combination could be a future method of choice, like the proposed 
split Cre-system, which could expand the targeting of specific subpopulations of cells for a 
more precise investigation of their role during normal and pathogenic processes208. 
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1.5. Considerations to use CD64 gene as a selection marker for specific 
depletion of DCs 
 
Leukocyte Fc receptor (FcRs) for IgG belong to the lg superfamily209,210. Up until now, four 
different classes of murine FcRs have been described, in particular CD64, also known as a 
high affinity Fc receptor for IgG type I (FcRI), CD32 (FcRIIB), CD16 (FcRIII) and CD16-2 
(FcRIV) based on the structural analysis. Moreover, FcRs can be also divided functionally 
into the activating (CD64, CD16 and CD16-2) and inhibitory (CD32) receptors209-211. CD64 is 
located in the Mus musculus genome at the reverse strand of 3rd chromosome, spanning the 
base pairs from 96,282,909 to 96,293,969 (Gene ID: 14129; ENS MUSG00000015947)212. The 
transcribed pre-RNA contains six exons and five introns. The sixth exon contains the stop 
codon, followed by the endogenous CD64 poly(A) sequence. Moreover, the coding sequence 
for the extracellular part is located at the beginning of the CD64 gene, while the coding 
sequence for the intracellular part is located at the end of the gene, upstream of poly(A) tail. 
Additionally, CD64 messenger RNA (mRNA) has two spliced variants, Fcgr1-201 and Fcgr1-
202, of which only the 2,589 base pare (bp) long Fcgr1-201 transcript is translated into the 
functional protein213. The expressed murine CD64 is a 72-kDa integral membrane 
glycoprotein, which contains 404 amino acids, composed of a short signal peptide (23 amino 
acids) and the functionally important CD64  chain214. The CD64  chain by itself is composed 
of an extracellular domain together with a membrane crossing helical domain and a 
cytoplasmic domain. Amongst them the extracellular domain is the biggest, composed of 273 
amino acids, and contains three disulphide bonded extracellular Ig-like domains. The smaller 
cytoplasmic part contains 84 amino acids and the smallest helical domain is composed of 23 
amino acids215. 
FcRs are expressed on broad variety of immune cells, which makes them potentially 
attractive as selection markers for cell identification. Specifically, CD64 is highly expressed on 
murine MØ, MO and MO-derived cells, but are also expressed at low levels on cDCs210,216,217. 
The CD64 expression level difference between moDCs and cDCs is so striking that several 
groups have proposed to use this marker for discrimination between moDCs and cDCs120,121. 
Furthermore, CD64 has been recently established as a MO/MØ depletion selection marker in 
at last two independent CD64 based cell depletion mouse models186,200. Interestingly, kidney 
tissue contains a bulk CLEC9A+ progenitor derived CD64 expressing population and recently 
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another CD64+ cDC population was identified in Listeria monocytogenes infected mice24,218. 
Therefore, a closer investigation of the functions connected to such subpopulations becomes 
of paramount interest to understand the specific role of DCs and specifically CLEC9A+ 
progenitor derived CD64+ cells in detail. This implicate amongst others the generation of new 
more subpopulation specific depletion models, because the existing ones affect all CD64+ 
cells, which makes it impossible to conclude any specific function related to these unique 
populations186,200. 
Nevertheless, the use of the CD64 gene to target specific cell populations for depletion bear 
the risk to induce a decrease in immune complex (IC)-induced inflammation, a reduction in 
antibody-depending killing of pathogens by MØs and impaired protection from bacterial 
infection in the organism219,220. As an example, CD64-/- mice showed an impaired clearance of 
bacteria during Bordetella Pertussis infection220. Specifically, CD64 favourably interacts with 
IgG2a opsonised pathogens, forming IgG2a-IC, and induces IgG2a-IC phagocytosis. Moreover, 
the CD64 accessibility to IgG2a-IC is regulated by monomeric IgG2a, which occupies the CD64 
recognition site221. Later investigations, supported the assumption that the amount of CD64 
bound monomeric IgG2a on the cell surface possibly influence the immune response to 
pathogens, because immunoglobulins lacking MT mice, treated with IgG2a, developed a 
IgG2a-induced systemic anaphylaxis220. Together, these data demonstrate that CD64 
mediates IgG2a-IC induced effector functions on mononuclear cells220. Therefore, any 
approach to disrupt the expression of this receptor need to be avoided. 
Furthermore, it needs to be taken under consideration, that the ligand binding CD64 alfa () 
chain interacts with the signal -transducing  chain dimer, which contains two immune 
receptor tyrosine-based activation motifs (ITAMs)211. If this interaction is damaged, the 
extracellular signal is not further transmitted into the immune cell, where it normally triggers 
biological responses210. In detail, ICs are recognised and bound by the Ig-like domains 1 and 
2, which form an Ig-binding motif. The Ig-like domain 3 is not critical in this process, however 
it is important in determining the specific and high affinity interaction of CD64 with IgG2a222. 
At last in human it has been shown, that the induced extracellular signal from the  chain is 
mediated by its transmembrane domain via the interaction with the  chain, which is most 
likely the same for murine CD64223. It was demonstrated, that the cytoplasmic tail of CD64 
does not have intrinsic enzymatic activity, but triggers immune cell activation, endocytosis 
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and phagocytosis224,225. Additionally, the human and murine CD64 cytoplasmic tail was shown 
to be important in intracellular trafficking of receptor-antigen complexes226,227. These data 
were further supported by the observation, that a serine residue of the cytoplasmic tail could 
be phosphorylated in vitro in response of phorbol-12-myristate-13-acetate (PMA) treatment 
in cell culture, leading to the conclusion of a possible involvement in signal transduction 
events after the binding of immune complexes228. 
Taken together, following the strategy to use CD64 as a selection marker to target renal CD64+ 
cells for later depletion can be an efficient way to investigate the specific role of these cells in 
kidney immunity. However, due to the broad expression of CD64 on other immune cells, the 
specific depletion of such subpopulations needs in any case the usage of more sophisticated 
approaches, like the combination with an inducible depletion of the cells using DTR-DT system 
and an expression restriction using Cre-loxP system. Independent of the chosen depletion 
strategy the disruption of the CD64 needs to be avoided in any case, to prevent any loss of 
function of the protein before cell depletion. 
 
1.6. Genome engineering 
 
Modern genomic engineering or gene editing offers the possibility of precisely manipulating 
genomic DNA (gDNA) of a living organism229-231. The technique encompasses insertions, when 
foreign DNA is incorporated into the genome, deletions, when specific parts of the gDNA are 
removed, or replacements, when DNA sequences are removed from the genome and foreign 
DNA is inserted at the same time232. The active engineering of living organisms at the drawing 
table, offers a huge potential for basic science, as well as for solving several medical needs or 
in the field of biotechnology. During the past decades genetic editing has been used for faster 
and easier generation of diverse genetic modified organisms and has become a promising 
tool for gene therapy232-238. 
The implementation of most genomic engineering techniques is made possible by sequence-
specific endonucleases, which create double-strand DNA breaks (DSBs) at the desired site of 
the genome, and is universally applicable to any cell type or organism that has DNA repair 
pathways236,239. This is desired, because these controlled induced DSBs activates in turn the 
endogenous host DNA repair pathways, resulting in non-homologous end-joining (NHEJ) or 
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homologous recombination (HR) repair mechanisms232. HR is a precise pathway, where a 
homologous sequence is utilized as a template for the repair of the DNA sequence at the 
break point240,241. In contrast, NHEJ uses a variety of enzymes to directly join two DNA ends 
in DSB. However, NHEJ is error-prone and has been shown to cause mutations at the repair 
site, which consequently, can affect gene expression242. Therefore, HR is the desired DNA 
repair pathway for generation of gene knock-in organisms or introduction of gene mutations 
in cell lines236,239,243,244. However, the HR repair pathway is a more complex, slower process 
and mainly active in S and G2 cell cycle phases245,246. Hence, it cannot be used for targeting 
post-mitotic cells such as neurons247,248. However, the HR mechanism is not fully understood 
to date, making its use sometimes unpredictable. One of the most commonly accepted HR 
pathway models is based on the following steps. First, DSB activates HR and the DSB DNA 
ends are modified, by forming a 3’-OH single strand DNA (ssDNA) region249,250. This ssDNA is 
covered by specific proteins forming a recombinase filament, which fuses into the 
homologous DNA molecule. This D-loop intermediate recruits the polymerase to extend the 
missing part of DSB ssDNA. Finally, the second DSB end is annealed to the extended D-loop 
forming a Holliday junction, which is later eliminated forming crossover or non-crossover 
products247. HR pathway uses donor DNA to restore lost information, as a template to repair 
the DSB247. This donor DNA can be a sister chromatid or foreign DNA, such as a plasmid 
containing a gene of interest or simply an oligonucleotide246. The aforementioned genetic 
changes can be introduced into gDNA during these repair mechanisms, with the prospect that 
these genetic modifications are later inherited by the daughter cells251. 
Due to the high interest and need of genome editing tools for various scientific and medical 
questions, several new editing technologies have been developed recent years, all with their 
own advantages and disadvantages236,239. In general, DSB causing genome engineering 
reagents can be divided into the group of protein-DNA interaction driven nucleases, which 
includes meganucleases, zinc-finger nucleases (ZFNs) and transcription activator-like effector-
based nucleases (TALENs)252-254. The second group of nucleases can be subdivided into the 
subgroup of RNA-guided nucleases, including the CRISPR/Cas9 system and targetrons255,256. 
The other subgroup comprising DNA-based guided systems, includes peptide nucleic acids, 
triplex-forming oligonucleotides and structure guided endonucleases239. 
Taken together, the discovery that various nucleases can be used as tools to precisely 
introduce changes at nearly any desired locus of the DNA of alive cell makes modern genome 
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editing tools highly attractive for generation of transgenic organisms as well as the 
investigation, prevention and treatment of various diseases. 
 
1.6.1. CRISPR-Cas9 technology as genome engineering tool 
 
Originally, the CRISPR/Cas systems was described to represent the adaptive immune system 
in prokaryotes by integrating short virus sequences in the CRISPR locus of the cell genome, 
allowing the cell to remember, recognize and remove the foreign genetic material257. 
Bacterial CRISPR/Cas systems, according to the phylogenetic analysis of the conserved Cas 
proteins, gene repertoires and arrangements in CRISPR-Cas loci, can be subdivided into the 
type I, II and III258. However, up to date the CRISPR/Cas system II from Streptococcus pyogenes 
provides the basic principle for CRISPR/Cas based genome editing257,259. So far it is the best 
characterised system and based on a single multifunctional Cas9 protein, CRISPR RNA (crRNA) 
and trans-activating CRISPR RNA (tracrRNA). Cas digests the invaders DNA into short 20 bp 
long DNA fragments, which are incorporated into the bacterial CRISPR locus between short 
palindromic repeats, forming new protospacers260. This CRISPR locus is then transcribed into 
long precursor CRISPR RNA (pre-crRNA), for which maturation tracrRNAs are required. 
TracrRNAs recognise repeated sequences on pre-crRNA, hybridise with them resulting in a 
complex, which is recognised and cleaved by RNase III261,262. Within the matured crRNA the 
protospacer, which is homologous to the targeted DNA is immediately followed by the 
protospacer adjacent motif (PAM) and serves as a guide for the Cas9 to bind and degrade the 
foreign DNA263. The recognised PAM sequence itself spans from 2 to 6 bp and is not conserved 
and depends on the species of the Cas9 protein264-266. Moreover, the PAM is an essential 
targeting component, not found in the bacteria genome and distinguishes host DNA from 
foreign DNA267. Additionally, it prevents the CRISPR locus from being targeted and destroyed 
by the nuclease. PAM is recognised by the Cas9 endonuclease, which creates than DSB 3 bp 
upstream of sequence259. The Cas9 protein itself is composed of two nuclease domains 
responsible for the cleavage of complementary and non-complementary DNA strand268. 
The CRISPR/Cas9 system as a gene editing tool has several advantages, it requires only few 
components and the protospacer sequence can be easily exchanged or adjusted to guide Cas9 
to the desired locus. Moreover, the only limitation to recognize any desired sequence within 
a genome lies principally on the accessibility of a PAM sequence at the 3’ end of the target 
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site268,269. Consequently, the CRISPR/Cas based gene editing was quickly adopted by several 
groups and utilised for targeting various species and cell types270-273. Finally, the great 
efficiency as well as specificity in gene editing applications, promoted CRISPR system as the 
most popular method in targeted gene editing, specifically in the development of new 
transgenic animals. 
 
1.6.2. CRISPR-Cas9 technology in transgenic mouse model generation 
 
Up till now, most of the targeted genome editing based mouse models have been developed 
using embryonic stem cells (ESCs), whose role as the “gold standard’ has been recently 
challenged by the CRISPR/Cas9 technology, mainly because this system has solved most of 
the limitations found in the ESC based methodologies232,274-276. Aside the increased HR 
efficiency, the CRISPR/Cas technology can be applied to all mammalian cells and all required 
reagents are commercially available277. The generation of CRISPR/Cas based transgenic 
mouse models can be achieved using several delivery strategies. Common to all are Cas9, the 
guide RNA (gRNA) and a target vector with the desired DNA modification surrounded by 
homology arms to be delivered successfully in vitro into mouse pronuclear256,278,279. Shortly 
after injection, the originating oocytes are implanted into pseudo-pregnant mice256,278,279. In 
contrast to the ESCs strategy, the whole process is less time consuming. This is mainly justified 
by the fact, that manipulation with CRISPR/Cas9 does not require cell culture incubation 
before the injection, selection and validation step after injection of the target cells. This allows 
the performance of all essential steps within one day230,280,281. Additionally, CRISPR/Cas9 
technology permits double and triple-mutant generation simultaneously, drastically reducing 
the time and cost for three transgenic mouse line development via ESCs and subsequent 
breeding to obtain homozygote mice for desired mutations281. Moreover, since the 
CRISPR/Cas system can be applied to all mouse lines, the mutation carrying founder mouse 
(FM) does not require any back breeding. However, the generated FM is mosaic and requires 
breeding for germline transmission280. Mice, with small genetic manipulations such as a single 
nucleotide exchange, can be even generated in not more than a month for subsequent 
investigations280. However, animals need to be first validated to exclude possible off-target 
effects and to confirm the correct targeting of the site, before the can be used for any 
experiment280. 
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In conclusion, CRISPR/Cas technology is an emerging genome editing tool, which has potential 
to replace completely the ESC-based transgenic animal development. Due to its versatile use, 
simplicity, robustness and efficiency this method greatly expands the opportunities to 
generate transgenic mouse models, like cell depletion models for basic and translational 
research. 
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2. Aims of the study 
 
1. Develop a new strategy for the specific ablation of the CLEC9A+ progenitor derived 
CD64+ subpopulation by generating a new inducible DTR expression based mouse 
model. 
2. Functionally validate the newly generated FM line by accessing DTR expression and 
cell depletion after DT treatment of CLEC9A+ progenitor derived CD64+ cells from 
Clec9a-Cre x CD64-LSL-2A-DTR mice in vivo. 
3. Establish the cisplatin induced AKI model and assess the function of DCs in AKI by using 
Clec9a-Cre x Rosa26-iDTR and XCR1-DTR-Venus.  
 
The results of this work will provide a new mouse model allowing to study the function of 
CLEC9A+ progenitor derived CD64+ cells by specific depletion of this subpopulation. 
Supplemented by cisplatin induced AKI based investigations, this offer a new tool to study DC 
functions not only during kidney steady state, but also under inflammatory conditions to 
understand better their role in modulating immune reactions. In a translational sense, 
understanding the role of renal CLEC9A+ progenitor derived CD64+ cells will help to gain a 
better understanding of the pathways underlying kidney inflammation and may help to 
develop an improved therapeutic strategy to treat kidney disease. 
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3. Materials and methods 
 
 
3.1. Materials 
 
 
3.1.1. Solutions 
 
Table 1. Stock Solutions 
Solution Ingredients 
Fluorescence-activated cell sorting 
 (FACS) buffer 
1X dulbecco’s phosphate buffered saline (PBS) (Merck, Darmstadt, 
Germany) with 1% (v/v) fetal bovine serum (FBS) (Merck, Darmstadt, 
Germany), 0.02% (w/v) sodium azide (Merck, Darmstadt, Germany) 
and 2 mM ethylenediaminetetraacetic acid (EDTA) (pH 8) (Thermo 
Scientific Waltham MA, United States of America (USA)) 
Lysis buffer 0.1 M Tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) 
(pH 8.0) (Merck, Darmstadt, Germany), 5 mM EDTA (pH 8.0), 0.2 M 
sodium chloride (NaCl) (Merck, Darmstadt, Germany) and 0.2% 
(w/v) sodium dodecyl sulfate (SDS) (Merck, Darmstadt, Germany) 
1X Tris-EDTA (TE) buffer 10 mM Tris-HCl (pH 7.5), 1 mM EDTA (pH 8.0) in water 
100% Percoll 90% (v/v) Percoll (GE Healthcare Bio-Science, Piscataway, New 
Jersey, USA) and 10% (v/v) 10X phosphate-buffered saline 
70% Percoll 70% (v/v) 100% Percoll in Hanks Balanced Salt Solution (HBSS) 
(Merck, Darmstadt, Germany) 
37% Percoll 37% (v/v) 100% Percoll in 1X PBS 
30% Percoll 30% (v/v) 100% Percoll in HBSS 
Hydrolysis buffer 0.25 M hydrochloric acid (Merck, Darmstadt, Germany) in water 
20X saline sodium citrate (SSC),pH7 3 M NaCl, 0.3 M trisodium citrate (Merck, Darmstadt, Germany) in 
water 
Maleic acid buffer, pH 7.5 0.1 M maleic acid (Merck, Darmstadt, Germany) and 0.15 M NaCl in 
water 
70% Ethanol 70% (v/v) ethanol (Merck, Darmstadt, Germany) in water 
Wash buffer I 2X SSC and 0.1% (w/v) SDS in water 
Wash buffer II 0.2X SSC and 0.1% (w/v) SDS in water 
Wash buffer III Maleic acid buffer with 3% (v/v) Tween 20 (Merck, Darmstadt, 
Germany) 
10X Phosphate-buffered saline 1.37 M NaCl, 27 mM potassium chloride (Merck, Darmstadt, 
Germany), 80 mM sodium phosphate dibasic (Merck, Darmstadt, 
Germany), 20 mM monopotassium phosphate (Merck, Darmstadt, 
Germany) in water 
1X Tris-acetate-EDTA (TAE) 40 mM Tris-HCl, 20 mM acetic acid (Merck, Darmstadt, Germany), 1 
mM EDTA in water 
Toothpick lysis buffer 7% (w/v) Ficoll PM 400 (Merck, Darmstadt, Germany), 0.5% (w/v) 
SDS, 5 mN sodium hydroxide (NaOH) (Merck, Darmstadt, Germany), 
5 mM EDTA, 0.025% (w/v) bromphenol blue (Merck, Darmstadt, 
Germany) in water 
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Digestion solution 200 unit (U)/milliliter (ml) collagenase IV (Worthington Biochemical 
Corporation, Lakewood, New Jersey, USA), 0.2 milligram (mg)/ml 
DNAse I (Roche, Basel, Switzerland) in Roswell park memorial 
institute (RPMI)-1640 medium (Merck, Darmstadt, Germany) 
6X Loading buffer 14% (w/v) Ficoll PM 400, 0.25% (w/v) bromphenol blue in water 
Denaturation solution 1.5 M NaOH, 0.5 M NaCl in water 
Neutralisation solution 1.5 M NaOH, 0.5 M Tris-HCl (pH 7.2), 10 mM EDTA in water 
Detection buffer 0.1 M Tris-HCl (pH 9.5), 0.1 M NaOH in water 
50% Glycerol solution 50% (v/v) glycerol (Merck, Darmstadt, Germany) in water 
Microinjection solution 10 mM Tris-HCl, 0.1 mM EDTA, pH 7.5 
 
3.1.2. Media 
 
Table 2. Media 
Solution Ingredients 
Lysogeny broth (LB) 0.17 M NaCl, 1% (w/v) tryptone, 0.5% (w/v) yeast extract in water 
Luria agar plate 1.5% (w/v) agar (Roth, Karlsruhe, Germany) in lysogen broth 
All solutions were sterilized by autoclavation. 
 
3.1.3. Plasmids and bacterial artificial chromosome (BAC) 
 
Table 3. Plasmid and BAC list 
Plasmid Sequence of interest Source 
Snap25-LSL-2A-green 
fluorescent protein 
(GFP) 
LSL, woodchuck hepatitis 
virus posttranslational 
regulatory element (WPRE) 
Addgene, Cambridge, Massachusetts, USA 
RPCIB731E08452Q CD64 gene Source BioScience, Nottingham, United Kingdom 
195 FrtneokanaFrt 
DTA* 
FrtneokanaFrt cassette Research Department "Molecular Medicine", AG 
Moser, Max Planck Institute (MPI) of Biochemistry, 
Plannegg-Martinsried, Germany 
GCDL-2A-DTR* 2A-DTR Department of Molecular Immunology, AG Garbi, 
Institute of Experimental Immunology, Bonn, Germany 
pBlueScript SK II (+)* Backbone Cardiovascular Physiology / Walter-Brendel Centrum, 
AG Brändli, Biomedical Center (BMC), Ludwig-
Maximilians-Universität (LMU) Munich, Germany 
pGem-T Easy Backbone Promega, Madison, Wisconsin, USA 
*the detailed plasmid sequences are provided in the Appendix 
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3.1.4. Antibodies 
 
Table 4. Antibodies 
AF488 - Alexa Fluor 488; AF594 - Alexa Fluor 594; AF647 - Alexa Fluor 647; AF700 - Alexa Fluor 700; APC – 
Allophycocyanin; BV421 - Brilliant™ Violet 421; BV605 –Brilliant™ Violet 605; BUV737 - Brilliant™ Ultraviolet 
737; BV785 - Brilliant™ Violet 785; Cy5.5 - Cyanine-5.5; Cy7 – Cyanine-7; FITC - Fluorescein isothiocyanate; PB 
– Pacific Blue; PE - Phycoerythrin; PerCP – peridinin-chlorophyll protein. 
Antigen Fluorophore Clone Catalogue 
number 
Dilution 
factor 
Provider 
Biotin PE Non 405204 1:100 BioLegend, San Diego, California, USA 
CD3epsilon (ε) FITC 145-2C11 100306 1:100 BioLegend, San Diego, California, USA 
CD3ε PB 145-2C11 100334 1:100 BioLegend, San Diego, California, USA 
CD3ε PE 145-2C11 553063 1:100 BD Bioscienes, San Jose, California, USA 
CD4 PB RM4-5 100531 1:400 BioLegend, San Diego, California, USA 
CD8a PB 53-6.7 100725 1:800 BioLegend, San Diego, California, USA 
CD8a BV605 53-6.7 100744 1:200 BioLegend, San Diego, California, USA 
CD11b APC/Cy7 M1/70 101226 1:200 BioLegend, San Diego, California, USA 
CD11b BUV737 M1/70 564443 1:800 BD Bioscienes, San Jose, California, USA 
CD11c AF488 N418 117313 1:200 BioLegend, San Diego, California, USA 
CD11c AF647 N418 117314 1:200 BioLegend, San Diego, California, USA 
CD11c APC/Cy7 N418 117324 1:200 BioLegend, San Diego, California, USA 
CD11c BV785 N418 117335 1:200 BioLegend, San Diego, California, USA 
CD11c PerCP/Cy5.5 N418 117328 1 :200 BioLegend, San Diego, California, USA 
CD16/CD32 
(2.4G2) 
Non 2.4G2 553142 1:50 BD Bioscienes, San Jose, California, USA 
CD16/CD32 
(2.4G2) 
Non 2.4G2 40-0161-
M001 
1:200 Tonbo bioscience, San Diego, California, 
USA 
CD24 BV605 M1/69 101827 1:200 BioLegend, San Diego, California, USA 
CD43 PE/Cy7 1B11 121218 1:300 BioLegend, San Diego, California, USA 
CD45.2 AF700 104 109822 1:200 BioLegend, San Diego, California, USA 
CD45.2 FITC 104 109806 1:200 BioLegend, San Diego, California, USA 
CD45.2 PE/Cy7 104 109830 1:200 BioLegend, San Diego, California, USA 
CD45R/B220 AF594 RA3-6B2 103254 1:200 BioLegend, San Diego, California, USA 
CD45R/B220 PB RA3-6B2 103227 1:400 BioLegend, San Diego, California, USA 
CD64 APC X54-5/7.1 139306 1:100 BioLegend, San Diego, California, USA 
CD64 PE X54-5/7.1 139304 1:100 BioLegend, San Diego, California, USA 
CD64 PE/Cy7 X54-5/7.1 139314 1:100 BioLegend, San Diego, California, USA 
CD115 BV605 AFS98 135517 1:200 BioLegend, San Diego, California, USA 
CD117 APC/Cy7 2B8 105826 1:300 BioLegend, San Diego, California, USA 
CD135 APC A2F10 135310 1:200 BioLegend, San Diego, California, USA 
CD161c/NK1.1 PB PK136 108722 1:100 BioLegend, San Diego, California, USA 
CD172a PerCP/Cy5.5 P84 144009 1:300 BioLegend, San Diego, California, USA 
F4/80 AF647 BM8 123122 1:100 BioLegend, San Diego, California, USA 
F4/80 AF700 BM8 123130 1:100 BioLegend, San Diego, California, USA 
F4/80 BV785 BM8 123141 1:100 BioLegend, San Diego, California, USA 
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HB-EGF Biotin polyclonal BAF259 1:100 R&D Systems, Minneapolis, Minnesota, USA 
MHCII AF700 M5/114.1
5.2 
107622 1:300 BioLegend, San Diego, California, USA 
MHCII PB M5/114.1
5.2 
107620 1:200 BioLegend, San Diego, California, USA 
Isotype PE/Cy7 MOPC-21 400125 1:100 BioLegend, San Diego, California, USA 
Isotype APC MOPC-21 400119 1:100 BioLegend, San Diego, California, USA 
Ly-6C AF488 HK1.4 128022 1:200 BioLegend, San Diego, California, USA 
Ly-6C BV605 HK1.5 128036 1:200 BioLegend, San Diego, California, USA 
Ly-6C PerCP/Cy5.5 HK1.4 128012 1:200 BioLegend, San Diego, California, USA 
Ly-6G APC 1A8 127614 1:200 BioLegend, San Diego, California, USA 
Ly-6G PerCP/Cy5.5 1A8 127616 1:200 BioLegend, San Diego, California, USA 
TER-119 PB TER-119 116232 1:100 BioLegend, San Diego, California, USA 
XCR1 BV421 ZET 148216 1:100 BioLegend, San Diego, California, USA 
 
3.1.5. Oligonucleotides 
 
All DNA oligonucleotides were purchased from Eurofins Genomics (Ebersberg, Germany). If 
not indicated in the text for specific primer combinations, the stated below melting 
temperature (Tm) was used for all experiments in this work. 
 
Table 5. DNA oligonucleotides for genotyping 
Primer Sequence 
BS49 5’ –AAA AGT TCC ACT TTC TGG ATG ATG A-3’ 
BS47 5’ –GGC TCT CTC CCC AGC ATC CAC A-3’ 
A65 5’ –TCA CTT ACT CCT CCA TGC TGA CG-3’ 
Rosa 1 5’ –AAA GTC GCT CTG AGT TGT TAT-3’ 
Rosa 3 5’ –GGA GCG GGA GAA ATG GAT ATG-3’ 
oIMR4982 5’ –AAG ACC GCG AAG AGT TTG TC-3’ 
iDTR-R BBO 0164 5’ –AAT AGG AAC TTC GTC GAG C-3’ 
mouse XCR1-a 5’ –CTA TCT TAA GAT TTC TCA GGG CCA GTC TAC-3’ 
mouse XCR1-b 5’ –CAG GAC AAT GGT AGA GAT GGT GGA AAA G-3’ 
mouse XCR1-c 5’ –CTG CAG CCA GAA AGA GCT TCA G-3’ 
CD64.3 5’ –TCA GGG TCA ACT TTG GGA AG-3’ 
CD64.4 5’ –CCA AAT GTA ACT TGG CTG GGT C-3’ 
CD64.5 5’ –GGT ACT CTG TTC TCA CCC TTC-3’ 
 
Table 6. DNA oligonucleotides for Southern blot probe amplification 
Primer Sequence Tm 
(Celsius 
(C)) 
Neo1 5’ –AAT ATC ACG GGT AGC CAA CG-3’ 
59 
Neo2 5’ –CAT TGA ACA AGA TGG ATT GCA CGC-3’ 
Probe1.1 5’ –ACT TCG CCC CAA AGT CCT AT-3’ 
58 
Probe1.2 5’ –TCT CGC TTA CTT GAG CAG CA-3’ 
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Table 7. DNA oligonucleotides for Gibson Assembly 
 
Table 8. DNA oligonucleotides for PCR amplification 
 
Table 9. DNA oligonucleotides for sequencing 
Primer Sequence  
SeqPrimer1 5’ –AGG GTT TTC CCA GTC ACG ACG TT-3’ 
SeqPrimer2 5’ –GAA CTG CAG CCA GAA AGA GC-3’ 
SeqPrimer3 5’ –TCA CGG GCT AAG AGA GGT TC-3’ 
SeqPrimer4 5’ –GGG CTG CAG GAA TTC GAT A-3’ 
SeqPrimer5 5’ –GGA AGT GTG GCC TTG TTG G-3’ 
SeqPrimer6 5’ –GGC AGC TGT GAA TGG GAA G-3’ 
SeqPrimer7 5’ –ACG GTA GGA AGG AGA GCA CA-3’ 
SeqPrimer8 5’ –CAA GAC TCT GGC AGG GAA AA-3’ 
SeqPrimer9 5’ –TGG GGC TTC TCA TGT TTA GG-3’ 
SeqPrimer10 5’ –GCA CTG ACA ATT CCG TGG TGT-3’ 
SeqPrimer11 5’ –GAG TTT ACG TCC AGC CAA GC-3’ 
SeqPrimer12 5’ –CTT TGC TCC TTC GCT TTC TG-3’ 
SeqPrimer13 5’ –TGC TCC TGC CGA GAA AGT AT-3’ 
SeqPrimer14 5’ –CCC GGT ACG TGG GAA TTA G-3’ 
SeqPrimer15 5’ –AAA GGG AGA TCC GAC TCG TCT G-3’ 
SeqPrimer16 5’ –ATG TGG AATGTG TGC GAG GC-3’ 
SeqPrimer17 5’ –GAT TAA TTG TCA ACA GGC TGC-3` 
SeqPrimer18 5’ –TCT TCG TCC AGA TCA TCC TG-3’ 
SeqPrimer19 5’ –AGC CAC TGC ACC CTT CTA AA-3` 
SeqPrimer20 5’ –TTA ATC TGG GCC ACA CCT TC-3’ 
SeqPrimer21 5’ –AGG GCA TGC AGA CAC AGA C-3’ 
SeqPrimer22 5’ –GAC CAG GCT TTG AGG TTT CA-3’ 
SeqPrimer23 5’ –GTG AGA TTC CTG CCC AGA AG-3’ 
SeqPrimer24 5’ –TCG CCT TCT TGA CGA GTT CT-3’ 
SeqPrimer25 5’ –GAC TGG GGA CCT GAA ACA GA-3’ 
Primer Sequence Tm (C) 
BL1 Fwd 5’ –GGG CGA ATT GGG TAC CTG AAC CCC TTC CTC CCA GTG ACA GTA CTG 
GGG CAC AAA CTT CCC AAA GTA TAA CTT CGT ATA ATG TAT GCT ATA CGA 
AG-3’ 
63 
Block1 Rev 5’ –GCT CCG GAC GGT GCT CCA GAA CCT CT-3’ 
DTR Fwd 5’ –GAG CAC CGT CCG GAG CCA CGA ACT TC-3’ 
63 
D Rev 5’ –AGG GGG GGC CCG GTA CGT GGG AAT TAG TCA TGC CC-3’ 
WPRE Fwd 5’ –GTA CCG GGC CCC CCC GAA ATC ACG TGA GCT TAT C-3’ 
57.4 
WPRE Rev 5’ –TTG CGG CCA TCT ATG CCA AGC TTT TAC-3’ 
F-Neo-F Fwd 5’ –GGC ATA GAT GGC CGC AAG CTT GAT ATC-3’ 
60.2 F-Neo-F Rev 5’ –TCG ATA CCG TCG ACC TAT ATT TGC TTT ATT TAA GAG TTG CAT GCC 
ATG GTC CCA CAG TTT CAG GGC CTG ACT GAT GAA GTT CC-3’ 
Primer Sequence Tm (C) 
Res_HOM1 Fwd 5’ –ATG GCG GCC GCA GAC AGA CAT GCA GGC AAA A-3’ 
59 
Res_HOM1 Rev 5’ –CAT GTC GAC CCA GGA TAA CCC CTG TCC TT-3’ 
Res_HOM2 Fwd 5’ –ATG GTC GAC AAG GCA GGA AAT AGT GTA GCC-3’ 
58 
Res_HOM2 Rev 5’ –CAT CTC GAG CTG ATG CTG TCT GCT GTG TTC-3’ 
DTR_Const Fwd 5’ –CTG AAC CCC TTC CTC-3’ 
59 
DTR_Const Rev 5’ –TAT ATT TGC TTT ATT TAA GAG TTG CAT GC-3’ 
CD64.1 5’ –ACA AAG ATG TCC CCT TGC AC-3’ 59 
CD64.2 5’ –CAA CAG GTG CTG GCA AGT AA-3’ 59 
CD64.6 5’ –ACC CTC CAA AAA CCA AAT CC-3’ 60 
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SeqPrimer26 5’ –TTT TGT CCT GCA TCC CTC TC-3’ 
SeqPrimer27 5’ –TGA GTT CCT GTC CTG ACT TCC-3’ 
SeqPrimer28 5’ –TTG GGG TGG CTA CTA ACC TG-3’ 
SeqPrimer29 5’ –TGA GAC TCC CTC CCC TTT CT-3’ 
SeqPrimer30 5’ –TGA GTC ACA GCG GCA TCT AC-3’ 
SeqPrimer31 5’ –CGT GGA TGC TTT TGT AGT GG-3’ 
SeqPrimer32 5’ –CAA GGT CAC CAG GAA CGT CT-3’ 
SeqPrimer33 5’ –TCT CAG GGC TCA GAA GTT GG-3’ 
SeqPrimer34 5’ –GCA TGA CAG AGG ACA GAA AGC-3’ 
SeqPrimer35 5’ –ACA GCA AGA ACA GCC ATT CC-3’ 
SeqPrimer36 5’ –AGT GGG AGG AAT GAG CTG G-3’ 
SeqPrimer37 5’ –ATG TGT CCG TGT GTC GAA TG-3’ 
SeqPrimer38 5’ –CAT ACG CTT GAT CCG GCT AC-3’ 
SeqPrimer39 5’ –TCA CTC ACA ACC ACC CGT AA-3’ 
SeqPrimer40 5’ –GCT TCA TTT TCT CGG TCC TG-3’ 
SeqPrimer41 5’ –GAT GAT TTT GGC TCC CAT CT-3’ 
SeqPrimer42 5’ –AGT CTA CGA GTT GTC AGT TTG A-3’ 
SeqPrimer44 5’ –TGT AAA ACG ACG GCC AGT-3’ 
SeqPrimer45 5’ –CAG GAA ACA GCT ATG ACC-3’ 
M13 rev (-49) 5’ –CAG GAA ACA GCT ATG ACC-3’ 
T3 5’-AAT TAA CCC TCA CTA AAG GG-3’ 
 
3.1.6. Mouse strains 
 
Table 10. Mouse strains 
Mouse strain Genetic 
modification 
Background Origin Genotyping 
Clec9a-Cre Cre recombinase 
gene knock-in into 
Clec9a locus; 
Genetic defect in 
the Clec9a locus; 
C57BL/6 24 Primers: BS49, BS47, A65 
Tm = 60 C 
Wild type PCR: 407 bp 
Mutated PCR: 597 bp 
Rosa26-iDTR DTR gene knock-in 
into Rosa26 locus; 
Genetic defect in 
the and Rosa26 
locus; 
C57BL/6 203 Primers: Rosa1, Rosa3, 
iDTR BB00164 
Tm = 61 C 
Wild type PCR: 600 bp 
Mutated PCR: 845 bp 
XCR1-DTR-
Venus 
DTR-Venus knock-in 
into XCR1 locus; 
Genetic defect in 
XCR1 locus; 
C57BL/6 Institute for 
Immunology, AG 
Krug. BMC Munich 
Planegg-Martinsried, 
Germany; 185 
Primers: XCR1-a, XCR1-b, 
XCR1-c 
Tm = 62 C 
Wild type PCR: 450 bp 
Mutated PCR: 450 bp 
Rosa26-
inducable 
enhanced 
yellow 
fluorescent 
protein (iEYFP) 
EYFP gene knock-in 
into Rosa26 locus; 
Genetic defect in 
the Rosa26 locus; 
C57BL/6 282 Primers: Rosa1, Rosa3, 
oIMR4982 
Tm = 60 C 
Wild type PCR: 320 bp 
Mutated PCR: 600 bp 
CD64-LSL-2A-
DTR 
LSL-2A-DTR-WPRE-
Frt-flanked 
neomycin resistance 
cassette (Neo) 
C57BL/6 Made in this work Primers: CD64.3, CD64.4, 
CD64.5 
Tm= 60 C 
Wild type PCR: 407 bp  
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knock-in into CD64 
locus; 
Mutated PCR: 561 bp 
C57BL/6 Non C57BL/6 Charles River, 
Wilmington, 
Massachusetts, USA 
Non 
 
3.1.7. Bacterial strains 
 
Table 11. Bacterial strains 
Bacterial strain Genotype Origin 
JM109 recA1, endA1, gyrA96, thi, hsdR17 (rK–
,mK+), relA1, supE44, Δ(lac-proAB), [F’, 
traD36, proAB, lacIqZΔM15] 
Promega, Madison, Wisconsin, USA 
MAX Efficiency 
Stbl2 
F-, mcrA, Δ(mcrBC-hsdRMS-mrr), recA1, 
endA1lon, gyrA96, thi, supE44, relA1, λ-, 
Δ(lac-proAB)  
Thermo Scientific, Waltham, 
Massachusetts, USA 
One Shot TOP10 F-, mcrA, Δ(mrr-hsdRMS-mcrBC), 
80lacZΔM15, ΔlacX74, recA1, araD139, 
Δ(ara-leu)7697, galU, galK, rpsL, (StrR), 
endA1, nupG, λ- 
Thermo Scientific, Waltham, 
Massachusetts, USA 
EL350 DY380 [(cro-bioA) <> araC-PBADcre] Research Department "Molecular 
Medicine", AG Moser, MPI of 
Biochemistry, Plannegg-Martinsried, 
Germany 
 
3.1.8. Analysis Software 
 
Table 12. Software used in the study 
Analysis Software Source 
BD FACSDiva BD Biosciences, Franklin Lakes, New Jersey, USA 
FlowJo 10 FlowJo LLC, Ashland, Oregon, USA 
GraphPad Prism 6 GrapgPad Software Inc., La Jolla, California, USA 
DNASTAR DNASTAR, Madison, Wisconsin, USA 
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3.2. Methods 
 
 
3.2.1. Molecular biology methods 
 
 
3.2.1.1. Absorbance based nucleic acid quantification and agarose gel 
electrophoresis 
 
DNA concentrations were measured using a NanoDrop 2000 Spectrophotometer (Thermo 
Scientific, Waltham, Massachusetts, USA) and the purity of the DNA was determined by the 
ratio of absorbance at 260 nanometre (nm) to 280 nm or 230 nm. Only samples showing a 
higher ratio than 1.8 (260/280) and 2.0 (260/230) were used for subsequent applications. 
Linear DNA fragments were separated on agarose gels. Based on the DNA fragment size an 
agarose content (Thermo Scinetific, Waltham, Massachusetts, USA) ranging from 0.8 - 1.5% 
(w/v) was used and visualized by the addition of Midori Green Direct dye (Biozym, Hessisch 
Oldendorf, Germany). In detail, a solution, containing the desired amount of agarose, was 
prepared with TAE buffer and heated up using a microwave until the agarose was dissolved 
completely. Next, Midori Green Direct was added directly to the cooled down solution or the 
solidified agarose gel was post-stained for 30 minutes (min) in the TAE buffer containing 
Midori Green Direct, with gentle shaking. Prior electrophoresis DNA samples were mixed with 
6X DNA loading buffer (Thermo Scientific, Waltham, Massachusetts, USA; New England 
BioLabs, Ipswich, Massachusetts, USA) and loaded into prepared wells. Electrophoresis was 
carried out in 1X TAE buffer. Depending on fragment size, the procedure was carried out at 
120 volts (V) or 90 V, until the separation of the individual bands was sufficient. Bands size 
was determined by adding appropriate DNA molecular weight standards to each gel (Gene 
ruler 1 kilobase (kb) DNA Ladder, GeneRuler 100 bp Plus DNA Ladder or Tracklt 1 kb Plus 
DNA Ladder (Thermo Scientific, Waltham, Massachusetts, USA), Quick-Load Purple 1 kb DNA 
Ladder (New England, BioLabs, Ipswich, Massachusetts, USA)). After electrophoresis, gel was 
visualized and pictures were made using UV-transilluminator (Intas, Göttingen, Germany) or 
Gel Doc XR+ Gel Documentation System (Bio Rad, Hercules, California, USA). 
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3.2.1.2. PCRs 
 
To amplify DNA fragments by PCR for subsequent cloning experiments or sequencing 
reactions Q5 Hot Start High-Fidelity DNA Polymerase (New England BioLabs, Ipswich, 
Massachusetts, USA) or GoTaq Long PCR Master Mix (Promega, Madison, Wisconsin, USA) 
were used according to the manufactures’ instructions. For PCR reactions, which did not 
require the use of high fidelity polymerase, like bacterial colony screening or genotyping PCRs, 
A-tailing GoTaq G2 Hot Start Polymerase (Promega, Madison, Wisconsin, USA) was used. All 
PCR reactions were performed using T-Advance Thermocycler or FlexCycler2 Thermocycler 
(Biometra, Göttingen, Germany) with deoxyribonucleotide triphosphates (dNTPs) from Roche 
(Basel, Switzerland) according to the manufacturer’s protocols for each polymerase with 
some modifications. For colony screening PCR, individual bacterial clones were picked with a 
plastic tip and directly placed into 30 microliter (l) LB for up to 5 min and 2.5 l of the 
obtained cell suspension was used for each amplification. In case of genotyping PCR, 1 µl of 
gDNA solution isolated from ear or toe biopsy tissues was used by default. Just for adenosine 
(A)-tailing, the individual amount of DNA used for the reaction was calculated at all times 
based on the required amount of insert for the optimal ratio between insert and vector 
backbone and incubated in a one-step reaction for 20 min at 72 C using only deoxyadenosine 
triphosphates (dATPs). All PCR products were analysed using agarose gel electrophoresis 
using 1.5% agarose gels. 
 
3.2.1.3. Primer design 
 
Primers, used in sequencing and PCR reactions, were designed using the free available online 
program Primer3 Input (version 0.4.0) (http://bioinfo.ut.ee/primer3-0.4.0/). To standardize 
the PCR conditions, the optimal temperature was always set at 60 C with a minimum at 57 
C and maximum at 63 C values. Primer size was chosen to be 20 nucleotide (nt) with a 
minimum and maximum length of 18 nt to 27 nt. In case of the amplification of PCR fragments, 
which were later used for cloning, the primers sequences were generated in the same way by 
Primer3 Input and the appropriate restriction enzyme recognition sites were placed at the 5’-
ends of forward and reverse primers, respectively. 
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Longer PCR primers (27-95 nt in size), which were used in Gibson Assembly cloning, were 
generated using New England BioLabs online tool (http://nebuilder.neb.com/). Different DNA 
sequences were supplied to the program for assembling primers with a minimal length of 18 
nt and minimal overlap between the fragments 15 bp. 
 
3.2.1.4. Restriction digestion and dephosphorylation of DNA 
 
All restriction endonucleases were purchased from New England BioLabs (Ipswich, 
Massachusetts, USA). Depending on the experimental requirements, different amounts of 
DNA was digested in 20 l, 50 l or 500 l volume using 20 U of enzyme per 1 microgram (g) 
of DNA. Restriction digestion reactions were carried out for 2 h, 5 h or overnight at the 
recommended temperature by the supplier for each restriction enzyme in the Innova 
incubator (Eppendorf, Hamburg, Germany). 
For dephosphorylation of all restriction digested DNA the alkaline phosphatase calf intestinal 
(CIP) (New England BioLabs, Ipswich, Massachusetts, USA) was used in a 40 l reaction mix, 
composed of 10 U CIP, 1X CutSmart buffer and restriction digested DNA. Reaction mix was 
incubated for 1 h at 37 C in the Innova incubator. 
 
3.2.1.5. Ligation of DNA fragments using Quick Ligation Kit, Gibson 
Assembly Master Mix Kit or pGEM-T Easy Vector System 
 
To ligate restriction digested DNA the Quick Ligation Kit (New England BioLabs, Ipswich, 
Massachutsetts, USA) was used and procedure was carried out according to the 
manufacturer’s instructions. Different ratios of linearized vector and DNA fragments were 
used, whereby the necessary amounts of DNA fragments were calculated using New England 
BioLAb online calculator (https://nebiocalculator.neb.com/#!/ligation). 
Gibson Assembly Master Mix Kit (New England BioLabs, Ipswich, Massachusetts, USA) was 
used to assembly the fragments previously amplified using long primers with Q5 Hot Start 
High-Fidelity DNA Polymerase (New England BioLabs, Ipswich, Massachusetts, USA). Briefly, 
1.25 l of DNA mixture, containing vector and DNA fragments, was mixed with 1.25 l Gibson 
Assembly Master Mix (2X). Reaction was carried out at 50 C for 1 h using T-Advance 
 Materials and Methods  
 35 
Thermocycler or FlexCycler2 Thermocycler. The ratios between vector and DNA fragments as 
well as their amounts were calculated using online available NEBuilder Assembly tool 
(http://nebuilder.neb.com/) and online calculator 
(https://nebiocalculator.neb.com/#!/ligation). 
The reaction mixture for pGEM-T Easy Vector System (Promega, Madison, Wisconsin, USA) 
was prepared according to the manufacturer’s protocol. Ratio between PCR product and 
vector was used 1:3 and the individual amounts were calculated using online calculator 
(https://nebiocalculator.neb.com/#!/ligation). 
After incubation all ligation mixtures were placed at -20 C or used immediately for 
transformation with competent bacteria. 
 
3.2.1.6. Measurement of bacterial cultures by optical density (OD) and 
bacterial glycerol stock preparation 
 
Cell density was measured using the Ultrospec10 (GE Healthcare Life Science, Massachusetts, 
USA). The OD around 0.6 was considered as an optimal cell density for further applications, 
representing bacteria growth in log phase. 
To prepare glycerol stock from bacterial cultures, 500 l of an overnight cell culture was 
transferred into cryovial and filled up with 500 l of 50% glycerol solution (Merck, Darmstadt, 
Germany). The tube was shaken several times to mix the solutions, snap frozen on dry ice for 
5 min and stored at -80 C. Bacteria were recovered by placing the tip directly into LB media, 
supplemented with proper antibiotic after scraping the top of a glycerol stock with the tip. 
Inoculated LB was placed into incubator adjusted to the optimal bacterial growing 
temperature. 
 
3.2.1.7. Transformation of bacteria by heat shock and electroporation 
 
In this work, different high-efficiency competent cells for transformation were used: JM109 
Competent cells, MAX Efficiency® Stbl2™ Competent Cells, EL350 and One Shot TOP10 
Chemically Competent Cells. 
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For transformation using heat shock 1 l of Gibson Assembly reaction mix, 2 l of pGEM-T 
Easy Vector System (Promega, Madison, Wisconsin, USA) reaction mix or 3-5 l of Quick 
Ligation reaction mix after ligation was used to transform 25 l of bacterial suspension. In 
detail, competent bacteria were placed into round bottom 2 ml Eppendorf tube, DNA was 
added directly to the bacterial suspension and the tube was gently swirled. This mixture was 
incubated for 20-30 min on ice followed by a 30 seconds (s) heat-shock at 42 C in the water 
bath (Memmert, Schwabach, Germany). After this treatment, the tube was placed back on 
ice for 2 min. Next, 250-900 l of LB was added to the cells and the tubes were incubated on 
a bacterial shaker with 150 revolutions per minute (rpm) for 1 h at the specific recommended 
temperature: 37 C for JM109 and One Shot TOP10 and 30 C for Stbl2 cells. Subsequently, 
cells were centrifuged for 30 s at 13000 rpm using a table centrifuge (Eppendorf, Hamburg, 
Germany) and the supernatant was removed except for approximately 100 µl, which was used 
to re-suspend the bacterial pellet. 
Transformation using electroporation was specifically used to introduce plasmid DNA into 
EL350 cells. For this purpose, 1 ml of the overnight cell culture was used to inoculate 50 ml 
fresh media. The flask, containing freshly inoculated media, was placed back into bacterial 
incubator and shook with 150 rpm at 32 C. During this process, the bacterial density was 
measured several times until OD was around 0.6. Then the flask was placed into an ice water 
bath to cool down and cells were transferred into a pre-chilled 50 ml conical tube and 
centrifuged for 5 min at 4200 rpm and 0 C in a Heraeus Multifuge X3R Centrifuge (Thermo 
Scientific, Waltham, MA, USA). The supernatant was removed completely and the residual 
cell pellet was first re-suspended in 1 ml ice cold sterile water and filled to a final volume of 
10 ml. Cells were centrifuged as described above and the procedure was repeated two more 
times to remove the remaining medium. After that, cells were re-suspended in 1 ml sterile 
ice-cold water and transferred into a pre-chilled 2 ml Eppendorf tube. Cells were centrifuged 
for 30 s 12700 rpm at 4 C, the supernatant was removed completely and the cells were re-
suspended in 250 l ice-cold sterile water. In a next step, the re-suspended cells were split 
into 5 pre-chilled 2 ml Eppendorf tubes and 1 μl of the DNA solution (150 ng- 1 g) was added 
to each tube. Suspension was mixed gently tapping the tube and transferred each into a pre-
chilled 1 mm cuvette, which was placed into Eporator (Eppendorf, Hamburg, Germany). The 
specific electroporation parameters were 1750 V, 200 ohms (), 25 farads (F). After 
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electroporation 1 ml LB was added to the cells and transferred into 2 ml Eppendorf tube. Cells 
were incubated for 1 h at 32 C with horizontal shaking at 150 rpm. Than bacteria were 
centrifuged for 30 s 12700 rpm, most of the supernatant removed, and bacteria re-suspended 
remaining left over media. 
In both methods the re-suspended bacterial cells were seeded after transformation on pre-
warmed Luria agar plates with the appropriate antibiotic, ampicillin (100 µg/ml), 
chloramphenicol (25 µg/ml or 12.5 µg/ml) or kanamycin (50 µg/ml) (Merck, Darmstadt, 
Germany). Plates with JM109 competent cells were incubated at 37 C and plates with MAX 
Efficiency® Stbl2™ competent cells were incubated at 30 C for 16-24 h, respectively. Plates 
with One Shot™ TOP10 chemically competent cells were placed into bacterial incubator at 32 
C for 24-36 h. 
 
3.2.1.8. Isolation of gDNA from mouse biopsies 
 
Fresh tissue material was taken from mice at the age of 4-5 weeks by animal care takers. 
Tissue material was placed directly into 500 l Lysis buffer, containing 0.2 mg/ml Proteinase 
K (Merck, Darmstadt, Germany). Digestion was carried on overnight at 56 C in a 
ThermoMixer C (Eppendorf, Hamburg, Germany) at 300 rpm. To remove undigested material, 
samples were centrifuged at 12700 rpm for 10 min at room temperature in a 5427R centrifuge 
(Eppendorf, Hamburg, Germany). The DNA containing supernatant was transferred into fresh 
tubes. Depending on the DNA purity requirements, DNA was extracted from the Lysis buffer 
according phenol/chloroform method or precipitated with isopropanol. 
For genotyping gDNA was precipitated from supernatant by adding 500 l 2-propanol (Merck, 
Darmstadt, Germany) and inverting the tubes several times. The precipitated gDNA was spun 
down at 12700 rpm for 10 min at room temperature using a 5427R centrifuge. The obtained 
gDNA pellets were washed with 500 l 70% ethanol, air dried at room temperature and 
dissolved in 100 l TE buffer. 
For Southern blot applications gDNA was extracted using the phenol/chloroform method. In 
detail, the gDNA containing lysate was mixed with equal volumes phenol:chloroform:isoamyl 
alcohol (25:24:1, v/v/v) (Merck, Darmstadt, Germany). Both solutions were mixed by shaking 
the tube for 10 s following centrifugation at 12700 rpm for 10 min at room temperature. The 
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tubes were carefully taken out without destroying the two formed phases. Then the top layer, 
referred as aqueous phase, was transferred to a fresh tube, mixed with an equal volume of 
chloroform (Merck, Darmstadt, Germany) and centrifuged again at 12700 rpm for 10 min at 
room temperature. From the two formed phases, the top layer (aqueous phase), was carefully 
collected. 3 M pH 5.2 sodium acetate (Merck, Darmstadt, Germany) to reach 10% (v/v) in the 
solution and 2 volumes of 99.8% ethanol (Merck, Darmstadt, Germany) were added to the 
aqueous phase and mixed. The obtained solution was kept on dry ice for 30 min and 
centrifuged at 12700 rpm for 30 min at room temperature in a 5427R centrifuge. The 
precipitated gDNA pellet was washed once with 500 l 70% ethanol, air dried and dissolved 
in 10-100 l 1X Loading Buffer or TE buffer. 
 
3.2.1.9. Plasmid and DNA fragment purification 
 
Depending on the individual needs, the following commercial plasmid DNA purification kits 
were used according to the manufacturer’s instructions: QIAprep Spin Miniprep Kit and 
HiSpeed Plasmid Maxi Kit (Qiagen, Hilden, Germany). Typical elution volumes were 30 µl for 
Miniprep isolations and 1 ml for Maxi Kit isolations. Plasmids were diluted in the water or TE 
buffer. 
If necessary DNA fragments, from PCR reaction and restriction digestions ranging from 40-50 
bp, were separated on agarose gels and cut out with a clean scalpel and extracted using 
QIAEX Gel Extraction Kit (Qiagen, Hilden, Germany). All steps were carried out according to 
the manufacturer’s protocol and the obtained DNA was diluted in 20 l DNase free water or 
TE buffer. 
DNA fragments ranging from 100-10 bp, obtained from PCR and other enzymatic reactions, 
were purified using QIAquick PCR Purification Kit (Qiagen, Hilden, Germany). The procedure 
was done according to the manufacturer’s instructions. All centrifugation steps were carried 
out on a 5427R centrifuge. Briefly, 5 volumes of Buffer PB was mixed with 1 volume of sample 
and applied on QIAquick spin column and centrifuged at 12700 rpm 30 s. After centrifugation, 
the column was washed with 0.75 ml Buffer PE, centrifuged at 12700 rpm for 1 min, followed 
by an additional centrifugation step at 12700 rpm, to remove residual liquid. The DNA was 
eluted in 30 l DNase free water, elution buffer or TE buffer. 
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3.2.1.10. BAC isolation 
 
BAC was isolated from overnight bacterial culture using reagents from HiSpeed Plasmid Maxi 
Kit (Qiagen, Hilden, Germany) with some specific adjustments to the supplied standard 
protocol. First, an overnight cell culture was transferred into 50 ml conical tubes and 
centrifuged for 5 min at 4200 rpm at 4 C in Heraeus Multifuge X3R Centrifuge. Supernatant 
was discarded, the cell pellet was re-suspended in 0.3 ml P1 solution and transferred to 2 ml 
fresh Eppendorf tube. Next, the tube was incubated for 5 min on ice and 0.3 ml P2 solution 
was added very slowly to cell lysate. The tube was gently inverted several times to mix 
solutions and left at room temperature for 5 min. Following, ice cold 0.3 ml P3 solution was 
added very slowly and the tube was gently inverted several times, until solutions were mixed. 
The cell lysate was further incubated for 15 min on ice with gently rocking on the ROCKER 2D 
digital (IKA, Staufen, Germany). Next, the lysate was centrifuged at 12700 rpm for 10 min at 
4 C in 5427R centrifuge. After centrifugation, the clear supernatant was transferred into new 
1.5 ml Eppendorf tube and ice cold 0.8 ml 2-propanol was added. The tube was inverted 
several times and placed on ice for 5 min, following centrifugation for 15 min at 4 C at 12700 
rpm. The supernatant was removed and 0.5 ml 70% ethanol was added to wash the pellet. 
Finally, the tube was centrifuged at 12700 rpm for 5 min at 4 C, supernatant was discarded 
and the DNA pellet air dried. The obtained DNA was re-suspended in 50 l TE buffer. 
Specifically for Southern blot applications, BAC DNA was extracted using the 
phenol/chloroform method, which in detail is described in the section “Isolation gDNA from 
mouse biopsies”. 
 
3.2.1.11. Plasmid screening using Toothpick analysis 
 
For Toothpick individual bacterial colonies were picked and wiped directly onto a 0.2 ml PCR 
tube walls after analysis after successful transformation and overnight incubation on Luria 
agar plates. 15 l of Toothpick lysis buffer was added to each tube and vortexed on the 
Vortex-Genie 2 for a few seconds. Next, the tubes were incubated for 10 min at 68 C in the 
T-Advance Thermocycler or FlexCycle2 Thermocycler. After this incubation step, the cell lysate 
was directly loaded on an agarose gel and DNA was separated using agarose gel 
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electrophoresis. Only colonies showing the presence of the desired insert cloned into plasmid 
DNA the desired DNA fragment were used for further analysis. 
 
3.2.1.12. HR in EL350 cells 
 
In this study, genetically a modified Escherichia coli strain EL350 was used, which is 
characterized by a heat inducible expression of three lambda () prophage recombination 
proteins. The expressions of these proteins are induced at 42 C and switch off growing cells 
at 32 C. HR was performed using EL350 cells, which already contained DNA of interest. Cells 
were placed into LB supplemented with appropriate antibiotic and were grown overnight. 1 
ml of overnight cell culture was used to inoculate 50 ml LB containing appropriate antibiotic. 
Cells were left incubator at 32 C 200 rpm and were let to divide until the OD 600 was around 
0.6. Red protein expression was induced by transferring 10 ml of EL350 culture into pre-
warmed 50 ml conical tubes and placing them into incubator for 15 min at 42 C shaking at 
200 rpm. The rest of the cell culture amount was incubated at 32 C and used as non-induced 
control. Immediately after incubation cells were cooled down by placing tubes into slurry bath 
and proceeded with electrocompetent cell preparation and electroporation. 
 
3.2.1.13. Southern blot and synthesis of Southern blot probes 
 
The following protocol was developed in this work. gDNA or BAC was digested with PsiI, EcoRI-
HF or KpnI-HF, restriction enzymes overnight in 500 l volume. The digested DNA was 
isolated with phenol-chloroform followed by ethanol precipitation. DNA pellets were air dried 
and re-suspended in 1X Loading Buffer and together with DNA Molecular Weight Marker II 
(Roche, Basel, Switzerland) loaded on a 0.8% agarose gel. After electrophoresis, the gel was 
incubated in hydrolysis buffer for 13 min at room temperature and washed shortly in water. 
Next, the hydrolysed gel was prepared for the transfer. Therefore, it was incubated in 
denaturation and neutralization buffer for 30 min each at room temperature with briefly 
rinsing the gel with water in between the incubations. To transfer DNA from the gel on a nylon 
membrane a transfer “sandwich” apparatus was set up as described as following. A tank was 
filled with 20X SSC solution and a platform was placed in the middle. Than the different layers 
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were placed using two filter papers soaked with 20X SSC, followed by the gel and covered 
with the nylon-membrane soaked with 2X SSC. On top of nylon-membrane 3 layers of filter 
papers soaked with 2X SSC were placed and topped with a stack of dry paper towels. All the 
levels were pressed together by a support weight. The final transfer “sandwich” apparatus 
was left overnight at room temperature using capillary forces to transfer DNA fragments from 
the gel onto nylon membrane. After successful transfer DNA fragments were cross-linked to 
the nylon membrane by exposing the membrane to UV light with CL508 UV-Cross-linker 
(Cleaver Scientific, Rugby, Warwickshire, UK). Next, the membrane was placed into pre-
warmed 10 ml DIG Easy Hyb solution (Roche, Basel, Switzerland) for 30 min and placed into 
an incubator at 42 C. After pre-hybridization step, old DIG Easy Hyb solution was replaced 
with fresh 4.5 ml pre-warmed digoxigenin(DIG)-labelled probe containing DIG Easy Hyb 
solution. The amount of the DIG labelled probe was calculated according to the DIG labelling 
efficiency. 9 l of Neo probe and 13.5 l of Probe1 was used for 4.5 ml DIG Easy Hyb solution. 
Afterwards, the membrane was incubated with the probe overnight at 42 C. Next day the 
membrane was washed twice in Wash buffer I for 5 min at room temperature, twice in Wash 
buffer II for 15 min at 68 C and once in Wash buffer III at room temperature for 3 min. DIG 
Luminescent Detection Kit (Roche, Basel, Switzerland) was used to detect DIG-labelled probe 
on the membrane. For this purpose, after washing, the membrane was placed into 1X 
Blocking solution for 30 min at room temperature and later incubated with anti-DIG-AP 
fragment (1:20 000 dilution) in 1X Blocking solution for 30 min room temperature. 
Subsequently, membrane was washed twice in Wash buffer III for 15 min at room 
temperature, incubated in the Detection buffer for 2 min at room temperature and placed in 
the reaction folder with disodium 3-(4-methoxyspiro {1,2-dioxetane-3,2′-(5′-chloro)tricyclo 
[3.3.1.13,7]decan}-4-yl)phenyl phosphate (CSPD) (1:100 dilution in Detection buffer). 
Membrane was placed in the incubator at 37 C for 10 min. After incubation nylon membrane 
was transferred to a fresh bag, sealed and exposed to X-ray film. 
To synthesize the DIG-label Southern blot DNA probes, a specific nucleotide sequence was 
PCR-amplified using appropriate sets of primers and PCR DIG Probe Synthesis kit (Roche, 
Basel, Switzerland). During this amplification, DIG-label was incorporated into the newly 
synthesized DNA. Using this method, the highly sensitive hybridization probes for Southern 
blot were generated, which was later used to detect low copy number DNA target sequences. 
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Neo1 and Neo2 primers with the Tm = 59 C were used for the Neo probe synthesis. Probe1.1 
and Probe1.2 primers with the Tm = 58 C were used for Probe1 probe synthesis. As a template 
during the study generated pGemT_Probe1 plasmid was used for Probe1 probe synthesis and 
pGemT_Neo plasmid for Neo probe synthesis. Probes were synthesized according the 
manufacturer’s instructions. 
 
3.2.1.14. BUN and creatinine measurement in the serum or plasma 
 
To evaluate kidney function and disease severity BUN and creatinine were measured in the 
murine blood. BUN levels in the serum were evaluated by Urea Assay Kit (Abcam, Cambridge, 
UK) according to the manufacturer’s instructions and the absorption was measured using a 
Spark® 10M multimode microplate reader (Tecan, Männedorf, Switzerland). In addition to 
this, plasma samples were sent for BUN and creatinine laboratory evaluation to our 
collaborator PD Dr. med. vet., Dr. med. vet. habil. Karin Weber at the Medizinische 
Kleintierklinik, LMU München. 
 
3.2.2. Flow cytometry 
 
 
3.2.2.1. Leukocyte isolation from spleen and kidney 
 
To analyse the leukocyte distribution and phenotype in the spleen and kidney, a single cell 
suspension from freshly tissue was prepared. In order to analyse the leukocyte distribution 
and phenotype in the kidney, mouse was overdosed with isoflurane (AbbBie Deutschland 
GmbH & Co. Ludwigshafen, Germany) and was perfused with cold PBS (Merck, Darmstadt, 
Germany) prior organ harvesting. Next, tissue homogenate was prepared by placing the 
harvested organ into Digestion solution for 30 min for spleen and 1 h for kidney at 37 C with 
shaking at 125 rpm. To remove undigested organ pieces, the obtained tissue homogenate 
was passed through 100 m cell strainers. Cells were washed with cold FACS buffer and 
centrifuged at 4 C for 5 min at 1350 rpm and supernatant was removed. Afterwards red 
blood cell lysis was performed on the isolated splenocytes by re-suspended the cell in 2 ml 
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red blood cell (RBC) buffer (Merck, Darmstadt, Germany) and incubated for 2 min at room 
temperature. Than cold FACS buffer was added to stop lysis and cells were centrifuged at 4 
C for 5 min at 1350 rpm. Supernatant was removed and cell pellet was re-suspended in cold 
5 ml FACS buffer. The isolated splenocytes were passed through 70 m cell strainers and 
proceed with cell counting and staining. 
In contrast to isolated cells from spleen, kidney leukocytes were enriched using low-speed 
iso-density percoll (GE Healthcare Bio-Science, Piscataway, New Jersey, USA) centrifugation 
method. After the digestion and washing, the cell pellet was re-suspended in 4 ml 70% percoll 
solution and transferred to a new 14 ml Conical tube. 4 ml of 37% and 30% percoll solutions 
were overlaid on top, without disturbing the individual layers. The tube was centrifuged for 
30 min at room temperature at 2000 rpm without breaking. Leukocytes were collected from 
70-37% interphase and once washed with FACS buffer. After supernatant was removed, pellet 
was re-suspended in 0.5 ml FACS buffer and proceeded with cell staining. 
 
3.2.2.2. Cell number and viability determination 
 
Prior the staining for flow cytometry, suspended in FACS buffer splenocytes were counted 
with Neubauer Chamber. Cell suspension was mixed 1:1 volume ratio with trypan blue 
solution (Merck, Darmstadt, Germany). Live cells were counted in four quadrats and the 
average cell per quadrat was multiple by dilution factor and 104 resulting in cell number per 
ml (cell/ml). 
CountBright Absolute Counting Beads (Thermo Scientific, Waltham, Massachusetts, USA) 
were used for counting renal leukocytes. Cells were calculated by adding 10 l 500 beads/l 
counting beads directly into the cells suspension prior sample acquisition on the flow 
cytometry machine. Cell concentration was calculated according the formula: 
 
𝑚 (𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠) ∗ 𝑛 (𝑎𝑑𝑑𝑒𝑑 𝑏𝑒𝑎𝑑𝑠)
𝑔 (𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑏𝑒𝑎𝑑𝑠) ∗ 𝑓(𝑠𝑎𝑚𝑝𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒,𝑙)
= 𝑐𝑒𝑙𝑙/𝑙 
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3.2.2.3. Cell surface marker staining using antibodies 
 
To identify and characterise different leukocyte cell populations within prepared single cell 
suspension, cells were stained with antibodies, conjugated with fluorescent dyes, against 
specific cell surface markers. First, Fc receptors were blocked by incubating cells in FACS 
buffer with CD16/CD32 antibody for 10 min dark at 4 C. Next, master mix of prepared 
antibodies in the FACS buffer was added directly on the cells. Cells were stained at 4 C in the 
dark for 20 min. After staining cells were washed three times with FACS buffer followed by 
centrifugation at 4 C 1350 rpm 3 min. After the last wash, cells were re-suspended in the 100 
l of FACS buffer. For live cell analysis, 4′,6-diamidino-2-phenylindole (DAPI) (Merck, 
Darmstadt, Germany) was added to the cells prior the acquisition. For fixed cells analysis, 
after surface marker staining cells were stained using Zombie dyes (Biolegend, San Diego, 
California, USA) according to the manufactures’ provided protocol and fixed with 2% 
paraformaldehyde (Thermo Scientific, Waltham, Massachusetts, USA) for 20 min at room 
temperature. After staining cells were washed three times with FACS buffer followed by 
centrifugation at 4 C 1350 rpm 3 min. After the last wash, cells were re-suspended in the 100 
l of FACS buffer and left at 4 C until data was acquired on BD Fortessa (BD Bioscienes, San 
Jose, California, USA). 
 
3.2.3. Animal Husbandry 
 
All animals were kept under specific pathogen free (SPF) conditions and routinely tested for 
pathogens. Clec9a-Cre, Rosa26-iDTR, XCR1-DTR-Venus, Rosa26-iEYFP, CD64-LSL-2A-DTR, 
C57BL/6 mice in the facility were kept under a 12 h light- 12 h dark light schedule. Food and 
water was available ad libitum. 
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3.2.4. In vivo methods 
 
 
3.2.4.1. CD64-LSL-2A-DTR mice generation using CRISPR-Cas9 technology 
 
After successful cloning of CD64-LSL-2A-DTR target vector the construct was sent to our 
collaborator Prof. Dr. Thorsten Buch in Switzerland and all further described steps were 
performed in his laboratory. Microinjection was done at the Institute of Laboratory Animal 
Science University of Zurich. 3-4 weeks old C57BL/6 female mice were superovulated prior 
embryos collection. For this purpose, the mice were intraperitoneal (ip) treated with 5 
international unit (IU) pregnant mare serum gonadotropin (PMSG) (Folligon, MSD Animal 
Health GmbH, Luzern, Switzerland) and 48 h later were injected with 5 IU human chorionic 
gonadotropin (hCG) (Pregnyl MSD Animal Health GmbH, Luzern, Switzerland). Superovulated 
female mice were mated overnight with C57BL/6 stud males and later zygotes were isolated 
and used for microinjections. Prior the procedure Cas9:crRNA:tracrRNA complex was 
assembled by incubating Cas9 protein (New England BioLabs, Ipswich, Massachusetts, USA) 
with tracrRNA:crRNA duplex (Integrated DNA technologies, Coralville, Iowa, USA) for 15 min 
at 37 C. The microinjection solution used to generate CD64-LSL-2A-DTR mice contained 30 
ng/µl EnGen™ Cas9 nuclear location signal (NLS), 0.4 picomole (pmol)/µl tracrRNA and 0.4 
pmol/µl crRNA and 10 ng/µl linearized CD64-LSL-2A-DTR target vector in microinjection 
solution. The CD64 locus specific sequences, used to guide Cas9:tracrRNA:crRNA complex, 
were the following: fw AAAGTTGACCCTGAAACTGT and rv ACAGTTTCAGGGTCAACTTT. Shortly 
after injection, oocytes have been implanted into a pseudo-pregnant mouse. All the zygote 
manipulations, including microinjection, culture and transfer into pseudopregnant foster 
female mice, were performed at the transgenesis core facility according to the standard 
mouse transgenesis protocols283 under license of the cantonal veterinary office in accordance 
with federal law. 
 
3.2.4.2. Blood collection and serum isolation 
 
The blood was collected from the heart of an isoflurane overdosed mouse into 2 ml syringe 
or into heparin coated 2 ml syringe (Hepatin-Nsturiu-25000-ratiopharma®, Ratiopharma, 
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Germany). The blood was transferred into a 1.5 ml tube and was kept on ice. All samples were 
centrifuged at 10000 rpm 4 C for 10 min, to separate blood cells from serum or plasma. Top 
clear layer, containing plasma or serum, was carefully collected and transferred to new tubes 
and snap frozen on dry ice. The samples were kept at -80 C until they were used. 
 
3.2.4.3. Depletion of DTR expressing cells 
 
To deplete DTR expressing cells, Clec9a-Cre x Rosa26-iDTR and XCR1-DTR-Venus mice were 
injected once and Clec9a-Cre x CD64-LSL-2A-DTR mice were treated twice, 24 h apart i.p. with 
a freshly prepared 4 ng/l DT solution (Merck, Darmstadt, Germany) at the dose of 25 ng/kg 
body weight (PBS Merck, Darmstadt, Germany) was used as control. All animal experiments 
were performed at The Core Facility Animal Models at the BMC of the LMU, Munich, in 
accordance with national and institutional guidelines for animal care. 
 
3.2.4.4. AKI induction 
 
AKI experiments were performed using adult Clec9a-Cre x Rosa26-iDTR, XCR1-DTR-Venus and 
C57BL/6 mice at the age of 8-12 weeks old. AKI was induced in the animals by injecting i.p. a 
single dose of freshly laboratory prepared (2 mg/ml) cisplatin (Merck, Darmstadt, Germany) 
or commercial available (1 mg/ml) cisplatin solution (Petah Tikva, Israel) at the concentration 
of 10 – 20 mg/kg body weight, depending on the performed experiment, or 0.9% NaCl 
(Fresenius Kabi Deutschland GmbH, BAD Homburg, Germany). The 2 mg/ml cisplatin solution 
was prepared by sonicating 3 min, followed by 30 min stirring at 35 C. Each animal was 
weighted and scored using an observation scoring system, evaluating mouse behaviour, fur 
condition, breathing, body weight lost, posture and excretion. Mice were monitored every 
morning/evening. Individual symptom scores were added together to give an overall 
symptom score and based on this score different actions were taken. Mice, which were given 
20 points, were terminated immediately. All AKI experiments were performed at The Core 
Facility Animal Models at the BMC of the LMU, Munich in accordance with national and 
institutional guidelines for animal care. 
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3.2.5. Statistical analysis 
 
Statistical analysis was performed using Prism 6 (GraphPad) program. Results with p value 
smaller than 0.5 was evaluated as statistically significant. In all analysis, unpaired Student’s t-
test with Welch’s correction was used. 
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4. Results 
 
 
4.1. CD64-LSL-2A-DTR mouse model generation 
 
 
4.1.1. CD64 expression on cDC progenitors 
 
The main aim of this thesis was the generation of a novel mouse model, allowing the selective 
depletion of CLEC9A+ progenitor derived CD64 expressing cells, in particular their renal CD64+ 
population. It was planned to achieve this by knock-in a Cre-inducible DTR gene in the CD64 
reading frame of a wild type mouse genome. To restrict later the DTR expression specifically 
to the renal CLEC9A+ progenitor derived CD64+ cells, a DC lineage Clec9a-Cre mouse line was 
planned to cross with this new generated DTR carrying mice. With this strategy DTR 
expression would be restricted to DCs, because a study has shown that Clec9a-Cre mice 
allowed the specific tracking of CLEC9A+ CDP derived cells, which was specifically 
demonstrated for crossing with Rosa26-iEYFP reporter mice24,282. In consideration of the fact, 
that Clec9a promoter is active in CDPs as well as in pre-cDCs24, it was mandatory to exclude 
the possibility, that DC progenitors express CD64, which would resulting in an unspecific 
depletion model. Thus, the CD64 expression was first investigated on the cDC progenitors 
using the Clec9a-Cre x Rosa26-iEYFP mice, which allow tracking of the CLEC9A+ expressing or 
CLEC9A+ progenitor derived cells based on EYFP expression. The BM of 
Clec9aCre/CreRosa26EYFP/EYFP mice were investigated by FACS for CD64 expression on EYFP 
positive and negative cDC progenitors pre-cDCs and CDPs as well as on MDPs (Fig. 4A). As 
shown in figure 4B, MDPs expressed similar levels of CD64 compared to MOs, used as a 
positive control17,121. Importantly, CD64 expression was not found on pre-cDCs or CDPs (Fig. 
4B). However, it was shown that not all pre-cDCs and CDPs are EYFP labelled in these mice. 
Nevertheless, an EYFP- progenitors transfer study has demonstrated that EYFP-lin-
(lymphocyte antigen 76 (ly76 also known as Ter119), NK1.1, CD4, CD8, CD45R, CD11b, 
MHCII)CLEC9A+ cells are able to give rise to EYFP+ cells and thus, suggesting that EYFP+ and 
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EYFP- CDPs are not qualitative different24. In line with this previous data, there was no 
difference detected for the CD64 expression between EYFP+ and EYFP- CDPs in this study too 
(Fig. 4B). These data clearly demonstrated that CDPs and pre-cDCs isolated from 
Clec9aCre/CreRosa26EYFP/EYFP mice do not express the CD64 making this model suitable for the 
later crossing. 
 
 
Figure 4. CD64 expression analysis on cDC progenitors. 
(A) Gating strategy to identify MOs (CD115+CD11b+), pre-cDCs (lin-(CD3, CD4, CD8, Ter119, NK1.1, CD45R)CD11b-
CD11c+CD135+CD172alo) as well as MDPs (lin-CD11b-CD11c-MHCII-CD115+CD135+CD117-) and CDPs (lin-CD11b-
CD135+CD117+) in BM from Clec9aCre/CreRosa26EYFP/EYFP mice by flow cytometry is shown. Cells from BM in 
Clec9aCre/CreRosa26EYFP/EYFP mice were stained with antibodies against indicated surface markers. The numbers in 
the dot plots indicates the percentage of the cells within the indicated gates. (B) pre-cDCs, CDPs and MDPs were 
analysed for CD64 expression. 
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4.1.2. In silico analysis of CD64 target region for DTR gene knock-in and design 
of DTR construct 
 
The basic requirements for the successful generation of the novel DTR expressing transgenic 
mouse model were the knock-in of DTR gene into CD64 locus reading frame and the 
prevention of undesired “neighborhood effects”. Therefore, the CD64 locus (gene ID14129) 
itself and all relevant genes, in close proximity upstream and downstream of the possible 
insertion site, were analysed in advance in silico. As indicated in figure 5A, CD64 gene is 
located between two histone cluster sequences and n-TNgtt4 nuclear encoded tRNA 
asparagine 4 (anticodon GTT), located within a 13-28 kbp distance from the CD64 gene. In 
detail, histone cluster 2, H3b sequence (geneID: 319154) was found 13,4 kbp and histone H2B 
type 2-B sequence (geneID: 319189) was found 12,7 kbp downstream of CD64 gene 3’ 
untranslated region (UTR) sequence. Additionally, 28,1 kbp upstream of the CD64 5’-UTR a n-
TNgtt4 nuclear encoded tRNA asparagine 4 (anticodon GTT) (geneID: 102467475) sequence 
was found, making it most unlikely that knock-in into CD64 locus would cause undesired side 
effects by affecting other important gene expression. 
 
 
Figure 5. Analysis of CD64 region for repair construct insertion. 
(A) Part of Mus musculus 3rd chromosome is shown spending the region of 96265000 - 96325000. In the track, 
dark triangles indicate histone cluster sequences derived by automated computational analysis. (B) Mus 
musculus CD64 gene and mRNA is shown. In both tracks, black arrow indicates the CD64 gene; the grey arrows 
represent different CD64 exons. 
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Since it was described, that CD64 gene deficient mice demonstrate a decrease in immune 
complex-induced inflammation, a reduction in antibody-depending killing of pathogens by 
MØs and impaired protection from bacterial infection, it was taken in consideration to place 
the DTR gene downstream of the CD64 protein coding sequence (CDS)219,220. With this 
strategy, it was decided to fuse the DTR gene with CD64 without disrupting or affecting the 
gene expression. In detail, the approach was to combine CD64 with DTR by replacing the 
endogenous stop codon within the 6th exon of CD64 at position 96, 284,276 – 96,284,278 (Fig. 
5B), resulting in a polycistronic mRNA. To ensure the production of equimolar levels of both 
genes a “self-cleaving” 2A peptide was placed between CD64 and DTR genes. To increase DTR 
expression specificity, LSL was planned to be cloned in front of the 2A-DTR sequence. To 
stabilize the transcribed mRNA and to further increase gene expression efficacy, WPRE was 
designed to be cloned downstream of DTR. As a matter of course, it was taken into the 
consideration to place all these elements, LSL, 2A sequence, DTR, WPRE respectively in frame 
with CD64 CDS. To keep at this point both possibilities for generating knock-in mice, using HR 
in ESC or CRISPR-Cas9 technology, a Neo cassette was additionally cloned behind the WPRE 
sequence. A schematic diagram illustrating the final design of the knock-in DTR construct, 
containing LSL, 2A, DTR, WPRE and Neo cassette sequences, is shown in figure 6. 
 
 
Figure 6. Structure of DTR construct. 
Schematic overview of the 3882 bp DNA integration construct. All essential sequences, required for efficient 
DTR expression, are shown and indicated in 5’-3’ order as boxes with the individual sequence name and length. 
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4.1.3. Cloning of DTR construct (pBlueScript_LSL_2A_DTR_WPRE_Neo plasmid 
generation) 
 
To generate the designed DTR construct, I took advantage of Gibson Assembly method. Since 
the Gibson Assembly efficiency drops as the number of used DNA fragments of interest 
increases, synthesis of DTR construct was done in a two-step process. First, LSL cassette and 
2A-DTR sequence were assembled into empty pBlueScript SK II (+) vector, generating the 
intermediate pBlueScript_LSL_2A-DTR plasmid. This was achieved by capturing a 590 bp 
fragment containing LSL cassette from Snap25-LSL-2A-GFP target vector and a 687 bp 2A-DTR 
sequence from GCDL-2A-DTR plasmid by PCR (Figure 7A, B). The forward primer to amplify 
LSL cassette sequence was designed to have a homology with the vector backbone and the 
fragment, containing the LSL cassette. Moreover, it contained an additional 50 nt sequence, 
which was homologous to 50 bp upstream of the endogenous the CD64 stop codon. This 50 
bp sequence was later used as a guide sequence for the replacement of the CD64 endogenous 
stop codon. In detail, pBlueScript SK II (+) vector was linearized using KpnI-HF restriction 
enzyme and assembled with the final 711 bp 2A-DTR PCR and 663 bp LSL PCR products. To 
confirm correct assembly, isolated plasmid DNA was restriction digested and analysed by 
agarose gel electrophoresis (Fig. 7C). Only plasmid isolations with the expected fragment 
pattern was sent for Sanger sequencing analysis using primers SeqPrimer 2-4 and was used 
for the next cloning step. A schematic overview of the finally obtained plasmid is shown in 
figure 7D. 
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Figure 7. Generation of pBlueScript_LSL_2A-DTR plasmid. 
(A) PCR of LSL cassette fragment using primers BL1 and Block1. A representative agarose gel electrophoresis 
image is shown. The expected 633 bp PCR product (lane 3), marker (lane 1) and non-template control (NTC) 
(lane 2) are indicated. (B) PCR of 2A-DTR fragment using DTR and D primers. A representative agarose gel 
electrophoresis image is shown. The expected 711 bp PCR product (lane 3), marker (lane 1) and NTC (lane 2) are 
indicated. (C) Restriction digestion of pBlueScript_LSL_2A-DTR plasmid. A representative agarose gel 
electrophoresis image of all plasmid DNAs isolated from different colonies after ScaI-HF/BbsI digestion is 
shown. Clone 4 (lane 5) showed the expected digestion pattern of 2181 bp, 1118 bp, 561 bp and 432 bp 
fragments. (D) Plasmid map of pBlueScript_LSL_2A-DTR. All ScaI-HF and BbsI restriction sites, to confirm the 
integrity of the plasmid, are indicated. The calculated fragment sizes after ScaI-HF/BbsI digestion of 432 bp, 
561 bp, 1118 bp and 2181 bp are shown. 
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Following the same strategy, WPRE sequence and Neo cassette were combined into the newly 
created pBlueScript_LSL_2A-DTR plasmid in the second step of assembly process. Therefore, 
the 864 bp fragment containing WPRE sequence was amplified by PCR from Snap25-LSL-2A-
GFP target and the 1864 bp fragment containing Neo cassette from 195 FrtneokanaFrt DTA 
plasmid (Fig. 8A). Analogue to the first step, reverse primer to amplify Neo cassette was 
designed to include a 50 nt sequence, which was homologous to the 50 bp downstream of 
the endogenous CD64 stop codon. The pBlueScript_LSL_2A-DTR plasmid was linearized using 
XhoI restriction enzyme and the WPRE and Neo cassette sequences were assembled into the 
linearized vector. Different individual bacterial clones were picked and verified by colony 
screening PCR for correct assembly (Fig. 8B). Only clones showing the expected fragment size, 
were used for pBlueScript_LSL_2A-DTR_WPRE_Neo plasmids isolation and sent for Sanger 
sequencing using primers SeqPrimer 1-4, SeqPrimer 9-18, and M13 rev (-49) to confirm the 
correct assembly. The validated pBlueScript_LSL_2A-DTR_WPRE_Neo plasmid contained the 
full length DTR construct, composed of LSL cassette, 2A sequence, DTR gene, WPRE sequence 
and Neo cassette is shown in figure 8C. 
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Figure 8. Generation of pBlueScript_LSL_2A-DTR_WPRE_Neo plasmid. 
(A) PCR of WPRE and Neo cassette fragments using WPRE Fwd/WPRE Rev and F NeoF Fwd/F Neo F Rev primers 
respectively. A representative agarose gel electrophoresis image is shown. The expected 887 bp of WPRE and 
1937 bp of Neo PCR products, marker (lane 1) and NTC (lane 3, 5) are indicated. (B) Colony screening PCR to 
confirm pBlueScript_LSL_2A-DTR_WPRE_Neo integrity. A representative agarose gel electrophoresis image is 
shown. The primer combination SeqPrimer10 and WPRE Rev (Tm 57.4 C) were used to identify positive clones. 
A representative agarose gel electrophoresis image of the fragments obtained from all screened colonies is 
shown. All samples showed the expected fragment size of 486 bp as indicated (lane 2-18). Marker (lane 1), NTC 
(lane 19) are indicated. (C) Plasmid map of pBlueScript_LSL_2A-DTR_WPRE_Neo. The location and amplified 
region of the SeqPrimer10 and WPRE Rev used for colony screening is indicated. 
 
 
 
 Results  
 56 
4.1.4. Design of homology arms 
 
At this step, the generated DTR construct contained all necessary elements, required for the 
successful DTR expression. To accomplish the later targeted-orientated integration into the 
mouse genome, two homology arms were designed at the 5’ and 3’ end of DTR construct, 
with the length of 5497 bp for the main guiding 5’ arm and 3885 bp for the shorter 3’ arm 
(Fig. 9). In detail, these homology arms contained a partial CD64 gene sequence spanning 
from intron 3rd intron until the endogenous poly(A) sequence followed by a sequence of 2,5 
kbp 3rd mouse chromosome. A RPCIB731E08452Q BAC, below designed as CD64_BAC, 
containing a part of the Mus musculus 3rd chromosome (spanning 96,173,608 – 96,349,578 
bp) was used as a template for the source of CD64 gene sequence. 
 
 
Figure 9. Schematic diagram of the Mus musculus CD64 locus. 
Boxes represent CD64 gene exons, with the name indicated in the box, and bold black lines indicates introns. 
Double side arrows indicate right and left rescue homology and homology arms, with the specific name, size and 
position in the CD64 locus; TSS- transcription start site. 
 
4.1.5. Cloning of homology arms (pBlueScript_Homo1_Homo2 rescue vector 
and pBlueScript_CD64 plasmid generation) 
 
For capturing the necessary homology arms from the CD64_BAC by HR, a rescue vector was 
generated. The recombination mediated rescue vector was planned to contain two short 
rescue homology arms called Homo1 and Homo2, which designed to serve as guides (Fig. 9). 
Homo1 sequence was homologous to the 477 bp upstream of homology arm 5’ and Homo2 
was identical to 508 bp downstream of homology arm 3’. These rescue homology arms were 
planned to get ligated into empty pBlueScript SK II (+) vector in a two-step process. First, 
Homo1 fragment was amplified from the CD64_BAC (Fig. 10A). The initially designed primer 
sequences to capture Homo1 were modified by introducing a SalI-HF restriction site to 
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Res_HOM1_Rev primer and a NotI-HF site to Res_HOM1_Fwd primer 5’-ends. Prior ligation 
the obtained PCR product and pBlueScript SK II (+) vector were digested with SalI-HF and 
NotI-HF to generate the intermediate pBlueScript_Homo1 plasmid. To assure the correct 
plasmid sequence, several bacterial clones were screened for Homo1 integration by fragment 
analysis after restriction digestion. Only plasmids, which showed the expected fragment size, 
were further confirmed by sequencing using SeqPrimer44 and T3 primers (Fig. 10B). A 
schematic overview of the finally obtained plasmid is shown in figure 10C. 
 
 
Figure 10. Generation of pBlueScript_Homo1 plasmid. 
(A) PCR of Homo1 fragment using primers Res_Homo1 Fwd and Rev. A representative agarose gel 
electrophoresis image is shown. The expected 497 bp PCR product (lane 3), marker (lane 1) and NTC (lane 2) are 
indicated. (B) Restriction digestion of pBlueScript_Homo1 plasmid. A representative agarose gel electrophoresis 
image of all plasmid DNAs isolated from different clones after ScaI-HF digestion is shown (lane 3-12). All 
samples showed the expected fragment size of 3381 bp as indicated. The marker (lane 1) and pBlueScript 
plasmid (lane 2), used as a negative control, are shown. (C) Plasmid map of pBlueScript_Homo1. The ScaI-HF 
recognition site, to confirm the integrity of the plasmid, are indicated. 
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In the next step of rescue vector generation, Homo2 sequence was cloned behind the Homo1 
sequence using pBlueScript_Homo1 plasmid. The specific Homo2 fragment was amplified 
from the same CD64_BAC (Fig. 11A). Initially designed primer sequences were modified by 
adding a SalI-HF restriction site to Res_HOM2_Fwd and a XhoI site to Res_HOM2_Rev primer 
5’-end. The obtained PCR product of Homo2 PCR and the pBlueScript_Homo1 plasmid were 
digested with XhoI and SalI-HF ligated to generate pBlueScript_Homo1_Homo2 plasmid. For 
pre-screening several bacterial clones were picked-up for Toothpick analysis (Fig. 11B). To 
finally confirm the correct Homo2 orientation, plasmid DNA was restriction digested and the 
fragments were analysed (Fig. 11C). To further confirm that the cloned Homo2 sequence was 
without mutations, pBlueScript_Homo1_Homo2 plasmid sequence was confirmed by Sanger 
sequencing using SeqPrimer44 primer. The final rescue vector map is shown in figure 11D. 
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Figure 11. Generation of pBlueScript_Homo1_Homo2 plasmid. 
(A) PCR of Homo2 fragment using primer Res_Homo2_ Fwd and Rev. A representative agarose gel 
electrophoresis image is shown. The expected 527 bp PCR product, marker (lane 1) and NTC (lane 2) are 
indicated. (B) Toothpick analysis. Representative agarose gel electrophoresis image of crude plasmid DNA 
extracts from agar plate of different colonies (lane 2-5). Colony 3 (lane 4) and 4 (lane 5) displayed the expected 
shift of the supercoiled DNA and confirmed for Homo2 sequence integration into the pBlueScript_Homo1 
plasmid. The marker (lane 1) and pBlueScript_Homo1 (lane 6), used as a negative control, are indicated. (C) 
Restriction digestion of pBlueScript_Homo1_Homo2 plasmid. Agarose gel electrophoresis image of 5 
representative plasmid DNAs isolated from different colonies after SalI-HF/NotI-HF digestion (lane 3-7) is 
shown. Out of 29 samples tested only colony 1 (lane 3) and 3 (lane 4) showed the expected fragment size of 484 
bp and 3412 bp. Marker (lane 1) and pBlueScript_Homo1 plasmid (lane 2), used as the negative control, are 
indicated. (D) Plasmid map of pBlueScript_Homo1_Homo2. All SalI-HF and NotI-HFrestriction sites, to confirm 
the integrity of the plasmid, are indicated. The calculated fragment sizes after SalI-HF/NotI-HF digestion of 
484 bp and 3412 bp are shown. 
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For capturing homologous arms from the CD64_BAC into rescue vector by HR, first EL350 cells 
were transformed. To exclude at this step any occurring rearrangements during 
transformation, CD64_BAC integrity was confirmed by two PCRs and restriction digest (Fig 
12A, B, C). As shown in figure 12 all clones showed the expected amplification product and 
the same digestion pattern of 6 prominent fragments above 8000 bp compared to the original 
CD64_BAC DNA (Fig. 12C). Finally, one of these bacterial clones, which contained the 
validated CD64_BAC, was used for homology arm generation. This was achieved by 
transformation with linearized pBlueScript_Homo1_Homo2 rescue vector, after SalI-HF 
digestion, to generate the homology arms containing pBlueScript_CD64 plasmid. 
 
 
Figure 12. Verification of the transformed CD64_BAC integrity. 
(A) PCR of Homo1 using primers Res_Homo1 Fwd and Rev. A representative agarose gel electrophoresis image 
is shown. The expected 497 bp PCR product, marker (lane 1) and original CD64_BAC (lane 2), used as a positive 
control, are indicated. (B) PCR of Homo2 fragments using primers Res_Homo2 Fwd and Rev. A representative 
agarose gel electrophoresis image is shown. The expected 527 bp PCR product, marker (lane 1) and original 
CD64_BAC (lane 2), used as a positive control, are indicated. (C) Restriction digestion of isolated BAC after 
transformation. A representative agarose gel electrophoresis image of BAC DNAs isolated from different 
colonies is shown before and after SwaI digestion (lane 4-9). The expected signature of 6 prominent fragments, 
marker (lane 1) and original undigested and digested CD64_BAC (lane 2-3), used as a positive control, are 
indicated. 
 
To confirm successful homology arm insertion into pBlueScript_Homo1_Homo2, isolated 
plasmid from different clones was digested individually with restriction enzymes. 
Unexpectedly, only the BamHI-HF® digestion showed for all clones the expected restriction 
digestion pattern of three bands (6916 bp, 4498 bp, 881 bp) (Fig. 13A). In contrast to that, 
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two fragments (1562 bp and 907 bp) out of five expected ones (4833 bp, 3590 bp, 1562 bp, 
1397 bp, 907 bp) were missing after XbaI digestion, as shown in figure 13C. Instead, only four 
fragments (4833 bp, 3590 bp, 2469 bp, 1397 bp) could be detected, leading to the assumption 
that this site was not cut by the enzyme. However, sequencing with primers SeqPrimer6-7 of 
the respective DNA area spanning the uncut XbaI site confirmed the integrity of the 
questionable enzyme recognition sequence in all clones and confirmed thereby the plasmid 
integrity. To further verify the two sequences of homology arms at the start position of gap 
repair mechanism, the obtained pBlueScript_CD64 plasmid was sent for Sanger sequencing 
analysis using SeqPrimer44 and T3 primers. The final plasmid map is shown in figure 13B, D. 
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Figure 13. Generation of pBlueScript_CD64 plasmid. 
(A) Restriction digestion of pBlueScript_CD64 plasmid. Agarose gel electrophoresis image of 6 representative 
plasmid DNAs isolated from different colonies and BamHI-HF digestion is shown (lane 3-8). All samples showed 
the expected fragment sizes of 881 bp, 4498 bp and 6910 bp. Marker (lane 1) and pBlueScript_Homo1_Homo2 
plasmid (lane 2), used as a negative control, are indicated. (B) Plasmid map of pBlueScript_CD64. All BamHI-HF 
restriction sites, to confirm the integrity of the plasmid, are indicated. The calculated fragment sizes after BamHI-
HF digestion of 881 bp, 4498 bp and 6910 bp are shown. (C) Restriction digestion of pBlueScript_CD64 plasmid. 
Agarose gel electrophoresis image of 6 representative plasmid DNAs isolated from different colonies and XbaI 
digestion is shown (lane 3-8). All samples showed the expected fragment sizes of 4833 bp, 3590 bp and 1397 
bp. Instead of expected 907 bp and 1562 bp fragments, a 2469 bp fragment was found. Marker (lane 1) and 
pBlueScript_Homo1_Homo2 plasmid (lane 2), used as a negative control, are indicated. (D) Plasmid map of 
pBlueScript_CD64. All XbaI restriction sites, to confirm the integrity of the plasmid, are indicated. The calculated 
fragment sizes after XbaI digestion of 907 bp, 1397 bp, 1562bp, 3590 bp and 4833 bp are shown. 
 
4.1.6. Synthesis of CD64-LSL-2A-DTR target vector 
 
Using HR, the full length CD64-LSL-2A-DTR target vector was generated by insertion of the 
DTR construct from pBlueScript_LSL_2A_DTR_WPRE_Neo between the homology arms of 
pBlueScript_CD64. Therefore, first pBlueScript_CD64 plasmid was electroporated into EL350 
cells and the integrity was verified by restriction digestion after plasmid isolation. As shown 
in figure 14A all digested plasmids showed the expected three fragments (6916 bp, 4498 bp 
and 881 bp) after BamHI-HF® digestion and four fragments (4774 bp, 3590 bp, 2469 bp and 
1397 bp) after XbaI, thereby confirming that no rearrangements have occurred. Second, the 
DTR construct was amplified from pBlueScript_LSL_2A-DTR_WPRE_Neo plasmid (Fig. 14B) 
and the fragment (Fig. 14C) was purified and transformed for HR into EL350 cells harbouring 
validated pBlueScript_CD64 plasmid. 
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Figure 14. Verification of the transformed pBlueScript_CD64 plasmid. 
(A) Restriction digestion of isolated pBlueScript_CD64 plasmid after transformation. A representative agarose 
gel electrophoresis image of plasmid DNAs isolated from different colonies is shown before and after BamHI-
HF (lane 6, 9, 12) or XbaI digestion (lane 7, 10, 13). All samples showed the expected fragment sizes of 881 bp, 
4498 bp and 6910 bp for BamHI-HF and 1397 bp, 2469 bp, 3590 bp and 4774 bp for XbaI. Marker (lane 1) and 
the original pBlueScript_CD64 plasmid (lane 2-4), used as a positive control, are indicated. (B) PCR of DTR 
construct fragment using DTR_Const Fwd and DTR_Const Rev. A representative agarose gel electrophoresis 
image is shown. The expected 4119 bp PCR product, marker (lane 1) and NTC (lane 2) are indicated. (C) Plasmid 
map of pBlueScript_LSL_2A-DTR_WPRE_Neo. The expected DNA construct of 4119 bp and amplification primers 
DTR_Const Fwd and Rev are indicated. 
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Two colonies were picked and DTR construct integration between the homology arms was 
confirmed by PCR and restriction digestion. First, a colony screening PCR was performed. As 
shown in figure 15A, only one clone showed the desired DTR construct integration. This result 
was confirmed by specific single and double restriction digestions. As seen in figure 15C 
digestion with NotI-HF resulted in the appearance of two band, where one shows empty 
pBlueScript_CD64 and a second linearized plasmid with the expected size of 16305 bp, 
thereby confirming the successful integration. Additional digestion with NotI-HF and EcoRV-
HF confirmed the correct orientation of the insert, due to the appearance of three additional 
bands below the linearized empty pBlueScript_CD64 plasmid band. 
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Figure 15. Verification of the generated CD64-LSL-2A-DTR plasmid. 
(A) Colony screening PCR to confirm DTR construct knock-in into pBlueScreen_CD64 plasmid. A representative 
agarose gel electrophoresis image of the fragment obtained from all screened colonies (lane 3-4) is shown. The 
primer combination SeqPrimer2 and 8 (Tm 65 C) was used to identify positive clones. Only colony 1 showed the 
expected fragment size of 1235 bp. Marker (lane 1) and NTC (lane 2) are indicated. (B) Plasmid map of CD64-
LSL-2A-DTR target vector. The expected product of 1235 bp and amplification primers SeqPrimer 2 and 8 are 
indicated. (C) Restriction digestion of isolated CD64-LSL-2A-DTR plasmid. A representative agarose gel 
electrophoresis image of DNAs isolated from colony 1 is shown before (lane 3) and after NotI-HF (lane 5) or 
NotI-HF/EcoRV-HF (lane 7) digestion. The colony 1 showed the expected fragment sizes of 1889 bp, 5739 bp, 
8677 bp and 12289 bp. Marker (lane 1) and empty pBlueScript_CD64 plasmid (lane 2, 4, 6), used as negative 
control, are indicated. (D) Plasmid map of CD64-LSL-2A-DTR. All NotI-HF and EcoRV-HF restriction sites, to 
confirm the integrity of the plasmid, are indicated. The calculated fragments size after NotI-HF digestion of 
16305 bp and NotI-HF/EcoRV-HF digestion of 1889 bp, 5739 bp and 8677 bp are shown. 
 
To separate the targeted pBlueScript_CD64 plasmid from the empty vector, the plasmids 
were isolated and transformed into Stbl2 cells. To exclude any colonies with multiple plasmid 
uptakes, isolated plasmid was double digested (Fig. 16). As shown in figure 16 plasmid 
isolation, that showed the expected bands, were further processed for Sanger sequencing to 
confirm integrity and to exclude any mutations, using the following primers: SeqPrimer 5-41, 
SeqPrimer 1-3 and SeqPrimer44. Finally, these data confirmed that the cloned CD64-LSL-2A-
DTR target vector contained the desired sequence. After successful cloning of CD64-LSL-2A-
DTR target vector it was sent to our collaborator Prof. Dr. Thorsten Buch in Switzerland for 
transgenic mouse generation using CRISPR-Cas9 technology. 
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Figure 16. Screening of single event uptake in Stbl2 for CD64-LSL-2A-DTR target vector. 
Restriction digestion of isolated CD64-LSL-2A-DTR target vector after transformation into Stbl2. A representative 
agarose gel electrophoresis image of plasmid DNAs isolated from different colonies is shown before (lane 4, 6, 
8, 10, 12, 14) and after NotI-HF/EcoRV-HF digestion (lane 5, 7, 9, 11, 13, 15). Plasmids from colonies 1 (lane 
5), 4 (lane 11), 5 (lane 13) and 6 (lane 15) showed the expected fragment sizes of 1889 bp, 5739 bp, 8677 bp. 
Marker (lane 1) and the original empty pBlueScript_CD64 plasmid (lane 2-3), used as negative control, are 
indicated and showed the expected 12289 bp fragment. 
 
4.1.7. PCR approach for detection of DTR construct integration into mouse 
genome 
 
Due to the lack of a specific positive control to screen potential FM by PCR for DTR construct 
knock-in, I decided to mimic the existence of this sequence in the mouse genome by 
modifying the previously used wild type CD64 locus containing CD64_BAC sequence. This was 
achieved by inclusion of the DTR construct into the existing CD64 locus by HR. For this 
purpose, the previously generated CD64-LSL-2A-DTR target vector was linearized with XhoI 
and electroporated into CD64_BAC containing EL350 cells. To confirm the successful DTR 
construct integration, isolated plasmid was restriction digested (Fig. 17). Comparison 
between the original CD64_BAC and the modified BAC showed the same fragment pattern 
after SwaI digestion, indicating the integrity of the newly cloned CD64_DTRconstruct_BAC 
(Fig. 17A). Additionally, the integration of DTR construct was confirmed by KpnI-HF 
digestion. As expected the introduction of the additional KpnI-HF site let to the loss of the 
17099 bp fragment and appearance of two 9635 bp and 11480 bp fragments instead (Fig. 
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17A), compared to original CD64_BAC. Taken together, these results confirmed the successful 
generation of the desired positive control CD64_DTRconstruct_BAC. 
 
 
Figure 17. Generation of CD64_DTRconstruct_BAC. 
(A) Restriction digestion of isolated BAC DNAs after HR. A representative agarose gel electrophoresis image of 
the comparison between isolated CD64_DTR (lane 2, 4) and CD64_DTRconstruct_BAC (lane 3, 5) after SwaI or 
KpnI HF digestion is shown. Marker (lane 1), the expected signature of 6 prominent fragments after SwaI 
treatment and the expected 9635bp and 11480 bp products after KpnI-HF digestion, confirming a positive DTR 
construct insertion, compared to the expected 17099 bp fragment for the empty BAC after KpnI-HF digestion 
are indicated. (B) Plasmid map of CD64_BAC. All KpnI-HF restriction sites and expected restriction fragments 
after KpnI-HF digestion of 8632 bp, 11869 bp, 12937 bp, 14571 bp, 17099 bp and 24540 bp are indicated. (C) 
Plasmid map of CD64_DTRconstruct_BAC. All KpnI-HF restriction sites and the expected restriction fragments 
after KpnI-HF digestion of 8632 bp, 9635bp, 11480 bp, 11869 bp, 12937 bp, 14571 bp and 24540 bp are 
indicated. 
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In order to confirm DTR construct integration and correct orientation into the genomic CD64 
locus for later FM screening, two PCR strategies, called 3’INS_PCR and 5’INS_PCR, were 
developed (Fig. 18A). To assure the quality of the isolated gDNA a third PCR assay, called 
WT_PCR, to amplify a product independent of integration or orientation (Fig 18A). 
Furthermore, to detect possible off targets, a fourth PCR (DTR_PCR), was designed to detect 
specifically any DTR gene integration independent from the targeted location (Fig. 18A). All 
PCR settings were tested and confirmed in advance using the previous generated positive 
control CD64_DTRconstruct_BAC, containing an integrated DTR construct within the CD64 
locus. As indicated in figure 18B, C, D all expected fragment sizes of 1992 bp, 4990 bp and 
6021 bp where detected for each individual reaction, respectively. 
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Figure 18. Establishment of positive control for DTR construct integration into genomic CD64 screening to 
identify FM. 
(A) PCR strategy to confirm successful DTR construct integration. A schematic diagram of the targeted Mus 
musculus CD64 locus after DTR integration construct knock-in is shown. TSS represents the transcription start 
site. White boxes with numbers represent CD64 gene exons. Grey boxes indicate the full length DTR construct, 
composed of LSL cassette, 2A sequence, DTR gene, WPRE sequence and Neo cassette, parts. The location of 
individual primers is indicated by arrows together with the resulting PCR fragment and name of the PCR. Double 
side arrows represent right and left homology arms, with the specific name, size and position in the CD64 locus. 
The double side bar-head arrows indicate WT_PCR, 5’INS_PCR, DTR_PCR and 3’INS_PCR products. (B) 3’INS_PCR 
to confirm DTR construct integration and orientation into genome mouse DNA. A representative agarose gel 
electrophoresis image is shown. The primer combination SeqPrimer13 and CD64.1 (Tm= 59 C) were used 
together with wild type genome mouse DNA (lane 3) or CD64_DTRconstruct_BAC (lane 4) and the expected 
fragment size of 4990 bp, marker (lane 1) and NTC (lane 2) are indicated. (C) 5’INS_PCR to confirm DTR construct 
integration and orientation into mouse gDNA. A representative agarose gel electrophoresis image is shown. The 
primer combination CD64.5 and CD64.6 (Tm= 59 C) were used together with wild type mouse gDNA (lane 3) or 
CD64_DTRconstruct_BAC (lane 4) and the expected fragment size of 6021 bp, marker (lane 1) and NTC (lane 2) 
are indicated. (D) WT_PCR for quality control of the isolated mouse gDNA and DTR_PCR for the detection of off-
target effects. A representative agarose gel electrophoresis image is shown. For WT_PCR the primer 
combination CD64.2 and CD64.1 (Tm= 59 C) and for DTR_PCR SeqPrimer14 and SeqPimer3 (Tm= 59 C) were 
used together with wild type mouse gDNA (lane 4, 6) or RPCIB731E08452Q_DTR construct BAC (lane 5, 7), the 
expected fragment size of 1992 bp and 760 bp, marker (lane 1) and NTC (lane 2-3) are indicated. 
 
4.1.8. PCR based screening assay identified two FM based on DTR construct 
integration into their gDNA 
 
After successful cloning of the CD64-LSL-2A-DTR target vector and application for CRISPR-
Cas9 technology based knock-in, the generated mosaic offspring mice needed to be 
genotyped to ascertain the successful editing of the gene of interest. Therefore, previously 
established 3’INS_PCR, 5’INS_PCR, DTR_PCR and WT_PCR screening PCR assays were 
performed on gDNA isolated from ear biopsies. To ensure the quality of the PCR performance 
and to validate the correct size of the amplicons wild type mouse gDNA and CD64_BAC, 
containing the desired wild type CD64 gene, were used as negative controls. Furthermore, 
the previously cloned CD64_DTRconstruct_BAC, containing the modified CD64 locus, served 
as a positive control. Before the confirmation of DTR construct integration, all samples, 
passed through the quality control by WT_PCR application and demonstrated the appearance 
of a 1992 bp fragments (Fig. 19A), were further processed for DTR_PCR, 3’INS_PCR and 
5’INS_PCR. The first pre-screening step using DTR_PCR analysis detected a knock-in within 
the genome of mouse 3, 21 and 4, as demonstrated by the presence of the expected fragment 
(Fig. 19B). To further exclude DTR construct insertion, independent from the targeted 
location, the 3’INS_PCR analysis was performed and identified only two mice out of the initial 
three, FM number 3 (FM3) and FM number 21 (FM21), bearing the successful DTR construct 
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integration into their 3’ CD64 locus (Fig. 19C). Finally, these data were further confirmed by 
the use of 5’INS_PCR, which only shows a signal after integration of DTR construct in the 5’ 
CD64 locus (Fig. 19D). Since DTR_PCR confirmed that the genome of mouse 4 contained a 
CD64 locus independent DTR construct integration (Fig. 19C), only gDNA from FM3 and FM21 
was considered for the final verification of the successful knock-in by nonradioactive Southern 
blot, after they were used for line breeding. 
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Figure 19. PCR analysis to identify FM. 
(A) WT_PCR to confirm the isolated gDNA integrity. A representative agarose gel electrophoresis image is shown. 
CD64.1 and CD64.2 were used together with gDNA from possible FM to perform PCR analysis (line 6-16). gDNA 
from a wild type mouse (lane 3) and CD64_BAC (lane 4) served as negative control, CD64_DTRconstruct_BAC 
(lane 5), served as positive control. The expected fragment size of 1992 bp, marker (lane 1) and NTC (lane 2) are 
indicated. (B) DTR_PCR for the detection of off-target effects. A representative agarose gel electrophoresis 
image is shown. SeqPrimer14 and SeqPrimer3 were used together with gDNA from possible FM to perform PCR 
analysis (line 6-16). gDNA from a wild type mouse (lane 3) and CD64_BAC (lane 4) served as negative control, 
CD64_DTRconstruct_BAC (lane 5), served as positive control. The expected fragment size of 760 bp, marker (lane 
1) and NTC (lane 2) are indicated. (C) 3’INS_PCR to confirm DTR construct insertion and orientation into mouse 
gDNA. A representative agarose gel electrophoresis image is shown. SeqPrimer13 and CD64.1 were used 
together with gDNA from three positive FM to perform PCR analysis (lane 8-10). gDNA from a wild type mouse 
(lane 3), CD64_BAC (lane 4) and gDNA from negative mice 1 (lane 6) and 2 (lane 7) served as negative controls, 
CD64_DTRconstruct_BAC (lane 5) served as positive control. The expected fragment size of 4990 bp, marker 
(lane 1) and NTC (lane 2) are indicated. (D) 5’INS_PCR to confirm DTR construct and orientation into mouse 
gDNA. A representative agarose gel electrophoresis image is shown. CD64.5 and CD64.6 were used together 
with gDNA from two positive FM to perform PCR analysis (lane 5-6). gDNA from a wild type mouse (lane 3) 
served as a negative control, CD64_DTRconstruct_BAC (lane 4) served as a positive control. The expected 
fragment size of 6021 bp, marker (lane 1) and NTC (lane 2) are indicated. 
 
4.1.9. Generation of a specific Southern blot probe to detect DTR construct 
integration 
 
As a second line of proof to verify the correct DTR construct integration into the gDNA of 
potential FM and to exclude possible off-targets like DNA rearrangements, a Southern blot 
strategy was planned additionally using two specific probes. Probe1 was designed to bind 
behind 3’ homology arm and upstream of KpnI-HF digestion site (Fig. 20). Another probe, 
called Neo, was chosen to recognise a sequence located inside the Neo cassette and to 
confirm the correct integration by the detection of 3’ fragment (11480 bp) after KpnI-HF 
digestion and 5’ fragment (11224 bp) after PsiI digestion (Fig. 20). With this strategy, it was 
possible to use Probe1 for the validation of the correct size and to distinguish between 3’ part 
of wild type allele (18355 bp) and targeted allele (11480 bp) after KpnI-HF digestion (Fig. 20). 
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Figure 20. Schematic diagram of Southern blot strategy for the specific detection of DTR construct 
integration. 
Southern blot strategy to confirm DTR construct integration into CD64 using Probe1 and Neo probes. The 
location of Probe1 is indicated by the red bar together with the resulting fragment of 18355 bp after KpnI-HF 
digestion of wild type gDNA and of 11480 bp after KpnI-HF digestion of gDNA after DTR construct integration. 
Additionally, location of the Neo probe is indicated by a blue bar together with the resulting fragment of 11224 
bp after PsiI digestion of gDNA after DTR construct integration. White boxes represent CD64 gene exons. Grey 
boxes indicate the full length DTR construct, composed of LSL cassette, 2A sequence, DTR gene, WPRE sequence 
and Neo cassette. 5’ and 3’ homology arms are illustrated by bold double side arrows. KpnI-HF and PsiI 
recognition sites are indicated. TSS- transcription start site. 
 
To generate Probe1, a specific PCR was performed using CD64_BAC as a template (Fig. 21A). 
After A-tailing the PCR product was ligated into pGem-T vector resulting in pGem-T_Probe1 
plasmid. Correct insert integration was confirmed by colony screening PCR and sequence 
integrity of positive clones was confirmed by Sanger sequencing with primers SeqPrimer42, 
SeqPrimer44-45. 
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Figure 21. Cloning of Southern blot Probe1. 
(A) PCR of Probe1 fragment using the primers Probe1.1 and Probe1.2. A representative agarose gel 
electrophoresis image is shown. The expected 972 bp PCR product, marker (lane 1) and NTC (lane 2) are 
indicated. (B) Colony screening PCR to confirm Probe1 sequence insertion into pGem-T. A representative 
agarose gel electrophoresis image of the fragment obtained from all screened colonies is shown (lane 2-16). The 
primer combination of Probe1.1 and Probe1.2 was used to identify the positive clones. All samples showed the 
expected fragment size of 972 bp. Marker (lane 1) and NTC (lane 17) are indicated. 
 
The sequence of the second probe Neo was adopted from a published study24 and captured 
from 195 FrtneokanaFrt DTA plasmid (Fig. 22A) followed by the ligation into pGem-T vector 
resulting in pGem-T_Neo plasmid. To verify insert integration, a colony screening PCR was 
performed (Fig. 22B) and, that no mutations occurred, plasmids were send for Sanger 
sequencing analysis along with SePrimer44 and SeqPrimer45 primers. In both cases mutation 
free plasmids were used for the probe synthesis. 
Finally, these strategies ensured that the cloned pGem-T_Probe1 and pGEM-T_Neo plasmids 
contained the desired sequence for the following Probe1 and Neo probe synthesis and DIG 
labelling. As a quality control unlabelled and labelled PCR product was separated by 
electrophoresis and evaluated for a shift due to the DIG label (Fig. 22C). 
 
 
Figure 22. Cloning of Southern blot probe Neo probe and quality control if DIG labelled probes. 
(A) PCR of Neo fragment using primers Neo1 and Neo2. A representative agarose gel electrophoresis image is 
shown. The expected 682 bp PCR product, marker (lane 1) and NTC (lane 2) are indicated. (B) Colony screening 
PCR to confirm Neo sequence insertion into pGem-T. A representative agarose gel electrophoresis image of 
fragment obtained from all screened colonies (lane 3-8) is shown. The primer combination Neo1 and Neo2 was 
used to identify positive clones. All samples showed the expected fragment size of 682 bp. Marker (lane 1) and 
NTS (lane 2) are indicated. (C) Agarose gel electrophoresis of PCR-labelled Neo and Probe1 fragments. A 
representative agarose gel electrophoresis image is shown. The expected unlabelled 682 bp and 972 bp and 
labelled products, marker (lane 1) and NTC (lane 2) are indicated. Labelled probes (lane 4, 7) demonstrated a 
higher molecular weight than the unlabelled products (lane 3, 6). 
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4.1.10. Southern blot analysis confirmed successful CD64 gene editing for two 
CD64-LSL-2A-DTR FM 
 
To further exclude possible undetected off-targets and DNA rearrangements in the CD64 
locus of FM3 and FM21 a nonradioactive Southern blot was performed on genomic DNA. A 
wild type mouse gDNA served as a negative control. For the positive control, wild type mouse 
gDNA was spiked with the modified CD64_DTRconstruct_BAC, containing the desired CD64 
locus. The amount of the spiked BAC was calculated in a way to ensure that it contained the 
same amount of CD64 gene copy numbers as the expected single copy amount of the 
modified CD64 of FM gDNA used for the screening. Southern blot analysis using Neo probe 
confirmed the knock-in of the desired DTR construct into the 5’ CD64 locus (Fig. 23A). 
However, a small shift in the band size was observed in both samples compared to the positive 
control (Fig. 23B). Moreover, Southern blot analysis from the gDNA samples obtained from 
FM21 identified an additional shorter band at approximately 10000 bp, below the expected 
band size of 11480 bp, which appeared exclusively after KpnI-HF restriction digestion. 
Nevertheless, utilization of the second probe Probe1, which hybridizes with the same DNA 
fragment as the Neo probe (Fig. 20), resulted in the detection of fragments with the expected 
size (Fig. 23C). In addition, it needs to be mentioned that the knock-in and wild type bands of 
the gDNA of FM3 were slightly higher running. However, due to this worth mentioning 
difference between the artificial positive control CD64_DTRconstruct_BAC and the murine 
gDNA, we assumed at this point a successful DTR knock-in for these samples and included 
FM3 to be still valid to proceed together with FM21 for the further verification and 
establishment of the new mouse line. 
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Figure 23. Southern blot analysis of gDNA isolated from FM. 
(A) Southern blot to confirm DTR construct integration into 5’ CD64 gene. gDNA from FM3 and FM12 was 
digested with PsiI and further proceed for Southern blot analysis. A representative film after exposure is shown. 
DIG labelled probe Neo was used together with gDNA from FM3 (lane 3) and FM21 (lane 4) to perform the 
analysis. gDNA from wild type mouse (lane 1) served as negative control and CD64_DTRconstruct_BAC mixed 
with wild type gDNA (lane 2) served as a positive control. The expected fragment size 11224 bp is indicated. (B) 
Southern blot to confirm DTR construct integration into 3’ CD64 gene. gDNA from FM3 and FM21 was digested 
with KpnI-HF® and further processed for Southern blot analysis. A representative film after exposure is shown. 
DIG labelled probe Neo was used together with gDNA from FM3 (lane 3) and FM21 (lane 4) to perform the 
analysis. gDNA from wild type mouse (lane 1) served as negative control and CD64_DTRconstruct_BAC mixed 
with wild type gDNA (lane 2) served as a positive control. The expected fragment size of 11480 bp is indicated. 
(C) Southern blot to confirm DTR construct integration into 3’ CD64 gene. gDNA from FM3 and FM21 was 
digested with KpnI-HF® and further processed for Southern blot analysis. A representative film after exposure is 
shown. DIG labelled probe Probe1 was used together with gDNA from two positive FM (FM3 and FM21) (lane 3-
4) to perform the analysis. gDNA from wild type mouse (lane 1) served as negative control and 
CD64_DTRconstruct_BAC mixed with wild type gDNA (lane 2) served as a positive control. The expected 
fragment sizes of 11480 bp and 18355 bp are indicated. 
 
4.1.11. CD64-LSL-2A-DTR target vector integration into CD64 locus did not 
affect CD64 protein expression 
 
After successful confirmation, that the DTR construct was integrated into the CD64 locus, it 
became necessary to exclude if the genetic manipulations of the CD64 locus done so far 
together with the planned Cre excision of LSL cassette, had not affected CD64 expression level 
of the targeted cell population. To proceed in this regard, first offspring of both CD64-LSL-2A-
DTR FM lines were crossed with Cre recombinase caring Clec9a-Cre mice24 to enable the 
excision of the LSL cassette in these animals. Afterwards, renal leukocytes isolated from the 
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obtained F1 generation mice, caring Cre and DTR knock-in, were stained against surface 
markers and analysed by FACS. As a positive control renal leukocytes from a wild type CD64 
locus caring Clec9a-Cre mouse was used. To get a valid read out of CD64 expression it was 
necessary to select first the cell population of interest independent of CD64. This was 
achieved by the use of F4/80 surface marker, because it is well established that the 
application of F4/80 surface glycoprotein can be used as a replacement of CD64 marker to 
identify CD64+ cells17,24,124. With this strategy it was possible to prevent any falsification or 
misinterpretation of the final CD64 protein expression levels. The detailed gating strategy to 
identify renal CD64+ cells is shown in figure 24A. 
 
 
Figure 24. CD64 expression is not altered in Clec9a+/CreCD64+/DTR mice compared to Clec9a+/CreCD64+/+ mouse. 
(A) Flow cytometry gating strategy to identify renal CD64+ cells (liveCD45.2+CD11cMHCII+CD64+ and 
liveCD45.2+CD11cMHCII+F4/80+). Cells from kidney in Clec9a+/CreCD64+/+ mice were stained with antibodies 
against indicated cell surface markers. The numbers in the dot plots indicate the percentages of the cells within 
the indicated gates. (B) Histogram overlay of CD64 expression on renal CD64+ cells 
(liveCD45.2+CD11cMHCII+F4/80+). The histograms for CD64 expression on renal CD64+ cells from FM3 and FM21 
mouse line Clec9a+/CreCD64+/DTR mice (red line box), Clec9a+/CreCD64+/+ mice (green line box) and isotype control 
(grey box) are indicated. 
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As shown in figure 24B, the subsequent CD64 expression analysis from Clec9a+/CreCD64+/DTR 
mouse samples revealed, that CD64 receptor was highly expressed on renal CD64+ cells 
(liveCD45.2+CD11cMHCII+F4/80+), coming from both FM21 and FM3 lines. Moreover, the 
CD64 expression, independent of FM line, was comparable to the data obtained from the 
Clec9a+/CreCD64+/+ mouse sample, indicating that neither DTR construct integration behind 
CD64 gene, nor the expected LSL cassette excision did affect CD64 protein expression. 
Therefore, both FM lines were proceeded for further validation. 
 
4.1.12. DTR expression on renal CD64+ cells from Clec9a-Cre x CD64-LSL-2A-DTR 
mice is not detectable by FACS 
 
I next examined weather DTR was expressed on renal CD64+ cells coming from both FM21 
and FM3 breeding mouse lines. Similar to the before described FACS approach, F4/80 and 
CD64 surface markers were used to first identify renal CD64+ cells, which were subsequently 
used for DTR expression analysis. The detailed gating strategy is indicated in figure 24A. As a 
positive control for DTR staining on renal CD64+ cells, renal and splenic cDC1 from a Clec9a-
Cre x Rosa26-iDTR mouse were used, because of the genetic similarity to the new Clec9a-Cre 
x CD64-LSL-2A-DTR mouse model. Moreover cDC1 offer the advantage, that these cells 
express CLEC9A in their mature stage, which results in 95-100% prospective DTR+ cDC1 in the 
used Clec9a-Cre x Rosa26-iDTR mouse model24,204. The detailed gating strategies to identify 
renal and splenic cDC1 populations is shown in figure 25A and 25B. It need to be noted, that 
this double strategy was chosen to ensure validation of DTR staining, because previous DTR 
staining on fresh cell isolations from renal tissue showed regularly a weaker DTR FACS signals 
compared to freshly isolated splenic probes as shown in figure 25C. However, these 
expression data were obtained from other mouse model and could not be automatically 
transferred to the situation in the new Clec9a-Cre x CD64-LSL-2A-DTR model. 
 
 Results  
 79 
 
 
 
 Results  
 80 
Figure 25. DTR expression on renal cDC1 from Clec9aCre/CreRosa26+/DTR mice. 
(A) Flow cytometry gating strategy to identify renal cDC1 (liveCD45.2+MHCII+CD11c+CD64-CD24+CD11b- and 
liveCD45.2+MHCII+CD11c+F4/80-CD24+CD11b-), cDC2 (liveCD45.2+MHCII+CD11c+CD64-CD24-CD11b+ and F4/80-
CD24-CD11b+). Cells from kidney in Clec9a+/CreCD64+/+ mice were stained with antibodies against indicated cell 
surface markers. The numbers in the dot plots indicate the percentages of the cells within the indicated gates. 
(B) Flow cytometry gating strategy to identify splenic red pulp MØs (RPM) (live+CD64+F4/80+), cDC1 (liveRPM-
MHCII+CD11c+CD24+CD11b-) and cDC2 (liveRPM-MHCII+CD11c+CD24-CD11b+). Cells from spleen were stained 
with antibodies against indicated cell surface markers. The numbers in the dot plots indicate the percentages of 
the cells within the indicated gates. (C) Histogram overlay of DTR expression on cDC1. The histograms for DTR 
expression on splenic cDC1 and renal cDC1 (liveCD45.2+CD11c+MHCII+CD64-CD11b-CD24+) from 
Clec9aCre/CreRosa26+/DTR mouse (red line box) and Clec9a+/Cre mouse (grey box) are indicated. 
 
Unfortunately, also for these samples DTR expression was not detected on renal CD64+ cells 
by flow cytometry (Fig. 26A). Similarly, the DTR control staining performed on isolated renal 
cDC1 from a Clec9a-Cre x Rosa26-iDTR mouse showed a negative result (Fig. 26B). 
Nevertheless, we were still able to verify with splenic control the efficacy of the DTR staining, 
because usage of splenic cDC1 from the same mouse still resulted in a slight positive shift in 
the FACS analysis (Fig. 26B). The lower expression compared to freshly isolated splenic 
samples shown in figure 25C can be most likely explained, by the suboptimal conditions 
caused by the originated time delay between tissue removal, isolation and analysis caused by 
tissue transport, since the experiment was not performed inwards. However, this inconsistent 
data did not allow final concluding evidence of DTR expression at this point. 
 
 Results  
 81 
 
Figure 26. DTR expression on renal CD64+ cells from Clec9a+/CreCD64+/DTR mice. 
(A) Histogram overlay of DTR expression on renal CD64+ cells (liveCD45.2+CD11cMHCII+F4/80+ and 
liveCD45.2+CD11cMHCII+CD64+). The histograms for DTR expression on renal CD64+ cells from FM3 and FM21 
mouse line Clec9a+/CreCD64+/DTR mice (red line box) and Clec9a+/Cre mice (grey box) are indicated. (B) Histogram 
overlay of DTR expression on cDC1. The histograms for DTR expression on splenic cDC1 and renal cDC1 
(liveCD45.2+CD11c+MHCII+CD64-CD11b-CD24+) population from Clec9aCre/CreRosa26DTR/DTR mouse (red line box) 
and Clec9a+/Cre mice (grey box) are indicated. 
 
4.1.13. CD64-LSL-2A-DTR target vector integration into CD64 locus did not 
cause frame shift 
 
To excluded at this point that the before observed absence of DTR expression on renal CD64+ 
cells is not caused by unwanted and undetected genomic sequence mutations occurred 
during the knock-in. Therefore, a more detailed CD64 locus sequence analysis was performed. 
A specific region, starting within the 6th exon of CD64 spanning the 5’ loxP site in front of the 
DTR gene, and part of the poly(A) sequence was amplified by PCR (Fig. 27) using gDNA. gDNA 
from both FM showed the expected fragment, which was sent for Sanger sequencing analysis 
together with CD64.4 and SeqPrimer36 primers. This strategy confirmed the mutation free 
integrity of the targeted region for both FM and excluded the possibility to fail successful 
CD64 induced DTR expression due to a frame shift within this region. 
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Figure 27. Insertion of the transgenic CD64 segment did not cause frame shift. 
PCR strategy to exclude frameshift caused by DTR construct integration. A schematic diagram of a section 
comprised of the targeted Mus musculus CD64 locus, after DTR construct integration, is shown. White boxes 
represent CD64 gene exon, poly(A), 2A sequence, DTR gene and a part of WPRE sequence. Grey boxes indicate 
loxP sequence. The location of the individual primers CD64.4 and SeqPrimer36 are indicated by arrows together 
with the resulting PCR fragment. 
 
4.1.14. Cre recombinase removes LSL cassette allowing DTR expression in 
Clec9a-Cre x CD64-LSL-2A-DTR mice 
 
As the analysis of CD64 region in Clec9a+/CreCD64+/DTR mice coming from both FM lines 
confirmed the absence of any unwanted mutations, next I determined if the LSL cassette was 
excised by Cre. To confirm LSL excision, which is required for successful DTR expression, gDNA 
from renal percoll enriched leukocytes was isolated from Clec9a+/CreCD64+/DTR mice, originated 
from both FM lines and investigated by PCR, described in figure 28A. This PCR was designed 
to span the complete LSL cassette, resulting in fragment of 1100 bp, representing a full-length 
LSL cassette, or a 573 bp product, representing the excised LSL. As a negative control gDNA 
from both FM3 and FM21 was used, which were known to be Cre-. As expected, the data 
confirmed the presence of the additional 573 bp PCR products for the samples isolated from 
the F1 generation Clec9a-Cre x CD64-LSL-2A-DTR mouse lines compared to their parental 
probes from FM3 and FM21. These data clearly demonstrated that Cre recombinase was 
capable to remove the LSL cassette successfully as a requirement for later DTR gene 
expression within the renal leukocyte fraction of Clec9a-Cre x CD64-LSL-2A-DTR mice (Fig. 
28B). 
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Figure 28. Confirmation of successful LSL cassette excision in enriched Clec9a-Cre x CD64-LSL-2A-DTR mouse 
renal leukocytes. 
(A) PCR strategy to assess LSL cassette excision. A schematic diagram of a section comprised of the targeted Mus 
musculus CD64 locus, after DTR construct integration, is shown. White boxes represent CD64 gene exon, poly(A), 
2A sequence, DTR gene and a part of WPRE sequence. Grey boxes indicate LoxP sequences. The location of the 
individual primers CD64.4 and SeqPrimer2 in the LSL cassette are indicated by red arrows. The resulting PCR 
fragments are indicated for the full length LSL cassette (1100 bp, upper panel) or after LSL cassette excision (573 
bp, lower panel) as double side bar-head arrows. (B) PCR to confirm LSL cassette excision. A representative 
agarose gel electrophoresis image is shown. Primer combination of CD64.4 and SeqPrimer2 (Tm 61 C) was used 
together with gDNA from two Clec9a-Cre x CD64-LSL-2A-DTR mice (lane 5, 7) to perform the analysis. gDNA from 
a wild type mouse (lane 6) and gDNA from FM21 and FM3 lines (lanes 3 and 4) served as negative controls. 
Marker (lane 1), NTC (lane 2) and the expected fragment sizes of 1100 bp and 573 bp are indicated. 
 
4.1.15. Application of DT caused specific ablation of CLEC9A+ progenitor derived 
CD64+ cells in Clec9a-Cre x CD64-LSL-2A-DTR mice 
 
After completion of the detailed genomic analysis of the CD64 locus integrity of both FM lines 
and the finding, that the DTR construct was successfully integrated into the CD64 gene 
without any frameshift or mutation potentially affecting DTR expression I decided to proceed 
with cell depletion experiment for Clec9a-Cre x CD64-LSL-2A-DTR mice verification. Two 
groups of Clec9a+/CreCD64+/DTR mice, coming from FM3 line, were treated separately twice 
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with DT or PBS as negative control and analyzed 48 h after the first injection for the presence 
of renal CD64+ cells. F4/80 surface markers were used to identify renal CD64+ cells, using the 
same gating strategy as in figure 24A. As demonstrated, the analysis of CD64+ cells identified 
as liveCD45.2+CD11cMHCII+F4/80+ cells (Fig. 29A), revealed a significant depletion of this 
population in the kidney of the DT treated animals, as shown by the reduction in frequency 
and the absolute cell numbers (Fig. 29B). As a second line of proof another part of the samples 
was used in an independent staining approach to detect CD64+ cells as 
liveCD45.2+CD11cMHCII+CD64+ cells. Again these data revealed that these CD64+ cells from 
the DT treated animals, were also significantly ablated (Fig. 29C, D). 
 
 
Figure 29. Depletion of renal CD64+ cells in Clec9a-Cre x CD64-LSL-2A-DTR mice. 
(A) Depletion of CD64+ cells (liveCD45.2+CD11cMHCII+F4/80+) after DT treatment in Clec9a-Cre x CD64-LSL-2A-
DTR mice. Clec9a+/CreCD64+/DTR mice were treated i.p. twice 24 h apart, with DT (25 ng/g body weight) or PBS and 
one day after injections renal cells were stained using antibodies against surface markers as indicated figure 
24A. Upper panel shows percentage of cell populations within the indicated gates in the group treated with PBS 
and the lower panel shows percentage in the DT treated group. (B) Analysis of renal CD64+ population in 
Clec9a+/CreCD64+/DTR mice injected with PBS or DT. Total number and percentage with in the liveCD45.2+ cells per 
kidney is shown. Each symbol represents one mouse. (C) Depletion of CD64+ cells 
(liveCD45.2+CD11cMHCII+CD64+) after DT treatment in Clec9a-Cre x CD64-LSL-2A-DTR mice. Renal cells were 
stained using antibodies against surface markers as indicated figure 24A. Upper panel shows percentage of cell 
populations within the indicated gates in the group treated with PBS and the lower panel shows percentage in 
the DT treated group. (D) Analysis of renal CD64+ cells (identified as in C) in Clec9a+/CreCD64+/DTR mice injected 
with PBS or DT. Percentage with in the liveCD45.2+ cells per kidney is shown. Each symbol represents one mouse. 
* p < 0.05. 
 
After the confirmation of the successful depletion of CD64+ cells, it was also necessary to 
exclude that DT treatment had affected other CLEC9A+ progenitor derived cell populations in 
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these mice. Consequently, the specificity of the Clec9a+/CreCD64+/DTR mouse model was further 
tested by determining the presence of renal and splenic cDCs as well as RPM in the same 
samples. Similarly, F4/80 or CD64 surface markers were used to identify renal cDCs, using the 
same gating strategy as in figure 25A. As demonstrated by the comparison with the PBS 
treated animals, renal cDC1 and cDC2 were unaffected by DT treatment in the experimental 
group (Fig. 30A,B) as well as renal cDCs, identified as liveCD45.2+CD11cMHCII+CD64- cells (Fig. 
30C, D). 
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Figure 30. Depletion of cDCs in Clec9a-Cre x CD64-LSL-2A-DTR mice. 
(A) Depletion of cDC1 (liveCD45.2+CD11cMHCII+F4/80-CD11b-CD24+) and cDC2 (liveCD45.2+CD11cMHCII+F4/80-
CD11b+CD24) after DT treatment in Clec9a-Cre x CD64-LSL-2A-DTR mice. Clec9a+/CreCD64+/DTR mice were treated 
i.p. twice 24 h apart, with DT (25 ng/g body weight) or PBS and one day after injections renal cells were stained 
using antibodies against surface markers as indicated figure 25A. Upper panel shows percentage of cell 
populations within the indicated gates in the group treated with PBS and the lower panel shows percentage in 
the DT treated group. (B) Analysis of renal cDC1 and cDC2 in Clec9a+/CreCD64+/DTR mice injected with PBS or DT. 
Total number and percentage with in the liveCD45.2+ cells per kidney is shown. Each symbol represents one 
mouse. (C) Depletion of cDC1 (liveCD45.2+CD11cMHCII+CD64-CD11b-CD24+) and cDC2 
(liveCD45.2+CD11cMHCII+CD64-CD11b+CD24) after DT treatment in Clec9a-Cre x CD64-LSL-2A-DTR mice. Renal 
cells were stained using antibodies against surface markers as indicated figure 25A. Upper panel shows 
percentage of cell populations within the indicated gates in the group treated with PBS and the lower panel 
shows percentage in the DT treated group. (D) Analysis of renal cDC1 and cDC2 (identified as in C) in 
Clec9a+/CreCD64+/DTR mice injected with PBS or DT. Percentage with in the liveCD45.2+ cells per kidney is shown. 
Each symbol represents one mouse. * p < 0.05. 
 
Next, I have analysed if splenic cDC1 and cDC2 are affected by DT treatment in these mice. In 
addition, RPM were investigated, because it is assumed that DCs could contribute to RPM 
pool in the spleen, as supported by the observation of one study in Clec9a+/CreRosa26+/EYFP 
mice24. Therefore, I have examined weather RPM in these Clec9a+/CreCD64+/DTR mice were 
affected by DT treatment, since these cells also express high level of CD6417. The detailed 
gating strategy to identify RPM as well as splenic cDCs is shown in figure 25B. Unexpectedly, 
RPM from DT administrated Clec9a+/CreCD64+/DTR mice showed a strong reduction of more 
than 50% in counts and in frequency compared to the PBS treated controls (Fig. 31A, B). This 
was even more surprising, because according to previous published, only 2% of RPM are 
CLEC9A+ progenitor derived24. In contrast to this, cDC1 and cDC2 were unaffected in these DT 
injected mice (Fig. 31A, C). These data further supported the notion, that Clec9a-Cre x CD64-
LSL-2A-DTR mouse model allows to ablate CD64 expressing CLEC9A+ progenitor derived cells 
in the kidney and does not affect cDC subsets in this organ. 
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Figure 31. Analysis of cDCs and RPM in the spleen of Clec9a-Cre x CD64-LSL-2A-DTR mice after DT or PBS 
administration. 
(A) Depletion of splenic cDC1 (liveCD64-F4/80-CD11c+MHCII+CD11b-CD24+), cDC2 (live CD64-F4/80-
CD11c+MHCII+CD11b+CD24-) and RPM (live CD64+F4/80+) in Clec9a-Cre x CD64-LSL-2A-DTR mice. 
Clec9a+/CreCD64+/DTR mice were treated as in figure 29A. Upper panel shows percentage of cell populations within 
the indicated gates in the group treated with PBS and the lower panel shows percentage in the DT treated group. 
(B) Analysis RPM in Clec9a+/CreCD64+/DTR mice injected with PBS or DT. Total number and percentage with in the 
live cells per spleen is shown. Each symbol represents one mouse. (C) Analysis of cDC1 and cDC2 in 
Clec9a+/CreCD64+/DTR mice injected with PBS or DT. Total number and percentage with in the live cells per spleen 
is shown. Each symbol represents one mouse. * p < 0.05. 
 
4.1.16. Depletion of renal CD64+ cells did not cause monocytosis and 
neutrophilia 
 
Since it is known, that other DC depletion models, such as CD11c-DTR, are prone to develop 
monocytosis and neutrophilia upon DT treatment, I have also assessed if DT treatment 
influenced the number of MO and neutrophil in the affected kidney of the same 
Clec9a+/CreCD64+/DTR mice used before180. The gating strategy to identify these cell populations 
is shown in figure 32A. Analysis of Clec9a+/CreCD64+/DTR mice after DT treatment 
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demonstrated, in comparison to the PBS injected animals, a tendency of increased infiltration 
of MO and neutrophil into the kidney in counts and frequency within 48 h (Fig. 32B, C). 
Nevertheless, the observed effect of DT treatment on MOs and neutrophils was not 
statistically significant comparing to the PBS injected controls. Even though this observation 
needs to be taken into account for any further investigation of renal CD64+ cell function using 
these novel Clec9a-Cre x CD64-LSL-2A-DTR mice, the conclusion was made that this mouse 
model does not develop acute monocytosis or neutrophilia after DT treatment. 
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Figure 32. Analysis of neutrophils and MOs in the kidney of Clec9a+/CreCD64+/DTR mice. 
(A) Flow cytometry gating strategy to identify renal neutrophils (liveCD45.2+ lymphocyte antigen 6 complex, 
locus G (Ly6G)+CD11b+) and MOs (liveCD45.2+Ly6G-CD11b+ Ly6C+). Cells from kidney Clec9a+/CreCD64+/DTR mice 
were stained with antibodies against indicated cell surface markers. The numbers in the dot plots indicate the 
percentages of the cells within the indicated gates. (B) Investigation of neutrophils (liveCD45.2+Ly6G+CD11b+) 
and MOs (liveCD45.2+Ly6G-CD11b+Ly6C+) after DT treatment in Clec9a-Cre x CD64-LSL-2A-DTR mice. 
Clec9a+/CreCD64+/DTR mice were treated as described in figure 29A. Upper panel shows percentage of cell 
populations within the indicated gates in the group treated with PBS and the lower panel shows percentage in 
the DT treated group. (C) Analysis of renal neutrophils and MO in Clec9a+/CreCD64+/DTR mice injected with PBS or 
DT. Total number and percentage with in the liveCD45.2+ cells per kidney is shown. Each symbol represents one 
mouse. * p < 0.05. 
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4.2. Role of dendritic cells during AKI 
 
 
4.2.1. Effect of high concentrated cisplatin solution on AKI severity 
 
Owed to the fact, that at this time point no established nephrotoxic AKI disease model existed 
in our laboratory, I first aimed to evaluate the optimal cisplatin administration regime for 
animal treatment. Considering the welfare of the experimental animals and to minimize pain, 
suffering or restress, I chose as a refinement to minimize the injectable volume per animal at 
this step. This was achieved by using a 2 mg/ml cisplatin solution. 
According to previously published data for the induction of AKI, a set of C57BL/6 female mice 
were injected i.p. with a cisplatin dose of 20 mg/kg or the same volume of a 0.9% NaCl solution 
as a negative control. Since most of the published studies indicate 72 h to achieve cisplatin 
induced nephrotoxicity without reaching termination criteria I expected to see a similar 
result149,150. In contrast to that, the cisplatin treated animals demonstrated an inconsistent 
response. In detail, overall 25%-75% of the investigated mice developed a severe stage of AKI 
and needed to be sacrificed within 24-48 h, while other cisplatin treated animals did not show 
any severe disease characteristics at this time points. However, all animals from this group 
that reached the earlier termination criteria developed a severe cisplatin caused 
nephrotoxicity, as demonstrated by strongly increased BUN values as compared to the control 
group. A representative experiment is shown in figure 33. 
 
 
 
Figure 33. AKI induction in C57BL/6 females using 
cisplatin. 
C57BL/6 female mice were treated with 2 mg/ml 
cisplatin solution (20 mg/kg) or injected with 0.9% 
NaCl. 48 h later mice were scarified and blood was 
collected from the heart to measure BUN levels for 
kidney function evaluation. Each symbol represents 
one mouse. * p < 0.05. 
 
 
 
 Results  
 91 
4.2.2. Effect of different doses of cisplatin on AKI induction 
 
Due to the inconsistent result above, I decided to perform a cisplatin dose response 
experiment to find first the optimum drug dose to induce a uniform AKI severity in the 
experimental setting and to ensure the interpretability of any future AKI induction 
experiments. To investigate the optimal amount a 1 mg/ml cisplatin solution was used and 3 
different sets of C57BL/6 female mice were injected i.p. with a final dose of either 10 mg/kg, 
15 mg/kg or 20 mg/kg or an equivalent volume of 0.9% NaCl as a negative control. As before, 
in the experimental group treated with 20 mg/kg cisplatin, animals reached the termination 
criteria within 24 h after cisplatin administration and animals developed a kidney damage, as 
demonstrated by significantly increased creatinine and BUN levels in the plasma compared 
to the control group (Fig. 34A, B). In contrast to that, 3 out of 4 animals treated with 10 mg/kg 
and 1 out of 4 15 mg/kg cisplatin did not reached termination criteria within 48 h after 
cisplatin administration. Due to that, these experimental setups were determined after 48 h. 
Plasma creatinine and BUN levels later confirmed, that 1 out of 4 animals treated with 10 
mg/kg and 2 out of 4 animals treated with 15 mg/kg cisplatin developed nephrotoxicity at this 
time point (Fig. 34A, B). Based on differences to disease induction to cisplatin treatment in 
this experimental setup, 15 mg/kg cisplatin amount was chosen as an optimal amount to 
induce AKI for the following experiments. 
 
 
Figure 34. Dose response of C57BL/6 female mice to different cisplatin amounts to induce AKI. 
(A) BUN amount in the blood of C57BL/6 female mice. C57BL/6 female mice were treated with 10, 15 or 20 
mg/kg cisplatin or injected with 0.9% NaCl and monitored up till 48 h. 24-48 h later animals were scarified for 
blood collected from the heart. Each symbol represents one mouse. (B) Creatinine amount in the plasma of 
C57BL/6 female mice. Animals were treated as in indicated before and 24-48 h later scarified for blood collected 
from the heart. Each symbol represents one mouse. * p < 0.05. 
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4.2.3. Depletion of cDCs in Clec9a-Cre x Rosa26-iDTR mice 
 
In order to study the specific role of cDCs and CD64+ cells during AKI development, the in vivo 
cell depletion mouse model Clec9a-Cre x Rosa26-iDTR was considered to be used24. DT 
administration in these mice allows selective depletion of CLEC9A+ progenitor derived cells 
and does not induce monocytosis or neutrophilia 24,99,204. Since it was already shown that 
renal cDCs as well as both CD64+ cell subsets are derived from a CLEC9A+ progenitor24, it was 
expected to see depletion of the same populations. To determine the functional reliability of 
renal cDC population depletion efficiency and kinetics, 2 sets of Clec9aCre/CreRosa26DTR/DTR 
mice were treated i.p. with DT and compared with one control group for each time point. The 
presence of cDC subsets in the kidney was investigated on day 1 or day 2 after administration. 
The detailed gating strategy to identify renal cDCs as well as the CD64+ cell subsets F4/80hi 
and F4/80lo is shown in figure 35. 
 
 
Figure 35. Gating strategy to identify cDC populations and CD64+ cells in kidney. 
Flow cytometry gating strategy to identify renal cDC1 (liveCD45.2+CD11c+MHCII+CD64-CD24+CD11b-), cDC2 
(liveCD45.2+CD11c+MHCII+CD64-CD24-CD11b+) as well as two CD64+ population subsets F4/80hi cells 
(liveCD45.2+CD11c+MHCII+CD64+F4/80hiCD11b+) and F4/80lo cells 
(liveCD45.2+CD11c+MHCII+CD64+F4/80loCD11b+). Cells from kidney in Clec9aCre/CreRosa26DTR/DTR mice were 
stained with antibodies against indicated cell surface markers. The numbers in the dot plots indicate the 
percentages of the cells within the indicated gates. 
 
DT injection induced full depletion of renal cDC1 after 24 h and 48 h (Fig. 36A, B). In contrast 
to that cDC2 depletion efficiency was fully reached after 48 h (Fig. 36A, C). Surprisingly, none 
of the CD64+ cell subsets were affected by DT treatment, which is shown by count (Fig. 36A, 
D, E). 
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Figure 36. Depletion of renal cDC populations in Clec9a-Cre x Rosa26-iDTR mice. 
(A) Depletion of renal cDC1, cDC2, F4/80hi and F4/80lo populations after DT treatment in Clec9a-Cre x Rosa26-
iDTR mice. Clec9aCre/CreRosa26DTR/DTR mice were treated i.p. with DT (25 ng/g body weight) and on day 1 and day 
2 after injections renal cells were stained using antibodies against surface markers as indicated figure 35. Upper 
panel shows percentage of cell populations within the indicated gates in the control group and the lower panels 
show percentage in the DT treated group on different analysis days. (B) Analysis of renal cDC1 in 
Clec9aCre/CreRosa26DTR/DTR mice injected with DT. Total number per kidney is shown. Each symbol represents one 
mouse. (C) Analysis of renal cDC2 in Clec9aCre/CreRosa26DTR/DTR mice injected with DT. Total number per kidney is 
shown. Each symbol represents one mouse. (D) Analysis of renal F4/80hi cells in Clec9aCre/CreRosa26DTR/DTR mice 
upon DT administration. Total number per kidney is shown. Each symbol represents one mouse. (E) Analysis of 
renal F4/80lo cell population in Clec9aCre/CreRosa26DTR/DTR mice after DT administration. Total number per kidney 
is shown. Each symbol represents one mouse. * p < 0.05. 
 
Therefore, I concluded that 25 ng/g DT should be sufficient to successfully deplete cDC1 and 
cDC2 in Clec9a-Cre x Rosa26-iDTR mice and that this mouse model can be used for the 
investigation of functional role of cDCs during the AKI induction experiments. 
 
4.2.4. Depletion of cDC1 subset in XCR1-DTR-Venus mice 
 
As a second DTR-DT system based mouse model, the XCR1-DTR-Venus mice were selected to 
investigate the role of renal cDC1 during AKI development. This model was chosen, because 
it allows the selective depletion of XCR1 expressing cells, specifically cDC1 subset, without 
affecting additional DC populations or other cells, such as MOs, neutrophils, granulocytes as 
well as T and bursa of fabricius (B) cells185. XCR1-DTR-Venus mice were treated with DT as 
above. The presence of cDC1 in the kidneys was investigated on day 1 and day 2. In parallel 
one control group for each time point was also investigated. The gating strategy to identify 
renal cDC1 based on of the specific Venus expression of this model is shown in figure 37A. 
Similar to the before obtained results with Clec9a-Cre x Rosa26-iDTR, injection of DT induced 
full depletion of renal cDC1 in XCR1-DTR-Venus mouse samples after 24 h and 48 h (Fig. 37A, 
B). 
In summary, these data conclusively demonstrated that the administration of 25 ng/g DT in 
XCR1-DTR-Venus mice is enough to fully ablate renal cDC1 and this mouse model can be used 
for the cDC1 functional role investigation during the AKI. 
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Figure 37. Depletion of cDC1 in XCR1-DTR-Venus mice. 
(A) Depletion of renal cDC1 after DT treatment in XCR1-DTR-Venus mice. XCR1DTR-Venus/DTR-Venus mice were treated 
i.p. with DT (25 ng/g body weight) and on day 1 and day 2 after injections renal cells were stained using 
antibodies against surface markers. Flow cytometry gating strategy to identify renal cDC1 
(liveCD45.2+CD11cMHCII+CD11c+Venus+) is indicated. The numbers in the dot plots indicate the percentages of 
the cells within the indicated gates. Upper panel shows percentage of cell populations within the indicated gates 
in the control group and the lower panels show percentage in the DT treated group on different analysis days. 
(B) Analysis of renal cDC1 in XCR1DTR-Venus/DTR-Venus mice injected with DT. Total number and percentage with in 
the liveCD45.2+ cells per kidney is shown. Each symbol represents one mouse. * p < 0.05. 
 
4.2.5. Cisplatin treatment fails to induce consistent AKI induction in female 
mice and to draw conclusions about cDCs role during nephrotoxicity 
 
In order to investigate the contribution of cDC1 alone or cDC1 and cDC2 in combination during 
kidney homeostasis, the before validated XCR1-DTR-Venus and Clec9a-Cre x Rosa26-iDTR 
mouse models were used. To reach cell depletion a set of female mice were injected i.p. with 
a dose of 25 ng/g DT, followed one day later by i.p. injection with 15 mg/kg cisplatin to induce 
AKI or an equivalent volume of 0.9% NaCl used as a control (Fig. 38A). All cisplatin treated 
mice lost weight during the experiment (Fig. 38B). Unexpectedly, 20-34% of the animals 
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reached the termination criteria within 24 h after cisplatin administration and therefore, the 
experiment was terminated at this point to be able to compare disease severity between 
mice. As expected, animals treated with saline did not show signs of kidney damage, as 
assessed by BUN and creatinine levels (Fig. 38C, D). Within the cisplatin treated animals, 
kidney damage was observed in some, but not all animals (Fig. 38C, D), indicating a degree of 
disease variation. 
 
 
Figure 38. Effect of cDC depletion on kidney function in cisplatin induced nephrotoxicity. 
(A) Schematic representation of the experimental design. C57BL/6, Clec9aCre/CreRosa26DTR/DTR and XCR1+/DTR-Venus 
female mice were i.p. treated with DT (25 ng/g), followed by 1 mg/ml cisplatin (15 mg/kg) or 0.9% NaCl 
administration. Mice were monitored up to 24 h after second injection. (B) Mouse body weight change during 
the experiment. Line with black squares represents C57BL/6 mice treated with DT and 0.9% NaCl combination. 
Lines with open symbols indicate mice injected with DT and cisplatin. (C) BUN amount in the mouse plasma. 
Animals were treated as indicated before and 24 h later scarified for blood collected from the heart. Each symbol 
represents one mouse. (D) Creatinine amount in the plasma of mice. Animals were treated as in indicated before 
and 24 h later scarified for blood collected from the heart. Each symbol represents one mouse. * p < 0.05. 
 
Since tissue injury induced during AKI directly correlates with inflammation and infiltration of 
neutrophils149,152, the infiltration rate of neutrophils and MOs was additionally assessed by 
FACS. In concordance with the kidney function parameters found before, the quantity of 
neutrophils and MOs of DT and cisplatin treated mice from Clec9a-Cre x Rosa26-iDTR and 
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XCR1-DTR-Venus mouse models showed no significant difference compared to the wild type 
control group treated with DT followed by cisplatin injection (Fig. 39A, B). Nevertheless, 2 out 
of 4 XCR1-DTR-Venus mice showed the expected increased infiltration of neutrophils and 
MOs. Similarly, 1 out 5 Clec9a-Cre x Rosa26-iDTR mice had an increased neutrophil 
infiltration. However, in this model MO count was not increased in any animal (Fig. 39A, B). 
To estimate a possible protective effect in renal tissue damaging during AKI, the depletion 
efficiency of cDC1 and cDC1/cDC2 was analysed in parallel with a special focus on the CD64+ 
cell subsets. Regarding cDC1 a nearly complete ablation of their population was observed in 
both depletion models, compared to wild type control mice treated with the same 
combination of DT and cisplatin (Fig. 39C). As expected cDC2 were absent only in Clec9a-Cre 
x Rosa26-iDTR mice and F4/80hi as well as F4/80lo were not affected in both depletion models, 
compared to wild type control mice treated with the same combination of DT and cisplatin 
(Fig. 39D, E, F). 
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Figure 39. Effect of cDC2 and/or cDC1 depletion on infiltrating leukocytes in cisplatin induced 
nephrotoxicity. 
Analysis of renal neutrophils (A), MOs (B), cDC1 (C), cDC2 (D), F4/80hi (E) and F4/80lo (F) populations in C57BL/6, 
Clec9aCre/Cre Rosa26DTR/DTR and XCR1+/DTR-Venus female mice treated as described in 38.A. Cells were identified as 
described in figure 32A and figure 35. Total number of the cells per kidney is shown. Each symbol represents 
one mouse. * p < 0.05. 
 
Taken together, the observed inconsistent AKI induction data gained from these experimental 
setups at this point did not allow further conclusion about the role of cDCs during cisplatin 
induced nephrotoxicity. Furthermore, the unexpected termination after 24 h instead of 48 h 
after cisplatin injection challenge the before determined cisplatin dose of 15 mg/kg as the 
optimal amount to induce a reliable AKI response in these female animals. 
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5. Discussion 
 
 
5.1. Mouse generation 
 
In this thesis, a novel cell subset specific depletion mouse model, based on an inducible DTR-
DT system, was successfully developed to target renal CLEC9A+ progenitor derived CD64+ 
cells. This approach was mainly hindered by the fact that most immune cells share a common 
set of surface markers. Therefore, a strategy to develop a mouse model based on a broadly 
expressed protein to target just one cell population is not easy to design. This problem is 
specifically evident for the ontogenetically independent DC lineage, which is phenotypically 
similar to other MPS cells35,77-79,84. Like this, CD64 expression can be found on different MPS 
cell types24,120,121,218,284. To overcome this problem, recombinase based intersectional genetic 
approaches became nowadays the method of choice for the successful generation of cell-
specific depletion and labelling mouse models in multiple studies285-288. Another important 
requirement was the selection of a promising and efficient genome editing strategy. 
Therefore, as the basic concept to generate this mouse model I decided to use here a CRISPR-
Cas9 genome editing strategy combined with Cre-loxP, which allowed to prevent the 
necessity to identify a unique cell-subset specific marker. 
Even though CLEC9A+ progenitor derived CD64+ cell depletion was successfully reached in this 
work, some data were observed during the validation process of this mouse model, which 
need to be further investigated and discussed before it can be applied for future scientific 
applications. 
One observation was the missing detection of DTR expression after DT treatment on CD64+ 
cells, isolated from the kidney of Clec9a+/CreCD64+/DTR mice. This data was noticeable, since 
DTR expression in Clec9a+/CreCD64+/DTR mice was expected to be found on approximately 30% 
of the renal CD64+ cells, as this labelling efficiency of this population was observed in a 
genetically similar mouse model Clec9a+/CreRosa26+/EYFP24. However, here the expression of a 
cytosolic fluorescent dye was used to track CLEC9A+ progenitor derived cell. This had the 
advantage that a possible degradation of the reporter protein during the process of cell 
isolation from the tissue could be excluded, which in turn could explain the missing DTR signal 
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during FACS analysis in this work. Especially, the required conditions for renal cell isolation, 
including the necessary cell enrichment, were more prone for the loss of cell surface markers 
than for leukocyte isolation from spleen. This becomes especially evident for the direct 
comparison of DTR staining between splenic and renal cDC1, isolated from Clec9a-Cre x 
Rosa26-iDTR mouse samples used for this work. In consequence, the needed conditions for 
cell isolation can explain the occurred discrepancy, that the detected signal intensity most 
likely do not correlate with the real amount of protein expression on the isolated cells289-292. 
Nevertheless, it cannot be excluded that a missing DTR detection can also be explained by too 
low protein expression. This assumption is supported by a similar controversy observation in 
another CD64 based depletion model186. These CD64-DTR mice, generated by knocking-in of 
EGFP fused with DTR into CD64 3’-UTR sequence, showed also no detectable cytosolic EGFP 
expression by FACS186. However, likewise the data generated in this thesis, DT treatment 
successfully depleted skin CD64+ MØs in CD64-DTR mice. 
Unexpectedly, the depletion efficiency of renal CD64+ cells in Clec9a+/CreCD64+/DTR mice was 
even higher than labelling efficiency in the aforementioned Clec9a+/CreRosa26+/EYFP model and 
accounted for approximately 80% of renal CD64+ cells after DT treatment. This was surprising, 
since the investigated animals were just heterozygous and raised the expectations, that the 
planned inbreeding to produce homozygous animals will improve the depletion efficiency 
even more significantly in future. These obvious differences between labelling and depletion 
efficiency in Clec9a+/CreRosa26+/EYFP and Clec9a+/CreCD64+/DTR mice by itself can be most likely 
explained by different LSL excision efficiencies, because both mouse lines were heterozygous 
for all genetic manipulations and, more importantly, the same promoter was used to control 
Cre recombinase. Such differences between two genetically similar models can be caused by 
epigenetic modifications and DNA looping at the loxP sequence or the effective distance 
between the loxP sites192,293,294. Specifically the fact is crucial, at which position the loxP sites 
are located in the genome and how big the physical distance for the Cre recombinase is to 
bring both loxP sites together192,293. 
Another striking observation was the higher depletion efficiency of splenic RPMs, because DT-
administration in Clec9a+/CreCD64+/DTR mice induced more than 50% depletion of this 
population, in contrast to the expected 2% positive labelled RPMs as observed for genetically 
similar Clec9a+/CreRosa26+/EYFP mice24. However, recent studies indicate that RPMs mainly do 
not develop from DC lineage and are independent of CLEC9A+ CDPs or pre-cDCs20,295,296. 
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Nevertheless, the observed high depletion of RPMs in this work indicates, that RPMs or one 
of their progenitor expressed CLEC9A, resulting in Cre recombinase translation and LSL 
cassette excision allowing DTR translation. It is less likely, that the observed RPM depletion is 
nonspecific, since DT treatment did not affect any splenic cDC populations. In addition to this, 
a detail study of DT entrance into the cell has shown that unspecific DT uptake via pinocytosis 
pathway leads to its degradation in the lysosomes without affecting cell viability176,177. Only 
for very high concentration of DT a minimal protein synthesis inhibition in mouse MØs was 
observed176,177. Therefore, the detected high depletion of RPMs in Clec9a+/CreCD64+/DTR mice 
makes the Clec9a-Cre mouse model maybe not be an ideal in vivo model for an exclusive 
identification of DC lineage cells24. However, it needs to be taken into account that the limited 
number of Clec9a-Cre x CD64-LSL-2A-DTR animals used for this study not allows a final 
conclusion at this point without further investigations. Importantly, more detailed studies 
need to be performed to exclude potential systemic MØ ablation upon DT administration in 
Clec9a-Cre X CD64-LSL-2A-DTR mice. 
Even though the generated Clec9a+/CreCD64+/DTR mouse model allows now the selective 
depletion of CLEC9A+ progenitor derived CD64 expressing cells, in particular renal CD64+ 
population, it needs to be considered, that several other cDC and MØ targeting DTR-DT 
system based transgenic mouse models do exist127,166. However, most of them show a lower 
efficiency and specificity, because here DT administration affects not only the desired cell 
population127,164. Therefore, the published data from these models need to be interpreted 
and discussed carefully. Examples are displayed by the different CD11c based mouse models, 
which are commonly used to study cDC functions, even though DT administration also affects 
MØs and MOs164. In contrast to this, the Clec9a-Cre x CD64-LSL-2A-DTR mouse model allows 
the specific depletion of renal CLEC9A+ progenitor derived CD64+ cells, without affecting renal 
cDC1 and cDC2 and related subsets in spleen. This was expected, since cDCs develop from 
CLEC9A+ progenitors and do not or only at very low level express CD6424,120,121. 
Another drawback of several available DTR-DT based cDC depletion models so far was the 
reported an undesired development of neutrophilia or monocytosis upon DT 
treatment127,204,297. This side effect of DT administration complicates the interpretation of the 
data, since is not clear if the observed outcome of the study is due to the absence of the cells 
or due to an increased count of MOs and neutrophils. Like this, a study reported that DT 
treated CD11c-DOG mice were able to faster overcome a bacterial infection during bacterial 
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pyelonephritis180. Nevertheless, these data were put into question by Blijswijk et al., who 
stated that the observed result was rather due to the rapid influx of neutrophils, than due to 
the absence of CD11c+ cells127. Especially, because neutrophils are involved in bacterial 
pyelonephritis298. In contrast to CD11c based depletion mouse models180, DT treated 
Clec9a+/CreCD64+/DTR mice in this work did not develop neutrophilia or monocytosis within 48 
h. However, the development of neutrophilia in Clec9a-Cre x CD64-LSL-2A-DTR mice can be 
not excluded so far at later time points, based on the experimental setup used in this work. 
Finally, the question remains, how this new mouse model can be used in future to answer 
urgent basic scientific and translational questions. Generally, this new model has the 
advantage to offer the possibility to systemically deplete any CD64+ cell population, e.g. after 
crossing with any mouse model that contains generally expressed Cre. Beside this, the CD64-
LSL-2A-DTR mouse model can be crossed with any murine model, which contains a cell subset 
specific promoter regulated Cre, allowing to target now a specific CD64 expressing cell 
subpopulation, in contrast to systemic CD64+ cell depletion. 
Such a selective depletion of the cells could overcome the problem of multiplicity studies 
dealing with renal DC functions, which treated CD11c+ cells as a homogenous population 
without the possibility to resolve the observed effects to individual cDC1, cDC2 and CLEC9A+ 
progenitor derived CD64+ cell populations91,134,136-140. Even though several of these studies 
has phenotypically characterized the kidney CD64+ cells and addressed the functional 
question using different kidney disease models, their investigations were limited in their 
expressiveness, since the specific ablation of renal CD64+ cells was not possible at this time124-
126,128,299. One study, that could have benefited from the inclusion of the CD64-LSL-2A-DTR 
mouse model, had the aim to investigate the role of tissue MØs in type III hypersensitivity 
and identified a physiological function of tissue-resident MØs in the kidney interstitium128. In 
particular, the authors described a tissue-specific anatomical and functional unit, formed by 
resident MØs and peritubular capillary endothelial cells, which enabled them to detect 
potential infectious particles, in this case IC, and to initiate an immune response128. Assuming 
that the authors would have included the Clec9a-Cre x CD64-LSL-2A-DTR mouse model in 
their studies, the role of the physical contribution of the MØs as well as CLEC9A+ progenitor 
derived CD64+ cells to the tissue-specific anatomical and functional unit could have been 
addressed in more detail. Similarly, the CD64-LSL-2A-DTR mouse model could support the 
data of Puranik et al., who described a specific protective role of MØs during chronic ischemic 
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injury124. Especially because the role of kidney MØs was here investigated using liposomal 
clodronate based depletion, with the disadvantage to cause a possible neutrophil influx in the 
tissue, which was even critical discussed by the authors124. Nevertheless, these data open 
another interesting field for the application of the CD64-LSL-2A-DTR mouse model, since this 
work has shown that kidney resident CD64+ cells are important and play protective role during 
ischemic injury. Therefore, it would be important to investigate if the CLEC9A+ progenitor 
derived CD64+ cells respond to the sterile inflammation during nephrotoxic AKI in the similar 
way. Moreover, studies similar to Lee et al., were the authors just characterized renal 
CD45intCD11bint and CD45hiCD11b+ populations during ischemia-reperfusion injury, could be 
substantially improved by the application of the CD64-LSL-2A-DTR mouse model 
supplemented with a cDC specific depletion mouse models126. 
Beside the possibly to use the CD64-LSL-2A-DTR mouse model, crossed with Clec9a-Cre mice, 
to study CLEC9A+ progenitor derived CD64+ cells or CD64 expressing cDCs, also it can be 
crossed with Cre-carrying MO/MØ-specific mouse model. This would allow to specifically 
target MØs and MOs and to investigate their role in homeostasis of various tissues and 
disease models. Especially, because the recently developed CD64-DTR mouse model, which 
is the closest overlap in regard of applicability, is less specific due to the depletion of CD64 
expressing cells including MOs, MØs, MDPs as well as CD64+ cDCs24,186,218. The reason for this 
is the transcriptional regulation of DTR expression through the CD64 promoter alone in this 
model186. More importantly, these mice were generated by knock-in EGFP fused with DTR 
into the 3’-UTR region of CD64, which is known to be bound by various RNA-binding molecules 
involved in the fate of the expressed mRNA300,301. Among others, it was shown that human 
CD64 3’-UTR is a direct target of micro RNA (miR)-127, resulting in a translational repression 
of this protein302. Additionally, this study found that miR-127 expression in MØs was 
regulated during inflammation both in vitro and in vivo302. Even though the translational 
repression of the murine 3’-UTR of CD64 is just poorly investigated, these data suggest a 
similar influence on the murine CD64 mRNA regulation by the murine homolog of miR-127 
and other murine miRs. This assumption is made because the seed sequences within the 
transcribed mRNAs, responsible for the specific binding of the 3’-UTR, are normally highly 
conserved between Homo sapiens and Mus musculus303. Another possible drawback of this 
CD64-DTR mouse model, compared to the model developed in this thesis, is the dependency 
of DTR translation on an internal ribosome entry site (IRES) sequence. It is known, that such 
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IRES-based exogenous protein expression is often lower than the endogenous host protein, 
even though both proteins are translated from the same mRNA304,305. Even through the 
authors did not discuss this point, it can contribute to the observed and before discussed 
undetectable EGFP protein expression but still successful depletion of CD64+ cells in CD64-
DTR mice. Moreover, this could explain the high DT dose used in this study to compensate 
low DTR expression. Thus, not only the lack of specificity but also the required high DT amount 
to deplete the cells, which bear the risk of proteinuria306, make the CD64-DTR mouse model 
not the ideal choice for renal cell function investigations. In contrast, the new CD64-LSL-2A-
DTR mice showed a nearly complete depletion of the targeted cells with a lower dose of DT 
thereby, most probably preventing unspecific high dose DT treatment caused side effects306. 
Since these promising results and the performed experiments in this work were still at the 
very beginning, even a lower and in consequence, more beneficial DT dose could be 
conceivable for future experiments to obtain the same depletion effect as described for the 
treatment of CD64-LSL-2A-DTR mice. 
Another interesting application of the CD64-LSL-2A-DTR mouse model generated in this thesis 
is the crossing with Cre/loxP based MØ targeted mouse models, thereby generating novel 
MØ/MO-specific depletion mouse models. Most popular models are LysM-Cre, CX3CR1-Cre 
and CD11b-Cre198,201,307. Such a strategy could compensate that most of the Cre strains are 
indeed described to be specific to target certain cell population and tissues, but the detailed 
analysis often shows that increased efficiency is most of the time negatively correlated with 
the found specificity127,207. In this context a study by Abram et al., made a substantial 
contribution by investigating the complete expression pattern of EYFP, between various MØ 
as well as DC Cre-models, crossed with the same reporter Rosa26-iEYFP model207. Amongst 
others, the authors showed conclusively that LysM-Cre significantly deleted LSL cassette in 
the Rosa26 locus, thereby allowing high MØ labelling across the organism. Nevertheless, this 
was accompanied by a high EYFP labelling in polymorphonuclear neutrophils (PMNs) and 
some labelling in DCs. Moreover, similar observations were made for CD11c-Cre and CD11b-
Cre207. Therefore, one can assume that the crossing of the newly established CD64-LSL-2A-
DTR mouse model with one of these high efficient Cre recombinase models would help to 
overcome their specificity problem. Moreover, the strategy from this work to increase 
specificity and efficiency of depletion can be utilized as a basis for the design and generation 
for future mouse models. Especially the development of cDC2 subset specific depletion 
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mouse models could benefit from this, since they are up to date lacking specificity to target 
this population308. 
In conclusion, the novel Clec9a-Cre x CD64-LSL-2A-DTR mouse model can be used to 
specifically deplete CLEC9A+ progenitor derived CD64+ cells. Additionally, the CD64-LSL-2A-
DTR mouse model offers the possibility to increase the depletion specificity of other Cre-
based models, opening the perspective to study highly selective any CD64 expressing cell 
subpopulation and draw conclusions about its specific functions. Therefore, this mouse model 
will hopefully be a substantial help in future to study the functional role of CD64+ cells in more 
detail for disease pathogenesis and progression with the long-term objective to test and 
develop convenient drugs for new therapeutic approaches and treatments. 
 
5.2. cDC role in AKI 
 
In the second part of this thesis cisplatin was used to induce AKI in mice with C57BL/6 
background. The aim was to establish a spontaneous reproducible protocol with a high 
disease incidence for studying the role of cDC during nephrotoxic AKI. Since C57BL/6 have 
been used routinely in studies to investigate actual cancer related and immunological needs, 
I intended to use them as the basic background strain309. Furthermore, most of the routinely 
used mouse models in the laboratory were based on C57BL/6 and transgenic mice with 
C57BL/6 background at this time24,99,185,204. 
However, even though the cisplatin mouse model is widely accepted as a simple and 
reproducible disease model, the initial establishment can be extremely challenging if the 
method is not standardized and routinely used in the laboratory310. Unfortunately, the 
success of AKI induction depends not only on obvious factors, like drug application, dose, and 
the biomarkers to estimate disease severity. It becomes more and more clear that also factors 
like animal age, genetic background, gender, circadian rhythm, diet, hydration status, or 
microenvironment can have a crucial impact on disease induction and reproducibility310. 
One of the most challenging problems in this study was the appearance of high disease 
variation within the experimental group. As it was mentioned before, the cisplatin mouse 
model is indeed often described as a reproducible model, which requires small amount of 
animals for the investigation311,312. Most of the published studies refer to a protocol, which 
 Discussion  
 106 
contains a single injection of a high dose of 20 mg/kg cisplatin with a duration of 72 h before 
the successful AKI induction is measured by BUN and creatinine149-151,313-315. Therefore, I 
decided in the present work to refer to a protocol published by Ramesh et al., where the 
authors used a dose of 20 mg/kg cisplatin for nephrotoxic AKI induction311. However, this dose 
was reduced to 15 mg/kg for the last investigations, because the mice got too sick and 
reached termination criteria before the expected end point with the initial cisplatin dose. 
Nevertheless, it was not possible to reproduce the previously published data for a study 
endpoint of 72 h, due to earlier termination of the experiments caused by low survival rate 
of the animals. Instead, only a part of the treated animals reached a severe stage and the 
experiments needed to be terminated within 24-48 h. After several modifications it was finally 
possible to induce AKI after a single i.p. injection of cisplatin with a dose of 15 mg/kg. 
Cisplatin toxicity can be influenced by the animal genetic background, microbiological state 
or even physical conditions310. Therefore, often rodents do not respond equally to cisplatin 
treatment, which in consequence, make it sometimes difficult to draw conclusions from the 
published studies to the data gained in this work. Additionally, valuable data about animal 
mortality during the experiments are rarely published in most of the cisplatin studies310. Only 
a few investigations are an exception from that, supporting the notion that a high disease 
variation obviously sometimes occurs310,316. One exception is the study published by Liu et al., 
where they reported similar observations, that only some animals in an experimental group 
showed an increased susceptibility, as demonstrated by the survival of less than 60% of 
treated mice over a period of 72 h316. In contrast to these data, it was also observed that 9 
out of 10 mice developed severe AKI, while 1 did not show any signs of cisplatin induced 
nephrotoxicity310. These data keep the question unanswered if the group size of each 
individual setup in this pilot study may cause the absence of any significant difference even if 
it would exist in a setup with a higher number of animals. 
Another obvious difference of this study to most of the published data is the preference to 
use male mice for AKI induction154,158,311,313,314,316-330. This leads to the point, that the choice 
of the gender plays a potential role for the success of these experiments. This observation is 
further supported by recent scientific discussions that the observed susceptibility to 
damaging mechanism in the body often depends on the gender of the animals selected for 
the in vivo study310,331,332. In line with this, several studies have analyzed such a gender based 
influence on AKI susceptibility during the last years. For instance, it was shown that males are 
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more susceptible to ischemia-reperfusion injury induced AKI than females, due to enhanced 
inflammatory responses observed in male mice333. Most probably some of these observed 
differences can be explained by sex hormones, since their influence on ischemia-reperfusion 
injury induced AKI was already demonstrated333-336. Nevertheless, in contrast to this, the 
exact role of the animal gender during nephrotoxic AKI is still not clear and needs to be further 
investigated, since one study concluded that males survived better than females, while 
another found that males were more susceptible337,338. A recent study, which investigated the 
transcriptome and proteomic profile of male and female microglia, found, that male microglia 
expressed higher levels of MHCI and MHCII339. In consequence these MØs had a higher 
antigen presenting capacity compared to female microglia cells. These results gained from 
microglia cells even lead to the assumption that the observed differences need to be also 
considered for a critical interpretation of any data gained in relation to the role of renal MØs 
and other innate immune cells during AKI. Vice versa these gender dependent differences 
raise the question, to which extend preclinical animal models, that are based only on one 
gender, are representative enough to answer a scientific question in this field 
comprehensively. 
Another problem with cisplatin treatment is the ability to penetrate systemically into all 
tissues, without a specific preference146,340. Here it affects all fast dividing cells, but also tends 
to accumulate over the time in some tissues like kidney. Depending on the tissue, cisplatin 
can cause gastrointestinal toxicity, myelosuppression, nephrotoxicity, neuropathy, vascular 
injury and ototoxicity147. Generally, mice treated with high dose of cisplatin develop minimal 
clinical signs of toxicity after 2 days, while obvious physiological reaction are observed on day 
3, followed by the death of the animals on the 4th -7th day after treatment310. Unexpectedly 
in this work and in contrast to published data, where the severe pain is normally observed 
after 4 days during cisplatin caused toxicity, several mice per experimental group reached 
termination criteria within the first 24 h after injection310. Those mice showed rapidly 
developed signs of severe pain, such as hunched posture, lethargy, loss of coordination, 
rotating body movements after upholding mice by the tail, and were all confirmed for 
nephrotoxicity by increased BUN and creatinine levels. Importantly, these results were 
observed independent of the dose. In conclusion and to prevent most likely the loss of 
animals within the desired time frame of 72 h a lower dose of cisplatin (< 10 mg/kg) need to 
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be considered and tested in future experiments. Finally, this approach should rather lead to 
the desired induction of nephrotoxicity, than the observed systemic toxicity. 
Cisplatin is not very soluble in the aquatic solutions341. Nevertheless, injectable cisplatin 
solution is mostly prepared in 0.9% NaCl solution, where Cl ions help to stabilize cisplatin in 
the therapeutically active cis-isomerization form311,341. Cisplatin is routinely administrated 
i.p., but can be also injected intravenously or subcutaneously310,342. This need to be taken in 
consideration, since it was shown that in rats i.p. administration of cisplatin resulted in a 
reservoir effect, which in consequence led to an increased half-life of the drug in the serum, 
compared to intravenous application342. Beside the way of cisplatin administration, there are 
multiple other factors described to have in impact of the successful induction of 
nephrotoxicity using this drug. For instance, it is published that dietary plays important role. 
In particular, magnesium depletion in the animal dietary enhances cisplatin treatment 
nephrotoxicity, causing early death of the animals343. The same effect was observed with 
selenium, where selenium-reduce dietary enhanced nephrotoxicity324. In addition to this, the 
hydration status of the animal also affects the animal sensitivity to cisplatin344,345. It was 
shown that an increased hydration status led to reduced nephrotoxicity in rats by 60-70%344. 
To limit such variation in disease severity within the group, several studies decided to 
withhold food and water from the animals few hours before the cisplatin 
injection154,158,318,346,347. However, timing of cisplatin administration and circadian rhythm also 
needs to be taken into the account328,329,348,349. It was demonstrated that cisplatin treatment 
in rats near midactivity span, shortly after the maximum of the circadian rhythm reduces 
cisplatin caused nephrotoxicity345. In addition to this, it is speculated that also inflammatory 
reactions depend on circadian rhythmicity in the kidney and contributes for cisplatin 
susceptibility, since murine renal interleukin IL-6 production shows circadian rhythmicity and 
IL-6 is known to play a protective role during cisplatin induced AKI325-327,329. Moreover, the 
microbiological status of the animals is also considered to be the cause for nephrotoxic AKI 
severity variations317,330. A study published by Ramesh et al., demonstrated that mice treated 
with cisplatin in combination with LPS developed severe renal failure and showed increased 
mortality compared to the just cisplatin treated control group317. Therefore, all these 
examples of variables, that potentially can influence the data obtained from induced 
nephrotoxicity, show the importance of standardized conditions for the reproducibility of 
each experimental setup within a study, but also to compare the data obtained from different 
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studies. In consequence, the importance needs to be emphasized to include these additional 
variables to the initial experimental setup of this work to exclude, that variables like the way 
of administration, time point of administration or the diet of the animals caused the 
inconsistent data so far. 
BUN and creatinine were used as a screening test for kidney function evaluation. These 
metabolic biomarkers were mainly chosen because they are routinely used as a fast and 
simple method for kidney function evaluation for clinical diagnostic and in vivo studies113,116. 
However, it needs to be pointed out, that these biomarkers lack specificity and sensitivity and 
are obviously not fully reliable indicators of renal function113. For instance, they can be easily 
influenced by various physiological factors leading to an overestimation of the kidney tissue 
disruption degree. This include changes in protein synthesis, protein degradation due to loss 
of body weight, bleeding in intestine or stomach or dehydration350-352. Indeed, since a drastic 
weight lost was also observed in this work for cisplatin treated mice, this effect may 
contribute to BUN and creatinine level variation. However, assuming that the elevated BUN 
and creatinine levels measured in this work were not significantly influenced by the described 
factors lead to the conclusion, that these animals developed a premature AKI. Especially 
because it was shown that BUN and creatinine levels in the blood do not increase before 70-
75% of murine nephrons are damaged, which than refers as severe stage of kidney 
damage346,350. Thus, it would be important to test first lower doses of cisplatin on both sex 
animals in the future to prevent the loss of animals before the planned experimental end 
point. 
In this regard it need to be also mentioned, that apparently the age of the animals also 
influences susceptibility to cisplatin toxicity, because young mice as well as older mice are 
more susceptible for cisplatin treatment310. For instance, a single dose of 16 mg/kg cisplatin 
injection into 24 month old mice resulted in 100% mortality, while 4-8 weeks old mice showed 
only 40% mortality within 7 days353,354. Therefore, in this work exclusively 8-12 weeks old mice 
were selected for treatment, to eliminate the described age dependent increased 
susceptibility to cisplatin toxicity. 
In conclusion, this work established a preliminary AKI induction protocol using female mice 
with a single dose of 15mg/kg. Since the initial goal to induce severe AKI not before 72 h was 
still not reached at this point, the before critically discussed variables need to be taken in 
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consideration for the future establishment of an adjusted and standardized protocol to 
induce AKI at an appropriate study end-point in a reliable and repeatable way. 
The long-term objective of this AKI induction model is to investigate the role of each individual 
cDC subsets, with a special focus on CD64+ cells. Even though the final establishment of this 
cisplatin based nephrotoxic model is still owing, the pilot experiments to deplete cDC1/cDC2 
or cDC1 in Clec9a-Cre x Rosa26-iDTR and XCR1-DTR-Venus mice were successfully done. Here, 
interesting observation applies to the decreased counts of F4/80hi and F4/80lo in Clec9a-Cre 
x Rosa26-iDTR mice after DT/Cisplatin treatment leading to the conclusion that DT/Cisplatin 
combination induces this effect, since the influence of DT treatment on these populations 
was not observed in previous experiments. However, these results are at moment in contrast 
to the majority of publications, where the cisplatin treatment led to increased infiltration of 
MØs158,320. Since the establishment of the AKI induction model is still under investigation in 
the laboratory, future experiments will most probably answer the question, if this described 
discrepancy is just a unique effect of this experiment or will be reproduced significantly under 
these experimental conditions. 
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7. Appendix 
 
 
7.1. Plasmid sequences 
 
7.1.1. GCDL-2A-DTR 
 
CAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCA
GATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTA
GTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTG
ACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAA
TAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTA
CATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGC
CTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTAT
TAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGG
TTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCA
CCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCG
GTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACT
GCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTTCGAATTCTGC
AGTCGACGGTACCGCGGGCCCGGGATCCATCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGC
GTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCAC
CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGT
GCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAA
GGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGA
GGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGG
AGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATC
ATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGA
CGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGC
TGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAG
CGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGA
GCTGTACAAGGGTTCCGGTGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGACGTGGAAG
AAAACCCCGGTCCCATGGATATCTCCAACCTGCTGACTGTGCACCAAAACCTGCCTGCCCTC
CCTGTGGATGCCACCTCTGATGAAGTCAGGAAGAACCTGATGGACATGTTCAGGGACAGGCA
GGCCTTCTCTGAACACACCTGGAAGATGCTCCTGTCTGTGTGCAGATCCTGGGCTGCCTGGT
GCAAGCTGAACAACAGGAAATGGTTCCCTGCTGAACCTGAGGATGTGAGGGACTACCTCCTG
TACCTGCAAGCCAGAGGCCTGGCTGTGAAGACCATCCAACAGCACCTGGGCCAGCTCAACAT
GCTGCACAGGAGATCTGGCCTGCCTCGCCCTTCTGACTCCAATGCTGTGTCCCTGGTGATGA
GGAGAATCAGAAAGGAGAATGTGGATGCTGGGGAGAGAGCCAAGCAGGCCCTGGCCTTTGAA
CGCACTGACTTTGACCAAGTCAGATCCCTGATGGAGAACTCTGACAGATGCCAGGACATCAG
GAACCTGGCCTTCCTGGGCATTGCCTACAACACCCTGCTGCGCATTGCCGAAATTGCCAGAA
TCAGAGTGAAGGACATCTCCCGCACCGATGGTGGGAGAATGCTGATCCACATTGGCAGGACC
AAGACCCTGGTGTCCACAGCTGGTGTGGAGAAGGCCCTGTCCCTGGGGGTTACCAAGCTGGT
GGAGAGATGGATCTCTGTGTCTGGTGTGGCTGATGACCCCAACAACTACCTGTTCTGCCGGG
TCAGAAAGAATGGTGTGGCTGCCCCTTCTGCCACCTCCCAACTGTCCACCCGGGCCCTGGAA
GGGATCTTTGAGGCCACCCACCGCCTGATCTATGGTGCCAAGGATGACTCTGGGCAGAGATA
CCTGGCCTGGTCTGGCCACTCTGCCAGAGTGGGTGCTGCCAGGGACATGGCCAGGGCTGGTG
TGTCCATCCCTGAAATCATGCAGGCTGGTGGCTGGACCAATGTGAACATAGTGATGAACTAC
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ATCAGAAACCTGGACTCTGAGACTGGGGCCATGGTGAGGCTGCTCGAAATCAAACGGTCGGC
CGCAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAA
AGAAGAGAAAGGTAGATACGGCCGCATCCGGAGCCACGAACTTCTCTCTGTTAAAGCAAGCA
GGAGACGTGGAAGAAAACCCCGGTCCCATGAAGCTGCTGCCGTCGGTGGTGCTGAAGCTCTT
TCTGGCTGCAGTTCTCTCGGCACTGGTGACTGGCGAGAGCCTGGAGCGGCTTCGGAGAGGGC
TAGCTGCTGGAACCAGCAACCCGGACCCTCCCACTGTATCCACGGACCAGCTGCTACCCCTA
GGAGGCGGCCGGGACCGGAAAGTCCGTGACTTGCAAGAGGCAGATCTGGACCTTTTGAGAGT
CACTTTATCCTCCAAGCCACAAGCACTGGCCACACCAAACAAGGAGGAGCACGGGAAAAGAA
AGAAGAAAGGCAAGGGGCTAGGGAAGAAGAGGGACCCATGTCTTCGGAAATACAAGGACTTC
TGCATCCATGGAGAATGCAAATATGTGAAGGAGCTCCGGGCTCCCTCCTGCATCTGCCACCC
GGGTTACCATGGAGAGAGGTGTCATGGGCTGAGCCTCCCAGTGGAAAATCGCTTATATACCT
ATGACCACACAACCATCCTGGCCGTGGTGGCTGTGGTGCTGTCATCTGTCTGTCTGCTGGTC
ATCGTGGGGCTTCTCATGTTTAGGTACCATAGGAGAGGAGGTTATGATGTGGAAAATGAAGA
GAAAGTGAAGTTGGGCATGACTAATTCCCACGGTTCCGGAGCCACGAACTTCTCTCTTTTAA
AGCAAGCAGGAGACGTGGAAGAAAACCCCGGTCCCATGGTGAAGCGTGAGAAAAATGTCATC
TATGGCCCTGAGCCTCTCCATCCTTTGGAGGATTTGACTGCCGGCGAAATGCTGTTTCGTGC
TCTCCGCAAGCACTCTCATTTGCCTCAAGCCTTGGTCGATGTGGTCGGCGATGAATCTTTGA
GCTACAAGGAGTTTTTTGAGGCAACCGTCTTGCTGGCTCAGTCCCTCCACAATTGTGGCTAC
AAGATGAACGACGTCGTTAGTATCTGTGCTGAAAACAATACCCGTTTCTTCATTCCAGTCAT
CGCCGCATGGTATATCGGTATGATCGTGGCTCCAGTCAACGAGAGCTACATTCCCGACGAAC
TGTGTAAAGTCATGGGTATCTCTAAGCCACAGATTGTCTTCACCACTAAGAATATTCTGAAC
AAAGTCCTGGAAGTCCAAAGCCGCACCAACTTTATTAAGCGTATCATCATCTTGGACACTGT
GGAGAATATTCACGGTTGCGAATCTTTGCCTAATTTCATCTCTCGCTATTCAGACGGCAACA
TCGCAAACTTTAAACCACTCCACTTCGACCCTGTGGAACAAGTTGCAGCCATTCTGTGTAGC
AGCGGTACTACTGGACTCCCAAAGGGAGTCATGCAGACCCATCAAAACATTTGCGTGCGTCT
GATCCATGCTCTCGATCCACGCGTGGGCACTCAGCTGATTCCTGGTGTCACCGTCTTGGTCT
ACTTGCCTTTCTTCCATGCTTTCGGCTTTAGCATTACTTTGGGTTACTTTATGGTCGGTCTC
CGCGTGATTATGTTCCGCCGTTTTGATCAGGAGGCTTTCTTGAAAGCCATCCAAGATTATGA
AGTCCGCAGTGTCATCAACGTGCCTAGCGTGATCCTGTTTTTGTCTAAGAGCCCACTCGTGG
ACAAGTACGACTTGTCTTCACTGCGTGAATTGTGTTGCGGTGCCGCTCCACTGGCTAAGGAG
GTCGCTGAAGTGGCCGCCAAACGCTTGAATCTTCCAGGGATTCGTTGTGGCTTCGGCCTCAC
CGAATCTACCAGCGCTAACATTCACTCTCTCGGGGATGAGTTTAAGAGCGGCTCTTTGGGCC
GTGTCACTCCACTCATGGCTGCTAAGATCGCTGATCGCGAAACTGGTAAGGCTTTGGGCCCG
AACCAAGTGGGCGAGCTGTGTATCAAAGGCCCTATGGTGAGCAAGGGTTATGTCAATAACGT
TGAAGCTACCAAGGAGGCCATCGACGACGACGGCTGGTTGCATTCTGGTGATTTTGGATATT
ACGACGAAGATGAGCATTTTTACGTCGTGGATCGTTACAAGGAGCTGATCAAATACAAGGGT
AGCCAGGTTGCTCCAGCTGAGTTGGAGGAGATTCTGTTGAAAAATCCATGCATTCGCGATGT
CGCTGTGGTCGGCATTCCTGATCTGGAGGCCGGCGAACTGCCTTCTGCTTTCGTTGTCAAGC
AGCCTGGTAAAGAAATTACCGCCAAAGAAGTGTATGATTACCTGGCTGAACGTGTGAGCCAT
ACTAAGTACTTGCGTGGCGGCGTGCGTTTTGTTGACTCCATCCCTCGTAACGTAACAGGCAA
AATTACCCGCAAGGAGCTGTTGAAACAATTGTTGGAGAAGGCCGGCGGTTAGGGATCAGCCT
CGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACC
CTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCT
GAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGG
AAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACC
AGCTGGGGCTCGAGGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCGCGGCCGCTCGCGC
ACTACTCAGCGACCTCCAACACACAAGCAGGGAGCAGATACTGGCTTAACTATGCGGCATCA
GAGCAGATTGTACTGAGAGTCGACCATAGGGGATCGGGAGATCTCCCGATCCGTCGACGTCA
GGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTC
AAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGA
AGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTT
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CCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGC
ACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCG
AAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGT
ATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGA
GTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTG
CTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCG
AAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGA
ACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGG
CAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTA
ATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGG
CTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCAC
TGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACT
ATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAAGA
AGTTCCTATTCTCTAGAAAGTATAGGAACTTCTTAATTAACGGCTAGCTGCATTCTAGTTGT
GGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAG
CTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCAC
ACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTC
ACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCA
TTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCT
CGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAG
GCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGG
CCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCC
CCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTA
TAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCC
GCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCAC
GCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCC
CCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAG
ACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAG
GCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTT
GGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGG
CAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAA
AAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAA
AACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTT
AAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAG 
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TAGATATCGATGGCCATAGCGGCCGCTCTAGAACTAGTGGATCCCCCACCTGACTGATGAAG
TTCCTATACTTTCTAGAGAATAGGAACTTCGAAGGGTTCCGCAAGCTCTAGTCGAGCCCCAG
CTGGTTCTTTCCGCCTCAGAAGCCATAGAGCCCACCGCATCCCCAGCATGCCTGCTATTGTC
TTCCCAATCCTCCCCCTTGCTGTCCTGCCCCACCCCACCCCCCAGAATAGAATGACACCTAC
TCAGACAATGCGATGCAATTTCCTCATTTTATTAGGAAAGGACAGTGGGAGTGGCACCTTCC
AGGGTCAAGGAAGGCACGGGGGAGGGGCAAACAACAGATGGCTGGCAACTAGAAGGCACAGT
CGAGGCTGATCAGCGAGCTCTAGAGAATTGATCCCCTCAGAAGAACTCGTCAAGAAGGCGAT
AGAAGGCGATGCGCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAGGAAGCGGTCAGCC
CATTCGCCGCCAAGCTCTTCAGCAATATCACGGGTAGCCAACGCTATGTCCTGATAGCGGTC
CGCCACACCCAGCCGGCCACAGTCGATGAATCCAGAAAAGCGGCCATTTTCCACCATGATAT
TCGGCAAGCAGGCATCGCCATGGGTCACGACGAGATCATCGCCGTCGGGCATGCGCGCCTTG
AGCCTGGCGAACAGTTCGGCTGGCGCGAGCCCCTGATGCTCTTCGTCCAGATCATCCTGATC
GACAAGACCGGCTTCCATCCGAGTACGTGCTCGCTCGATGCGATGTTTCGCTTGGTGGTCGA
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ATGGGCAGGTAGCCGGATCAAGCGTATGCAGCCGCCGCATTGCATCAGCCATGATGGATACT
TTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATCCTGCCCCGGCACTTCGCCCAATAGCAG
CCAGTCCCTTCCCGCTTCAGTGACAACGTCGAGCACAGCTGCGCAAGGAACGCCCGTCGTGG
CCAGCCACGATAGCCGCGCTGCCTCGTCCTGCAGTTCATTCAGGGCACCGGACAGGTCGGTC
TTGACAAAAAGAACCGGGCGCCCCTGCGCTGACAGCCGGAACACGGCGGCATCAGAGCAGCC
GATTGTCTGTTGTGCCCAGTCATAGCCGAATAGCCTCTCCACCCAAGCGGCCGGAGAACCTG
CGTGCAATCCATCTTGTTCAATGGCCGATCCCATGGTTTAGTTCCTCACCTTGTCGTATTAT
ACTATGCCGATATACTATGCCGATGATTAATTGTCAACAGGCTGCAGGTCGAAAGGCCCGGA
GATGAGGAAGAGGAGAACAGCGCGGCAGACGTGCGCTTTTGAAGCGTGCAGAATGCCGGGCC
TCCGGAGGACCTTCGGGCGCCCGCCCCGCCCCTGAGCCCGCCCCTGAGCCCGCCCCCGGACC
CACCCCTTCCCAGCCTCTGAGCCCAGAAAGCGAAGGAGCAAAGCTGCTATTGGCCGCTGCCC
CAAAGGCCTACCCGCTTCCATTGCTCAGCGGTGCTGTCCATCTGCACGAGACTAGTGAGACG
TGCTACTTCCATTTGTCACGTCCTGCACGACGCGAGCTGCGGGGCGGGGGGGAACTTCCTGA
CTAGGGGAGGAGTAGAAGGTGGCGCGAAGGGGCCACCAAAGAACGGAGCCGGTTGGCGCCTA
CCGGTGGATGTGGAATGTGTGCGAGGCCAGAGGCCACTTGTGTAGCGCCAAGTGCCCAGCGG
GGCTGCTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGCGCCTCCCCTACCCGGTAGAATT
TCGACGACCTGCAGCCAAGCTAGCTTGGCTGGACGTAAACTCCTCTTCAGACCTGAAGTTCC
TATACTTTCTAGAGAATAGGAACTTCGGAATTCGATATCAAGCTTGCGGCCGGCCGCCACCT
CGAGCCCCAGCTGGTTCTTTCCGCCTCAGAAGCCATAGAGCCCACCGCATCCCCAGCATGCC
TGCTATTGTCTTCCCAATCCTCCCCCTTGCTGTCCTGCCCCACCCCACCCCCCAGAATAGAA
TGACACCTACTCAGACAATGCGATGCAATTTCCTCATTTTATTAGGAAAGGACAGTGGGAGT
GGCACCTTCCAGGGTCAAGGAAGGCACGGGGGAGGGGCAAACAACAGATGGCTGGCAACTAG
AAGGCACAGTCGAGGCTGATCAGCGAGCTCTAGGATCTGCATTCCACCACTGCTCCCATTCA
TCAGTTCCATAGGTTGGAATCTAAAATACACAAACAATTAGAATCAGTAGTTTAACACATTA
TACACTTAAAAATTTTATATTTACCTTAGAGCTTTAAATCTCTGTAGGTAGTTTGTCCAATT
ATGTCACACCACAGAAGTAAGGTTCCTTCACAAAGAGATCGCCTGACACGATTTCCTGCACA
GGCTTGAGCCATATACTCATACATCGCATCTTGGCCACGTTTTCCACGGGTTTCAAAATTAA
TCTCAAGTTCTACGCTTAACGCTTTCGCCTGTTCCCAGTTATTAATATATTCAACGCTAGAA
CTCCCCTCAGCGAAGGGAAGGCTGAGCACTACACGCGAAGCACCATCACCGAACCTTTTGAT
AAACTCTTCCGTTCCGACTTGCTCCATCAACGGTTCAGTGAGACTTAAACCTAACTCTTTCT
TAATAGTTTCGGCATTATCCACTTTTAGTGCGAGAACCTTCGTCAGTCCTGGATACGTCACT
TTGACCACGCCTCCAGCTTTTCCAGAGAGCGGGTTTTCATTATCTACAGAGTATCCCGCAGC
GTCGTATTTATTGTCGGTACTATAAAACCCTTTCCAATCATCGTCATAATTTCCTTGTGTAC
CAGATTTTGGCTTTTGTATACCTTTTTGAATGGAATCTACATAACCAGGTTTAGTCCCGTGG
TACGAAGAAAAGTTTTCCATCACAAAAGATTTAGAAGAATCAACAACATCATCAGGATCCAT
GGCGAGGACCTGCAGGTCGAAAGGCCCGGAGATGAGGAAGAGGAGAACAGCGCGGCAGACGT
GCGCTTTTGAAGCGTGCAGAATGCCGGGCCTCCGGAGGACCTTCGGGCGCCCGCCCCGCCCC
TGAGCCCGCCCCTGAGCCCGCCCCCGGACCCACCCCTTCCCAGCCTCTGAGCCCAGAAAGCG
AAGGAGCAAAGCTGCTATTGGCCGCTGCCCCAAAGGCCTACCCGCTTCCATTGCTCAGCGGT
GCTGTCCATCTGCACGAGACTAGTGAGACGTGCTACTTCCATTTGTCACGTCCTGCACGACG
CGAGCTGCGGGGCGGGGGGGAACTTCCTGACTAGGGGAGGAGTAGAAGGTGGCGCGAAGGGG
CCACCAAAGAACGGAGCCGGTTGGCGCCTACCGGTGGATGTGGAATGTGTGCGAGGCCAGAG
GCCACTTGTGTAGCGCCAAGTGCCCAGCGGGGCTGCTAAAGCGCATGCTCCAGACTGCCTTG
GGAAAAGCGCCTCCCCTACCCGGTAGAATTCGATTGGAGCTCCAATTCGCCCTATAGTGAGT
CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACC
CAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCG
CACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCG
GCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCC
CTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCG
TCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACC
CCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTT
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CGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAAC
ACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATT
GGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTT
ACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAA
ATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTG
AAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCAT
TTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAG
TTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTT
TCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTAT
TATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGAC
TTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATT
ATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCG
GAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGAT
CGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGT
AGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGC
AACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTT
CCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCAT
TGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTC
AGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCAT
TGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTA
ATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTG
AGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCT
TTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTG
TTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGA
TACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCA
CCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTC
GTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAA
CGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTA
CAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGT
AAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATC
TTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCA
GGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTG
CTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTA
CCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTG
AGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCA
TTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTA
ATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATG
TTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGC
CAAGCTCGAAATTAACCCTCACTAAAGGGAACAAAAGCTGTCGAGATCTAGA 
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CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCAT
TTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATA
GGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGT
CAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAA
GTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTT
AGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGC
GGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGC
TTAATGCGCCGCTACAGGGCGCGTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGG
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CGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCG
ATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAGC
GCGCGTAATACGACTCACTATAGGGCGAATTGGGTACCGGGCCCCCCCTCGAGGTCGACGGT
ATCGATAAGCTTGATATCGAATTCCTGCAGCCCGGGGGATCCACTAGTTCTAGAGCGGCCGC
CACCGCGGTGGAGCTCCAGCTTTTGTTCCCTTTAGTGAGGGTTAATTGCGCGCTTGGCGTAA
TCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACG
AGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTG
CGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATC
GGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGA
CTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATAC
GGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAG
GCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGA
GCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACC
AGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGA
TACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTA
TCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGC
CCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTA
TCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTAC
AGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCG
CTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACC
ACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATC
TCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTT
AAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAA
TGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTT
AATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCC
CCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATA
CCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGC
CGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGG
AAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGC
ATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAG
GCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCG
TTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCT
CTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATT
CTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCG
CGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTC
TCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATC
TTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCG
CAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATAT
TATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAA
AAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
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